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ABSTRACT 
 
Southern Africa has the highest prevalence of HIV worldwide, and South Africa has the 
highest number of HIV infected people. South Africa and other resource-limited 
countries provide antiretroviral therapy (ART) for people with HIV, with limited, 
standardized regimens for first line and second line. Patients who fail first line treatment 
are put on second line regimens, yet options for third line are very limited.  
 
The first study looks at predictors of first line treatment failure in South Africa and 
develops a predictive model that can estimate absolute risk of treatment failure over 5 
years on ART, given a baseline profile of clinical and demographic factors. The model 
was developed with accelerated failure time models, using predictors that maximized 
discrimination between patients. The model can be used to identify patients who need 
adherence interventions, and to estimate how changes in baseline parameters in the 
population influence long-term need for second line ART. 
 
The second study explores whether delays from detection of first line treatment failure 
iv 
 until second line treatment initiation, which are widespread in South Africa, decrease 
the effectiveness of second line ART. Marginal structural models were used to include 
patients who never switched to second line after failure in analysis. This study shows 
that, despite potency of second line drugs, short delays in second line among very sick 
patients can lead to worse outcomes. These findings may be due to drug resistance, 
immune system damage, and/or lack of adherence to medication. 
 
The third study examines whether switch in type of NRTI (nucleoside reverse 
transcriptase inhibitor, which is a drug class used in both first and second line regimens) 
from first line to second line improves outcomes on second line ART. While a switch in 
NRTI is recommended by treatment guidelines, it cannot always occur due to 
contraindications to some NRTIs. Using clinical data from South Africa and Zambia and 
adjusting for propensity scores, we see that switching from zidovudine in first line to a 
different NRTI in second line leads to less treatment failure on second line, suggesting 
that NRTI resistance may play a role in second line outcomes.  
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INTRODUCTION 
Globally, the human immunodeficiency virus (HIV) has caused nearly 70 million 
infections and about 35 million deaths since the beginning of the HIV/AIDS epidemic 
through 2011. In 2011 there were approximately 34 million people living with HIV 
worldwide, with the greatest number of HIV positive people in sub-Saharan Africa (1). 
Southern Africa has the highest HIV prevalence, reaching 26.5% in Swaziland, 23.0% in 
Botswana, 23.1% in Lesotho, and 17.9% in South Africa, among adults age 15 to 49 years 
in 2012 (2). Due to the size of its population, South Africa has the largest number of 
people living with HIV/AIDS among all countries, with close to 5 million adults living with 
HIV in 2011 (3). 
 
HIV treatment programs 
In 2004 South Africa began a national public sector HIV treatment program with 
the goal of providing universal access to antiretroviral therapy (ART). Many countries 
started large scale roll out of ART around this time, after the start of the President’s 
Emergency Plan for AIDS Relief (PEPFAR) in 2003. The goal of ART is to suppress the HIV 
replication of the virus and prevent disease progression, leading to low or undetectable 
virus levels, which then improves immune system function (4,5).  
As in most African countries, the South African national HIV treatment program 
has employed a public health approach recommended by the World Health 
Organization, providing limited, standardized treatment regimens. These programs 
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provide first line regimens for those who initiate treatment and second line regimens for 
patients who fail first line. In resource limited settings, switching to second line is done 
in the absence of genotype testing for drug resistance due to the high cost (6,7). To 
monitor treatment success, most countries in resource limited settings use CD4 cell 
counts, which is a common HIV treatment monitoring strategy in resource-limited 
settings due to its low cost. In South Africa, while CD4 counts are used to determine 
treatment eligibility, viral load measurements are used for treatment monitoring. 
Originally viral load testing was done every 6 months following ART initiation (8), but in 
2011 frequency of viral load monitoring was reduced to one measurement at 6 months, 
one at 12 months, and then annually following treatment initiation (9). If there is 
evidence of an elevated viral load >1,000 copies/mL, the patient is referred for 
adherence counseling and an additional viral load test is done in 2–4 weeks. If the 
second viral load test after adherence counseling is also >1,000 copies/mL, the patient is 
considered to have failed treatment. HIV viral suppression is a marker of treatment 
success and sustained elevated viral loads indicate treatment failure and typically the 
need for second line drugs.  
Current first line ART regimens in resource limited settings include two 
nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse 
transcriptase inhibitor (NNRTI). In South Africa the NRTIs currently available for first line 
regimens are tenofovir (TDF) plus lamivudine (3TC) or emtricitabine (FTC), stavudine 
(d4T) plus lamivudine, and zidovudine (AZT) plus lamivudine. Tenofovir was introduced 
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to the South African treatment guidelines in 2010 as the preferred NRTI for first line 
treatment, whereas originally the majority of patients were started on stavudine 
regimens, one of the first and cheapest antiretrovirals (ARVs) available in South Africa. 
In comparison, tenofovir was used much earlier in first line ART in Zambia, as 
recommended by World Health Organization (WHO) guidelines, but Zambia did not 
allocate resources to routine viral load testing and continues to use CD4 testing for 
treatment monitoring, like most other resource limited settings (Table 1). Currently in 
South Africa, stavudine is maintained for patients on a stavudine based-regimen, and 
zidovudine is used when there is a contraindication to tenofovir due to renal disease (9).  
The NNRTI used in addition to the NRTIs in a first line regimen is either efavirenz 
(EFV) or nevirapine (NVP). Efavirenz is usually the preferred first line NNRTI, but due to 
contraindications nevirapine is commonly used instead for pregnant women, night shift 
workers, and patients with some mental disorders. As of 2013 the World Health 
Organization guidelines for ART recommend use of efavirenz in first line, even in 
pregnant women (10). 
After first line treatment failure, the change to a second line regimen includes 
switching the NRTI (tenofovir, stavudine or zidovudine) that the patient is currently on 
when possible, plus the addition of a protease inhibitor (PI) instead of an NNRTI. In 
South Africa and most resource limited settings, the PI most commonly used is 
lopinavir/ritonavir (LPV/r). Thus the second line regimen is comprised of two NRTIs plus 
a PI, a more expensive class of drug (11). A summary of recommended ART regimens, 
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eligibility and monitoring for South Africa and Zambia according to the national 
guidelines is provided in Table 1. 
At the start of South Africa’s national HIV treatment program, patients with a 
CD4 count below 200 cells/mm3 or a WHO Stage IV condition were eligible for 
treatment. In 2010, to align with updated WHO recommendations, the national 
guidelines increased the CD4 threshold for treatment eligibility to 350 cells/mm3. In 
2013 WHO guidelines were updated to recommend treatment initiation for anyone with 
a CD4 count <500 cells/mm3, and South Africa is now updating their treatment 
guidelines to a threshold of 500 cells/mm3.  Identifying and providing treatment for all 
eligible patients has been and remains challenging. As of 2011, only 52% of those 
eligible under current guidelines were receiving ART in South Africa (3). Although the 
new guidelines allow for earlier ART initiation, patients typically present to clinics late 
and start ART at CD4 counts of 80 to 100 on average (12), when they are severely 
immune-compromised and often showing signs of illness. Additionally, retention in care 
after initiation of treatment is not ideal, with approximately 65% of patients remaining 
in care after 3 years on treatment, and especially high attrition due to death and loss to 
follow-up during the first 2 years (13). One study in rural South Africa showed high rates 
of death and loss to follow-up immediately following treatment initiation, with 14% 
mortality within 3 months (14). When excluding patients who have died, loss to follow-
up remains high and increases over time on ART (15). Expanding treatment coverage to 
80% of eligible people by 2016 is part of the government of South Africa’s 2012–2016 
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National Strategic Plan on HIV, STIs and TB (16). Expanding treatment coverage and 
initiating patients on ART at higher CD4 counts, as well as retaining patients in care is an 
ongoing effort throughout Southern Africa (17).  
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Table 1. Overview of national ART treatment guidelines for South Africa and Zambia. 
Country Time frame First line Second line Monitoring Eligibility 
South 
Africa 
2004–2010 
d4T + 3TC + EFV or 
NVP 
AZT + ddI + LPV/r Viral load 6 
monthly 
CD4 <200 or 
WHO stage 4 
 
2010–2013 
TDF + 3TC or FTC + 
EFV or NVP  
 
AZT + 3TC + EFV or 
NVP 
AZT + 3TC + LPV/r  
 
 
TDF + 3TC or FTC + 
LPV/r 
Viral load at 4–
6 months, 12 
months, and 
annually 
CD4 <350 or 
WHO stage 
3–4 
Zambia 
2004–2006 
AZT + 3TC + EFV 
 
d4T + 3TC + EFV or 
NVP 
 
AZT + 3TC + ABC 
 
 
d4T + ddI + LPV/r 
 
d4T + ddI + LPV/r + 
NNRTI 
CD4 at 3 
months, and 
then 6 monthly. 
Repeat CD4 and 
test viral load if 
evidence of 
failure. 
CD4 <200 or 
WHO stage 4 
2007–2010 
TDF + FTC + NVP or 
EFV 
 
AZT or d4T + 3TC + 
NVP or EFV 
AZT or d4T + 3TC or 
TDF + LPV/r 
 
TDF + FTC + LPV/r 
 
ABC + ddI + LPV/r 
CD4 at every 6 
months, repeat 
CD4 and viral 
load if evidence 
of failure 
WHO stage 
4, CD4 <200, 
or CD4 <350 
& WHO 
stage 3 
2010–2013 
TDF + FTC or 3TC + 
EFV or NVP 
 
ABC + 3TC + EFV or 
NVP 
 
AZT + 3TC + LPV/r 
 
TDF + FTC or 3TC + 
LPV/r 
 
d4T + 3TC + LPV/r 
 
CD4 at 6 
months, then 
annually. 
Repeat CD4 and 
viral load test if 
evidence of 
failure. 
CD4 <350, or 
WHO stage 
3–4 
SA National Guidelines 2004, 2010; Zambia National Guidelines 2004, 2007, 2010. 
(8,9,18,19,20) 
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Causes of first line ART failure 
Ten years after the launch of the South African national HIV program, a 
substantial number of patients have failed first line and require second line ART. In 
South Africa, approximately 14% of patients on first line treatment had virologic failure 
after 5 years, and approximately 12% had started second line ART, while overall 
mortality on first line ART was 15.5%, and combined mortality and loss to follow-up was 
35.3% in 5 years (21). In a review of 89 studies of HIV treatment in sub-Saharan Africa, 
few studies reported long-term virologic outcomes on first line treatment. Among five 
studies that reported on 3-year on treatment, 67% of patients who started first line 
treatment were virologically suppressed after 3 years (22).  
Treatment failure may be caused by baseline drug resistance, lack of adherence 
to ART, or drug resistance developed over time on treatment. Lack of adherence to ART 
has been consistently shown to be an important predictor of treatment failure 
(23,24,25). Measures of adherence to ART in resource-limited settings generally indicate 
adherence levels over 90% (25), yet lack of adherence will cause viral loads to become 
elevated, which also increases the likelihood of drug resistance mutations occurring 
(26). Even low levels of persistent, detectable viral load levels over time can lead to drug 
resistance mutations and an increased risk of treatment failure. In high-income 
countries, patients with suppressed viral loads less than 200 copies/mL had double the 
risk of treatment failure compared to patients with undetectable viral loads (27). 
Drug resistance at treatment initiation (i.e. transmitted resistance) continues to 
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be rare in South Africa, yet is developed over time and present in many patients at 
treatment failure. Even a low level of measured resistance to first line drugs has been 
associated with increased risk of virologic failure on first line (28). Overall, drug 
resistance mutations have been detected in approximately 83% to 96% of South African 
patients who fail first line therapy (29,30,31,32). The most common type of resistance 
mutation at first line failure is resistance to NNRTIs, which have a low genetic barrier to 
drug resistance mutations (33), but do not impact activity of drugs used in second line 
ART. 
Resistance to NRTIs is also commonly found at first line failure, and can 
potentially limit activity of second line regimens that include NRTIs. A cross-sectional 
study of 998 patients in 2010 showed approximately 64% of HIV patients in South Africa 
had some NRTI resistance at first line treatment failure (34), which may reduce activity 
of a second line regimen. Other studies have shown prevalence of NRTI resistance at 
first line failure is as high as 81% to 90% in South Africa (30,35,36,37), or up to 100% in 
an ART program in Nigeria (38).  
M184V was the most commonly detected NRTI resistance mutation detected, 
which causes resistance to lamivudine and emtricitabine, yet can increase activity of 
some NRTIs (39). In a review of studies in sub-Saharan Africa reporting types of 
resistance mutations at first line failure, including 27 studies with 734 patients, the 
M184V mutation was found in 65% of patients (22). Thymidine-analog mutations 
(TAMs) were the next most common NRTI resistance mutation, found in 40% to 56% of 
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South African patients at treatment failure, and 3 or more TAMs were found in 18% to 
25% of patients (30,35). TAMs cause resistance to zidovudine and stavudine, and in high 
numbers (≥3 TAMs) can cause resistance to tenofovir (40). The K65R was the next most 
common NRTI resistance mutation, found in 4%–7% of patients at first line failure 
(30,35,41). An estimated 15% to 64% of patients failing first line in South Africa had 
resistance patterns to NRTIs that could compromise activity of a second line regimen 
(30,34,35,42,43).  
 
Risk factors of first line ART failure 
Several studies have identified individual predictors of first line failure in 
resource-limited settings, which may cause failure through poor adherence to 
medication and/or development of drug resistance. These risk factors include male 
gender (14), younger age (44), low CD4 at ART initiation (14,21,44,45), elevated viral 
load at ART initiation (44), higher WHO stage at ART initiation (44), previous exposure to 
short-course ART for prevention of mother to child transmission (PMTCT)  (21,45), ART 
interruptions (21,44,45), use of nevirapine instead of efavirenz (21,44,45), low general 
health score (14), and low body mass index (BMI) and, in unadjusted models only, 
zidovudine use (14).  
Mortality on first line treatment is also associated with some of these factors, 
including low baseline CD4 count, AIDS diagnosis, and low body weight (21). May et al. 
have modeled risk of death over the first year on ART among 11,153 patients in South 
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Africa, Ivory Coast and Malawi and found mortality was associated with high baseline 
clinical WHO stage, older age, sex, low baseline CD4 count, low bodyweight and anemia 
(46). Most other predictive modeling for ART patients has used data from developed 
countries (47,48,49). Although individual predictors of first line ART failure have been 
identified, few studies in resource-limited settings have been large enough to model 
interactions between factors necessary for appropriate predictive modeling. Thus, there 
is little information about absolute risk of first line treatment failure given predictors of 
treatment failure, and therefore the need for second line ART, in resource-limited 
settings. Dissertation Study 1 will investigate predictive models for first line ART failure. 
 
Treatment outcomes after failure 
Mortality and virologic outcomes on HIV treatment are generally worse for 
patients who fail first line ART. Patients who have experienced treatment failure and 
switched to second line ART are less likely to be virally suppressed than patients who 
remain on successful first line treatment (21). After adjusting for age, sex, race, first-line 
regimen, and year of initiating ART, patients on second-line therapy in South Africa were 
somewhat less likely to be alive and in care at one year on ART (HR 0.84; 95% CI: 0.73–
0.97) than those still on first line for equal duration (50). However, switching to second 
line ART after first line failure greatly improves patient outcomes and decreases 
mortality compared to patients who remain on a failing regimen (50,51).  
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Switch to second line ART 
Although patients who switch to second line treatment after failure have 
improved outcomes compared to patients who do not switch, the proportion of patients 
failing second line ART remains high. Since lack of adherence is an important cause of 
first line failure, it is likely that patients on second line tend to have overall worse 
adherence than patients who never fail (52). Once on second line ART, 22%–23% of 
patients in low-income countries experienced virologic failure at 12 months after the 
start of second line (23,42). Estimates for mortality on second line at 12 months range 
from 5.3%–10.5%, and loss to follow-up at 12 months on second line range from 3.4%–
17% (42). In South Africa, virologic failure at two years on second line ART was 
approximately 25% (23). Patients who are lost to follow-up may have transferred, 
stopped attending care, or died (53). In South Africa about 17% of patients who have 
been lost to follow-up die within 4 years. With treatment scale-up ongoing and many 
patients reaching multiple years on second line ART, and given the high cost of second 
line ART and limited options if second line fails, it is important to assess who succeeds 
on second line and the implications of treatment decisions on second line ART 
outcomes.  
Unlike South Africa, in most resource-limited settings, decisions about when to 
switch regimens are usually made based on CD4 count or clinical signs despite their 
documented poor sensitivity for treatment failure (54,55,56). Using only immunologic 
criteria to identify failing patients does not accurately identify patients with high viral 
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loads. The positive predictive value of CD4 criteria to identify virologic failure is 28.4%, 
based on a study of 155 HIV patients in Malawi (57). Viral load monitoring of treatment 
in South Africa allows for earlier and more accurate identification of treatment failure 
than clinical or immunologic monitoring (54,58). Virologic monitoring results in patients 
switching treatment earlier and at higher CD4 counts (59,60).  
Yet, after detection of virologic failure among first line ART patients in South 
Africa some delay until switch to second line is inevitable. Not all patients who fail 
treatment switch to second line, with 26.5% of patients in a small rural South African 
treatment program ever switching to second line after documented virologic failure 
(14,44,61). Median time to switch to a second line regimen among patients who do 
switch has been estimated to be approximately 5.3 months (21,61). Predictors of 
switching to second line among those who fail include a lower CD4 count at time of 
failure and a larger CD4 count drop over time on first line, indicating physician 
motivation to switch sicker patients more quickly (44).  
 
Outcomes on second line ART 
Remaining on a failing first line regimen for a longer duration before switching 
increases drug resistance and could threaten the effectiveness of some second line 
drugs. Virologic detection of treatment failure and timelier switching to a new regimen 
should prevent the emergence of complex drug resistance patterns that could 
compromise future treatment (62). Several studies of patients in sub-Saharan Africa 
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have shown that prolonged, undetected treatment failure is associated with 
accumulation of NRTI resistance (55,56,63). There is some evidence that delaying a 
regimen switch after virologic failure leads to higher mortality among patients in the US 
(64), yet in a clinical trial in the US where 45 patients with low to moderately elevated 
viral loads (200–9999 copies/mL) were randomized to immediate or delayed regimen 
switch, subjects in both arms had similar drug resistance mutations and CD4 counts at 
48 weeks after randomization (65). A study in South Africa indicated that delaying 
switch to second line leads to a decrease in early suppression after switch (61). Another 
recent publication (66) showed that in South Africa, delaying switch to second line was 
associated with increased mortality. The focus of dissertation Study 2 will be to evaluate 
the effect of delays in switch to second line on virologic outcomes on second line 
treatment. 
Several studies have identified other factors that influence outcomes on second 
line ART. Research has shown mixed results on the effect of CD4 level at the start of 
second-line treatment on patient outcomes. In a cohort of 632 patients with 741 
person-years of follow-up in Asia and Africa, low CD4 count at the initiation of second 
line ART was associated with treatment failure after 6 months on second line (43). Other 
studies in Africa have seen no association between CD4 count at second line initiation 
and virologic suppression on second line (23,50,61). Other predictors of virologic failure 
on second line include lack of adherence on second line, switching because of failure 
related to non-compliance, having a history of TB, and a lower BMI at ART initiation 
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(23,42). Adherence on second line ART is an important predictor of viral suppression and 
has been consistently shown to be predictive of improved outcomes on second line ART 
(23,42).  
 
Drug resistance on second line ART 
NRTIs are used in both first and second line treatment, and patients in resource 
limited settings are switched to second line regimens without drug resistance testing. 
Although NRTI resistance has been identified at first line failure, its effect on the success 
of second line ART remains unclear. Even when patients have resistance to NRTIs used 
in second line, research suggests the high potency of PIs allows second line to remain 
effective since resistance to PIs at first line failure is rare (34,67,68,69). A study of 243 
patients in Africa found that patients on a PI based second line regimen attained viral 
load suppression despite NRTI-associated resistance mutations among over half of 
patients, although this study was limited to 12 months of follow-up (70). Several studies 
in South Africa have shown that lack of adherence was a more important factor than 
drug resistance in second line ART failure (71,52). 
Despite the ability of a PI to suppress HIV even in the presence of NRTI 
resistance, some studies show that drug resistance developed during first line ART 
impacts effectiveness of second line ART. One recent analysis of over 600 second line 
patients in Africa and Asia found second line failure rates were dependent on the 
number of NRTIs changed from first line (72). Patients on first line treatment for a 
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longer duration had more NRTI resistance at first line treatment failure (56).  
As described previously, NRTI resistance present at first line failure has the 
potential to compromise activity of second line regimens. NRTI resistance mutations 
have been detected more commonly among patients with high viral load or low CD4 
count at ART initiation (32), patients with a low CD4 count at failure (55), and among 
patients who have remained on a failing regimen for a longer time (73). At second line 
failure, NRTI resistance has been detected in 29% of patients in South Africa (34).  
TAMs (including M41L, D67N, K70R, L210W, T215Y/F, K219Q/E, and others) 
accumulate over time on zidovudine and stavudine regimens. TAMs have been found 
more often among South African patients whose first line regimen contained zidovudine 
rather than stavudine (35). At failure of first line treatment, TAMs were 3.5 times more 
likely in patients on a zidovudine regimen compared to a stavudine regimen (56). The 
drug resistance accumulation patterns for stavudine are less predictable than mutation 
patterns for zidovudine and tenofovir (62). TAMs cause reduced activity for zidovudine 
and stavudine, as well as for tenofovir when ≥ 3 TAMs are present (40,74,75,76,77). 
Other NRTI mutations include the M184V mutation that causes reduced activity for 
lamivudine and emtricitabine, and the K65R and K70E mutations. Both K65R and K70E 
accumulate while on tenofovir and cause resistance to tenofovir, yet these mutations 
have also developed in patients who are not on tenofovir (41). For example, K65R has 
been found in 7% of patients in South Africa who have failed a zidovudine or stavudine 
first line regimen, and this mutation can accumulate even more rapidly among patients 
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on tenofovir regimens (41). 
Due to these NRTI resistance patterns, switch in NRTI is recommended at the 
start of second line ART in national guidelines. Yet, the actual impact of change in NRTI 
to minimize NRTI resistance in the presence of a second line regimen with an active 
protease inhibitor is not fully understood. Dissertation Study 3 will investigate the 
impact of switch in NRTI from first line to second line on virologic and immunologic 
outcomes on second line ART. 
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STUDY 1: DEVELOPMENT OF A PREDICTIVE RISK MODEL FOR FIRST LINE 
ANTIRETROVIRAL THERAPY FAILURE IN SOUTH AFRICA 
 
OBJECTIVE 
 Although individual predictors of first line ART failure have been identified, few 
studies in resource-limited settings have been large enough to model interactions 
between factors necessary for appropriate predictive modeling. Previous studies have 
shown that CD4 count, gender, age, general health, and NNRTI in first line regimen are 
important predictors of first line failure (14,21,44,45), yet the relative impact of each of 
these predictors and the presence of any relevant interaction terms has not been 
thoroughly investigated. The aims of this study are to estimate absolute risk of failure of 
first line antiretroviral therapy (ART) over 5 years on treatment as a function of a 
baseline profile of key demographic, clinical, immunologic factors, and their 
interactions, and to develop a predictive model that can be applied to other South 
African clinic populations, giving estimates of proportion of patients needing second line 
ART over time. 
The predictive model developed in this study can have implications at both the 
population and individual level. At the population level, due to lack of predictive models 
for treatment failure in South Africa and other resource limited settings, there is little 
information about absolute risk of first line treatment failure given predictors of failure, 
and therefore the need for second-line ART in South Africa. This predictive model will 
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provide long-term estimates for the need for second line ART in South Africa over 5 
years, for the population as a whole and for sub-populations, for example patients who 
start ART at high or low CD4 counts. The model will not address outcomes for patients 
who do not remain in care, but will provide insight into the magnitude of need for 
second line ART depending on the characteristics of the population beginning ART.  
At the individual level, the predictive model will be useful for clinicians to 
identify patients at highest risk of failure. The predictive model is intended to be 
generalizable to other South African clinic populations, and the model will provide 
treatment failure risk group estimates for patients at 6 months following ART initiation. 
Identifying individuals at highest risk of failure will be useful for intervening among 
these patients for early referral to adherence counseling or other adherence 
interventions, and ideally avoiding treatment failure and the need for second line.  
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METHODS 
 
Data source and study population 
This study is a retrospective observational cohort study using prospectively 
collected routine medical record data. Medical records for the study come from the 
Right to Care (RTC) clinical HIV cohort, which includes patients from 9 HIV clinics across 
South Africa. Right to Care is a non-profit organization that supports and delivers care 
and treatment services for HIV for roughly 10% of all HIV positive persons in South 
Africa at geographically dispersed clinics. The clinics began initiating patients onto 
treatment in 2004 when large-scale public-sector roll out of HIV treatment began in 
South Africa. The largest and most well described site is Clinic A, which has initiated over 
30,000 patients on treatment since 2004 (78). Clinic A is part of a large, urban, public 
referral hospital in Johannesburg. The other sites include a nongovernmental full 
service, primary care clinic serving informal peri-urban settlements in Johannesburg 
area, Gauteng Province (Clinic B), a nongovernmental dedicated HIV/AIDS clinic in a 
rural setting in Mpumalanga Province (Clinic C), public clinics in Midrand, Gauteng 
Province (Clinics D and G), a rural public clinic in Mpumalanga Province (Clinic E), a 
hospital in the Johannesburg area (Clinic F), a primary healthcare facility in 
Johannesburg, Gauteng Province (Clinic H), and a small clinic in Johannesburg (Clinic I). 
An initiative to combine the HIV treatment data from all sites began in 2011.  
Each Right to Care supported clinic uses the same electronic medical record 
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system for tracking patients, called TherapyEdge-HIV™. Electronic data includes basic 
patient information on demographics (e.g. date of birth, sex) clinical information (e.g. 
height, weight), date of visits, lab results, diagnoses, and HIV treatment regimens. The 
clinics follow the South African national treatment guidelines, which call for patients to 
visit the clinic monthly for the first 6 months on treatment and every 2 to 3 months after 
6 months on treatment, if stable, for ARV pick-ups.  
The study population for this analysis includes treatment naïve adult patients 
over 18 years old initiating a standard first line HIV treatment regimen and who has ≥6 
months of follow-up. Currently data from the 9 sites include 88,305 treatment naïve 
adults starting first line ART. A standard first line regimen was defined as two nucleoside 
reverse transcriptase inhibitors (NRTI) (either stavudine (d4T), zidovudine (AZT) or 
tenofovir (TDF) plus lamivudine (3TC) or emtricitabine (FTC)) and one non-nucleoside 
reverse transcriptase inhibitors (NNRTI) (either efavirenz (EFV) or nevirapine (NVP)). 
Data from these sites were linked to the national death registry in 2013, which is 
estimated to have 90% sensitivity of capturing adult deaths (79). 
  
Study variables 
Predictors 
All predictor variables come from clinic data collected at the initiation of ART, 
including baseline age, sex, year of ART initiation, clinic, CD4 count, WHO stage, body 
mass index (BMI), hemoglobin level, total lymphocyte count, mean corpuscular volume 
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(MCV), red blood cell count (RBC), creatinine level, creatinine clearance, alanine 
transaminase (ALT), aspartate transaminase (AST), blood pressure, history of 
tuberculosis, peripheral neuropathy, pregnancy, NRTI in first line regimen, NNRTI in first 
line regimen, history of alcohol, and history of smoking. Having any missed visits by 
more than 7 days prior to the start of follow-up time at 6 months on ART was also 
included as a predictor. Values of lab variables for baseline measures were taken from 
the test closest to the day of ART initiation, using values from 90 days before ART 
initiation up to seven days after initiation.  
 
Outcomes 
The main outcome for this study is time to virologic failure after first line ART 
initiation. Date of virologic failure is defined as the date of the second of two 
consecutive viral load measurements >1000 copies/mL, at least 3 months after ART 
initiation. The two measurements had to be between 2 weeks and 12 months apart. The 
first viral load after treatment initiation is typically at 6 months on treatment, thus for 
most patients follow-up time began at 6 months after ART initiation to avoid immortal 
person time bias (80). Some of the clinics do viral load testing at 4 months on treatment. 
In order to include viral load results for patients who have viral load tests earlier than 6 
months, any viral load test done after 3 months was included in the outcome definition, 
and these patients began follow up time at the date of the viral load test in the 3–6 
month window. Person time ended at the earliest date of: first line treatment failure, 
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switch to a second line regimen (defined as switch to a PI-based regimen plus the 
addition of at least one new NRTI), loss to follow-up, death, transfer to another clinic, or 
the date of the dataset closure in March 2014. Loss to follow-up was defined as not 
having a visit within 6 months of the end of the study period and date of loss to follow-
up was the date of the last attended visit. Treatment changes that were not switches to 
a second line regimen and treatment interruptions were ignored.   
  
Statistical Methods 
Model development 
Distributions of all baseline variables are examined in summary and stratified by 
year of ART initiation and by clinic, to understand relationships between variables. The 
overall rate of failure and rates of failure within each clinic were also examined with 
Kaplan-Meier curves.  
For the predictive model, methods developed by May et al. (81) for predictive 
model selection and model fit were used. Accelerated failure time survival models with 
exponential, Weibull, gamma, loglogistic, and lognormal distributions were considered 
as candidate predictive models to calculate absolute risk. These parametric models 
allow for direct calculation of the survival function and predicted probability of survival 
at a specified time point. To investigate the fit of the distributions, fit diagnostic graphs 
and probability plots to compare the parametric fit to the data points plotted against a 
non-parametric model were created in SAS. Cox-Snell residuals were plotted to compare 
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all distributions. To test the differences between fit for Weibull, gamma and exponential 
distributions, and between gamma and lognormal, likelihood ratio tests were 
considered. The Lagrange multiplier test statistic also was used to test if a Weibull 
model would be a better fit than an exponential model. 
First, unadjusted models were run for each of the predictor variables to explore 
the relationship between the predictors and time to failure. For continuous variables, 
different categorizations of variables were considered based on clinical importance and 
distribution of data. Akaike's information criteria (AIC) scores were also used to 
compare different categorizations of variables, and to compare to use of continuous 
variables, to find the optimal version of the variable. The unadjusted models were run 
using all data, and also stratified by clinic to look for site-specific predictors. Year and 
clinic were included in this part of the analysis, but could not be predictors in the final 
model in order to make the model applicable for future use and other clinics. Models 
with estimates adjusted for year and clinic site were later considered in the candidate 
final models to determine if these adjustments would improve the predictive value of 
the model. 
As this was a not a causal but a predictive model, candidate multivariate 
predictive models were developed using stepwise selection of predictors and interaction 
terms with p-values < 0.2 in an accelerated failure time model predicting virologic 
treatment failure. The first model included all predictors, and variables were removed 
until all predictors had a p-value less than 0.2. Next, predictors were added back in one 
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by one. The variable with the lowest p-value < 0.2 was included, and this process was 
repeated until any variables added back into the model had a p-value > 0.2. Biologically 
plausible multiplicative interactions between predictors in the final model were tested. 
Interaction terms could potentially improve model predictive ability if the effect of one 
variable varied by another. Interaction terms with p < 0.20 were considered in candidate 
final models. Each of the predictor variables were also added back in to the model after 
multiple imputation (described below) to test for significance, since the large number of 
missing variables reduced the sample size in the non-imputed data.  
For missing data on predictor variables, multiple imputation was used (46,82,83). 
This method assumes variables are missing at random given observed data. Variables 
with over 50% missing values at baseline were not used in model development and 
were not imputed. The multiple imputation model to predict missing values included all 
baseline variables that were possible predictors in the model, as well as the outcome 
indicators for failure, loss to follow-up, switch to second line, transfer, or death, and a 
person-time variable for time to failure. No data on outcome variables was imputed. 
Seven imputations of the dataset were run, and these imputations were combined using 
proc mianalyze in SAS. 
 
Model fit 
The best candidate predictive models were selected based on several measures 
of model fit. AIC scores, which take the number of model parameters into account, were 
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used to assess overall model fit. Additionally, 2 statistics to measure model 
discrimination and calibration were calculated in a cross-validation procedure. Cross 
validation of the proposed models was used to ensure high predictive value of the 
models on independent data. Models that are not tested on independent data may be 
over-fit; that is, the model that gives the best prediction on data used to develop the 
model may not be the best model when it is subjected to external validation on 
independent data (81,84). Lack of validation of a model on independent data leads to 
lack of generality and lack of utility for clinical practice (85).  
Internal-external cross-validation (IECV) is one method used to validate 
predictive models, and was used in this study. It has been described in detail by May et 
al. (81). In IECV, each of the candidate predictive models was developed on all clinics 
excluding one, and then model performance was tested on the excluded clinic. Steps for 
IECV included denoting each clinic k = 1 through 9, and for each k, (1) excluding k, fitting 
the predictive model on the remaining clinics; (2) computing the linear predictors (B1X1 
+ B2X2 + B3X3…) from beta estimates calculated in step 1 for the excluded clinic k; (3) 
calculating Harrell’s C statistic using the linear predictor calculated in step 2; (4) 
calculating the predicted probability of failure at year 5 using estimates calculated in 
step 2 and calculating the difference from clinic k’s actual 5 year survival; (5) rotating 
the excluded clinic for k = 1 to k = 9 and repeating all steps. The IECV process allows the 
model to be developed on 8 of the clinics and evaluated for its performance on the 9th 
clinic. Thus, each version of the model in the IECV analysis was tested on each of the 9 
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clinics, and an average for the model discrimination and calibration statistics weighted 
by the population of the clinic was calculated for each model. 
Harrell’s C statistic, which measures the proportion of all subject pairs where 
prediction of an earlier time to event is consistent with the actual outcome, was used as 
a measure of model discrimination. Developed by Harrell et al. (86), it is used as a 
survival analysis approximate to the C-statistic, to give an approximation of the 
proportion of patients for whom the model can correctly determine if survival is better 
or worse than another patient’s survival. The statistic is calculated using all possible 
pairs of subjects in which at least one has experienced failure to determine the 
proportion of pairs whose actual survival is concordant with model prediction. If both 
individuals in a pair have equivalent survival predictions they are considered ties. A 
patient pair is unusable if both patients failed at the same time, or if one failed and the 
other is still in care but has not been followed long enough to determine whether they 
will remain in care longer than the one who failed (86). SAS code was developed to 
calculate Harrell’s C-statistic based on code from Liu et al. (87).  
 Predicted survival at 5 years was compared to actual survival at 5 years in the 
IECV procedure to assess model calibration. Estimates for difference in 5 year survival 
and the Harrell’s C-statistic for each model in the IECV analysis gave an estimate of 
overall model prediction for external data. When assessing validity of the model and 
selection of the best predictive model, clinical validity (results from IECV) was prioritized 
over statistical validity (AIC score) (70). Discrimination between patient survival was 
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prioritized over model calibration, so while AIC score, Harrell’s C-statistic, and difference 
in 5 year survival were all considered in the final model selection, priority was given to 
the C-statistic, then difference in 5 year survival, and finally AIC score. 
 The final model was used to assess the impact of individual baseline predictors 
and interactions between predictors on absolute risk of treatment failure. Outcomes 
from the final model include calculation of a predictive score for risk of failure based on 
quintiles of risk for an individual’s baseline variables, and absolute risk of failure 
calculation at 1,2,3,4 and 5 years on ART based on an individual’s baseline variables. 
 
Sensitivity analyses 
 Survival methods including Kaplan-Meier curves, Cox proportional hazards 
models, and accelerated failure time models assume no competing risks. Competing 
risks occur when the observation of the disease under study is preceded by another 
event that prevents the occurrence of the disease of interest. In this study, the 
observation of treatment failure on first line ART could never occur if death or switch to 
second line ART occurred first. Impact of these competing risks was assessed graphically 
using the cumulative incidence macro adjusting for competing risks (88). Cumulative 
incidence curves adjusting for competing risks and not adjusting for competing risks 
were compared. 
Predictors of loss to follow-up, death, switch to second line, and transfer were 
examined to determine how censored patients compared to patients remaining in care. 
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Predictors of censoring were explored with Cox proportional hazards models.  
Patients who remained in care but had a reasonable chance of having been 
misclassified as non-failures, such as patients who experience death while in care 
without documented treatment failure, and patients who switched to second line 
before documented treatment failure, were considered to have treatment failure in a 
sensitivity analysis.   
Additionally, analyses excluding clinics with much higher or lower rates of failure 
than average were also performed. Lastly, an analysis where person time was defined as 
time in treatment with regular viral load measurements, and patients without a viral 
load for more than 12 months were censored. This analysis helped to determine if there 
was a substantial impact of missing viral load measurements on the parameter 
estimates in the predictive model. 
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RESULTS 
 
Study Sample 
 There were 88,305 adult patients in 9 clinics who initiated a standard first line 
ART regimen. In each clinic, approximately 80% of subjects were eligible for inclusion. 
71,154 patients were included in the analysis. 16,533 patients were not eligible because 
they had less than 6 months of follow-up, and 437 patients were not eligible because 
they initiated treatment before 2004 when the standardized national treatment 
guidelines took effect (Table 2). Patients excluded because they had less than 6 months 
of follow-up time and did not return for a virologic monitoring visit tended to be sicker 
than patients who were included in analysis, with lower CD4 counts (36.5% vs. 23.6% 
<100 cells/mm3), higher proportion underweight (27.7% vs. 17.0%), and higher 
proportion with a history of TB (18.2% vs. 14.8%) at baseline (Table 3). The frequency of 
outcomes at the end of follow-up time for patients included in analysis is displayed in 
Table 4. The median follow-up time was 21.5 months (IQR: 8.8, 41.5). 
 
Data Quality 
 To explore the data quality at each site, the proportion of missing values for 
eligible subjects was calculated for a few key baseline predictor variables. Age and sex 
were not missing for any subjects. Clinic A had the most complete data, followed by 
Clinic C and Clinic B. At Clinics D, E, G, H and I over 50% of data were missing for some 
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variables (Table 5). The proportion of missing values decreased slightly over time for 
CD4 count, hemoglobin and BMI (Appendix Table A1A), however even for patients 
initiating in 2013, 19% of CD4 values were missing at baseline. 
 
Variable frequencies 
 Table 6 shows baseline values of available predictor variables, including 
demographic, clinical and lab values. Values which change over time were matched to 
the date of ART initiation. Total lymphocyte count and viral load testing is not commonly 
done at baseline. These variables were missing for over 80% of patients at baseline and 
were not included in predictive models. 
Values of select variables are shown by year of ART initiation in Appendix Table 
A1A to examine trends in predictor variables over time. TDF became commonly 
prescribed over d4T starting in 2011, as treatment guidelines changed. EFV was 
prescribed more often than NVP, especially in recent years. Generally, patients initiating 
treatment appeared to become slightly healthier over time, with decreasing amounts of 
TB, higher initiating CD4 counts (as the CD4 count threshold for treatment was raised 
over time), lower WHO stages, and fewer underweight patients in later years. Creatinine 
was available for very few patients who initiated before 2009 because it was not 
routinely done. Creatinine testing became more frequent in recent years when TDF 
became available. TDF is a renal toxic drug that cannot be prescribed to patients with 
renal disease. Creatinine could not be used as a predictor for patients initiating before 
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2010. Visit adherence (proportion of patients who missed visits during the first 6 months 
on ART) appeared to become worse over time. 
Values of predictor variables varied somewhat by clinic (Appendix Table A1B). 
Age and gender distributions of patients were similar across clinics, with 63% to 68% 
female patients and 38% to 49% initiating in their 30s. The year in which the majority of 
patients initiated ART differed by clinic, which could account for some differences in the 
health of the population between clinics. For example, Clinic B had patients initiating at 
a higher CD4 count compared to Clinic A, but also had patients initiating in later years, 
on average. Proportion with tuberculosis at baseline differed greatly by clinic, and may 
indicate that not all TB cases were recorded in medical records or patients were not 
always screened for TB. Missed visits in the first 6 months on treatment was close to 
20% for most clinics, but was higher at Clinic C (32%) and Clinic H (28%) and much lower 
at Clinic I (5%). Clinic C and Clinic H’s higher proportion of missed visits may be 
associated with patients in those clinics initiating in later years. 
 
Variable frequencies after imputation 
Due to the large proportion of missing values for many predictors, multiple 
imputation was used to obtain baseline values of variables and avoid excluding patients 
with missing data. Predictors with over 50% of data missing (creatinine serum, 
creatinine clearance, and AST) were not imputed and were not included in modeling. In 
order to impute values, variables that were not normally distributed were transformed, 
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which included taking the square root of RBC and BMI, and taking the log of age, CD4 
count, and ALT. The imputation model included the following baseline variables: person 
time, outcome (failure, switch, death, transfer, or loss to follow up), clinic, any missed 
visits in the first 6 months on treatment, age, sex, year, CD4 count, body mass index 
(BMI), WHO stage, TB, peripheral neuropathy, pregnancy, NNRTI in first line regimen, 
NRTI in first line regimen, history of alcohol, history of smoking, mean corpuscular 
volume (MCV), red blood cell count (RBC), diastolic blood pressure, systolic blood 
pressure, hemoglobin, and alanine aminotransferase (ALT). Seven sets were imputed, 
and all transformed variables were then back transformed. The distribution of baseline 
variables with missing data after imputation is displayed in Table 7.  
 
Overall failure rate 
 The overall rate of failure is displayed in Figure 1. After 5.5 years on treatment (5 
years in the study), over 15% of subjects experienced treatment failure. When 
stratifying the survival curve by clinic (Figure 2), the rate of failure was similar in all 
clinics except for Clinic E, which showed a much higher failure rate, and Clinic I, which 
had a lower failure rate. Sensitivity analyses were done excluding Clinics E and I. 
 The proportion of patients experiencing failure and all other outcomes at the 
end of person-time are displayed in Table 8. The majority of failures and deaths 
occurred among patients initiating ART earlier, since they had the most potential follow-
up time to experience these outcomes. 
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Survival model distributions 
Data from all sites were used when testing if an exponential, Weibull, gamma, 
loglogistic or lognormal distribution fit the data best, but model fit was also considered 
excluding Clinics E and I, which appeared to have a different rate of failure compared to 
the other clinics (Figure 2). The Cox-Snell residual plot (Appendix Figure A1A) indicated 
that any of these distributions could be considered as a possible fit for the data, with the 
gamma model showing the worst fit. The gamma model also failed to converge so it was 
not used. 
Diagnostic plots looked similar when excluding Clinic E, and when excluding both 
Clinic E and Clinic I. The exponential diagnostic plot showed that exponential was a good 
fit for the data (Appendix Figure A1B). The Weibull model is equivalent to the 
exponential model with an additional parameter that can be used to improve fit, thus 
both exponential and Weibull models fit the data well. The lognormal diagnostic plot 
showed that the lognormal distribution could fit the data, although the fit did not 
appear to be better than the exponential model. All parametric models appeared to 
over-predict failure for early time points of data (Appendix Figure A1C). By visual 
inspection of probability plots, the loglogistic distribution (Appendix Figure A1C) did not 
appear to improve model fit and was not used. The likelihoods for exponential, Weibull 
and lognormal models are listed in Appendix Table A1C. These models were run before 
imputing missing variables. Due to missing baseline CD4 values, only 76% 
(53,898/71,154) of subjects were included. Both the -2 log likelihood test to compare 
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Weibull to the exponential distribution and the Lagrange multiplier test (chi-square = 
180, df = 1, p<0.001) showed that the Weibull distribution offered improved fit over the 
exponential distribution. The log likelihood for the lognormal distribution was close to 
the log likelihood for the Weibull distribution, so the Weibull distribution was chosen to 
fit the models. 
 
Unadjusted Weibull Model 
 The Weibull model was first fit to non-imputed data. Creatinine clearance was 
considered as a predictor variable in a model only for patients initiating in 2011 through 
2013 to see if there was any association between creatinine and failure. Year, clinic, age, 
sex, NRTI, NNRTI, missed visits, CD4 count, BMI, WHO stage, hemoglobin, RBC, ALT, AST, 
blood pressure, TB, smoking, MCV and creatinine clearance were statistically significant 
predictors at p <0.2. Peripheral neuropathy, pregnancy and alcohol use at baseline were 
not associated with failure. Appendix Table A1D displays the unadjusted associations 
between predictor variables and time to failure.  
 
 The following trends in failure rate were observed:  
1. Year: The failure rate increased in later years for most sites, particularly in 
2010 through 2013, but was less pronounced for Clinic A. The HR for 
treatment failure in 2012 compared to 2014 was 1.83 (95% CI: 1.58, 2.12).   
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2. Age: The trend was similar across all sites, with youngest patients at greatest 
risk of failure. The HR for failure for patients age 30–35 years compared to 
patients age 18–25 years was 0.67 (95% CI: 0.60, 0.74). 
3. Sex: Males were at higher risk for failure, although this effect was not seen at 
Clinic E. In the entire population the HR for failure among males compared to 
females was 1.15 (95% CI: 1.10, 1.21), while at Clinic E, the HR for failure 
among males compared to females was 0.93 (95% CI: 0.85, 1.03). 
4. NRTI in first line regimen: It appeared as though TDF was associated with a 
greater risk of failure (HR for failure for patients on TDF compared to patients 
on d4T was 1.30 (95% CI: 1.23, 1.37)), however when controlling for year of 
ART initiation the association was no longer significant (HR = 0.95 (95% CI: 
0.88, 1.03)).  Due to the high correlation between NRTI and time, it appeared 
as though the effect of NRTI was due to trends over time only. 
5. NNRTI in first line regimen: The trend was similar across sites, with NVP 
associated with an increased rate of failure compared to EFV. The HR for 
failure for patients on NVP compared to EFV was 1.32 (95% CI: 1.24, 1.40). 
This association remained when controlling for year of ART initiation (HR 
adjusted for year was 1.35 (95% CI: 1.27, 1.43).  
6. CD4 count: Lowest CD4 counts were associated with the highest rates of 
treatment failure, especially for counts <100 cells/mL. The HR for failure was 
1.47 (95% CI: 1.34, 1.61) for patients with CD4 count <100 compared to 
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patients with CD4 count >250. Data at Clinic E was not consistent with this 
trend. 
7. BMI: Underweight patients generally had the highest rates of failure (HR for 
failure for underweight patients compared to normal weight was 1.13 (95% 
CI: 1.05, 1.22)), and overweight patients had lowest rates (HR for failure for 
obese patients compared to normal BMI was 0.82 (95% CI: 0.74, 0.91). 
However, this association was not seen at some clinics (Clinics B, C, D, and E). 
Lower BMI was likely a marker for sicker patients, because in adjusted 
models BMI was not a significant predictor of treatment failure. 
8. WHO stage: Lower WHO stage was associated with less failure, and this 
association was strongest at Clinic A. For patients with WHO stage 1–2 
compared to patients with WHO stage 3–4, the HR for failure was 0.88 (95% 
CI: 0.84, 0.93).  
9. Hemoglobin: The trend was similar across all sites. A value < 12 g/dL was 
associated with an increased rate of failure. For patients with hemoglobin 
<12 g/dL compared to patients with hemoglobin 12+ g/dL, the HR for failure 
was 1.18 (95% CI: 1.12, 1.25). Cut-offs at 8 and 10 were also considered, but 
a cut-off at 12 showed the greatest association with failure. 
10. MCV: Higher MCV was associated with higher risk of failure, although this 
varied somewhat by site. The HR for failure for patients with MCV 95+ fL/red 
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cell compared to patients with MCV <80 fL/red cell was 1.13 (95% CI 1.01, 
1.26). 
11. RBC: Higher RBC was associated with a lower risk of failure, although this 
varied somewhat by site. The HR for treatment failure for patients with RBC < 
4 million cells / microliter compared to patients with RBC 4+ million cells / 
microliter was 1.13 (95% CI: 1.06, 1.20).  
12. Creatinine clearance: Creatinine clearance was evaluated for patients 
initiating ART in 2011–2013 only. Low creatinine clearance was associated 
with increased failure at some sites, but the association was inconsistent and 
was not seen at Clinic A, the largest site. 
13. Blood pressure: Hypertension appeared to be associated with less failure in 
the unadjusted models. The hazard ratio for failure for patients with stage 2 
hypertension compared to patients with normal blood pressure was 0.75 
(95% CI: 0.67, 0.83). To see if high blood pressure was associated with 
reduced failure due to its association with high BMI, a model adjusted for 
BMI was also run. In the adjusted model, the association between high blood 
pressure and decreased failure was only slightly reduced. 
14. ALT: Elevated ALT was associated with increased failure (HR for patients with 
ALT levels 40+ U/L compared to <40 U/L was 1.08 (95% CI: 1.01, 1.16). This 
association was not seen at all sites. 
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15. AST: Elevated AST was associated with increased failure at Clinic A and Clinic 
G only (HR for patients with AST levels 40+ U/L compared to <40 U/L at Clinic 
A was 1.17 (95% CI: 1.06, 1.29). 
16. TB: History of TB was associated with increased failure overall (HR for failure 
for patients with history of TB compared to those without history of TB was 
1.16 (95% CI: 1.09, 1.24)), but there was no association in Clinic C, E and G. 
17. Peripheral neuropathy: No association with failure. There were very few 
subjects with peripheral neuropathy at baseline. 
18. Pregnancy: No association with failure. There were very few pregnant 
women in the sample. The largest site in the sample (Clinic A) refers out 
pregnant women. 
19. Alcohol history: The association between alcohol and treatment failure 
varied by site. 
20. Smoking: The association between smoking and treatment failure varied by 
site. At Clinic A, smoking was associated with increased failure. 
 
Multivariate Weibull Model 
Using piece-wise selection of baseline variables with a cut-off of p = 0.20, several 
potential predictors of treatment failure were identified. The final predictors before 
testing interactions included age, sex, missed visits during the first 6 months on 
treatment, TB history, NNRTI, CD4, MCV, and hemoglobin. NRTI was only significant 
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when time was left out of the model. 
Next, biologically plausible multiplicative interactions between predictors were 
tested, including: interactions between sex and all other predictors, interaction between 
hemoglobin and MCV (because high or low MCV can be an indicator of type of anemia), 
and interactions between CD4 count with age, hemoglobin, and NNRTI. Interactions 
between sex and age, sex and CD4 count, sex and hemoglobin, NNRTI (NVP vs. EFV) and 
CD4 count, and hemoglobin and CD4 count were statistically significant at p < 0.20. 
Interactions between NNRTI and CD4 count, hemoglobin and CD4 count, and between 
sex and CD4 count were included in the final Weibull non-imputed model (Table 9).  
 
Weibull Model with Multiple Imputation 
 The Weibull model was also fit to the imputed baseline data. The model 
developed using non-imputed data was run using the imputed data, and the hazards 
ratios developed from the imputed data were compared (Table 9). All variables 
remained statistically significant at p < 0.20 level, and the hazards ratios using imputed 
data were consistent with the non-imputed data. Other predictors and interactions 
between predictors were then added back into the model and kept if they had a p-value 
< 0.20.  Blood pressure was the only predictor variable that was statistically significant 
at p < 0.20 in the imputed model that was not a significant predictor in the non-imputed 
model. High blood pressure appeared to be associated with decreased failure. Inclusion 
of the BMI and blood pressure variables was tested in the cross-validation analysis. 
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Interaction terms between age and sex, sex and hemoglobin, and sex and NNRTI were 
statistically significant in the imputed model and were also included in the cross 
validation analysis. The first model tested in the cross validation analysis was the final 
Weibull model identified in piecewise selection using non-imputed data, and included 
the following predictors: age, sex, NNRTI, CD4, hemoglobin, MCV, missed visits in the 
first 6 months on ART, history of TB, an interaction between NNRTI and CD4, an 
interaction between CD4 and hemoglobin, and an interaction between sex and CD4. The 
following variations of the model were considered in the model cross validation 
analysis: 
• Exclude Clinic E and/or Clinic I 
• Adjust for year and clinic  
• Exclude MCV 
• Include BMI 
• Include blood pressure 
• Exclude interaction terms and test them individually 
• Include age and sex interaction 
• Include CD4 and sex interaction 
• Include NNRTI and sex interaction 
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Cross-validation of models 
 Each potential model was validated using the internal-external cross validation 
(IECV) procedure to see how it performed on independent data and to test the model’s 
ability to discriminate between patients not used in the development of the model. In 
total, 14 models were tested. The results of the IECV analysis are displayed in Table 10.  
Model 10 had the highest Harrell’s C statistic (at 60.1%) and one of the lowest 
differences in 5-year survival prediction. Although it did not have the lowest AIC score, 
model 10 was selected to be used in calculation of the predictive score. Model 10 
excluded Clinic I in the prediction of model parameters. The addition of BMI or blood 
pressure to the model and adjustments for year and clinic did not improve model 
discrimination or calibration.  
 
Survival Prediction  
 The transformed hazard ratio estimates from the final predictive model are 
displayed in Table 11. The Weibull model allows for calculation of the survivor function 
(89), through the model S(t) = exp{-[t*exp(-Bx)]^1/s}, where t = time, B = a vector of 
coefficients, x = a vector of covariate values, and s = the scale parameter estimated in 
the model. The survivor function was used to calculate survival estimates at 1, 2, 3, 4 
and 5 years on ART given an individual’s covariates at ART initiation.  
 The survival function was also used to create risk groups for ART failure based on 
predicted quintiles of risk of failure (low, medium-low, medium, medium-high, and high; 
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Table 12). Beta estimates from the models were used to directly calculate an individual’s 
predictive score for risk of failure. A simplified version of the prognostic score that can 
be calculated by hand is displayed in Table 13. Sex and age group, along with baseline 
CD4 count, were the most influential components of the risk score, with the highest 
magnitude parameter estimates. 
Figures 3 and 4 display actual failure for individuals in the study population by 
risk group in comparison to model prediction of failure by risk group. The model predicts 
that 24.4% of patients in the high-risk group will fail treatment in 5 years compared to 
9.4% of patients in the low risk group (Table 12). Figure 5 shows Kaplan-Meier estimates 
of failure on second line ART by risk group with confidence intervals over 6 years. The 
confidence intervals show very little overlap between the risk groups, particularly for 
the highest risk group. When comparing patients with a predicted risk in the lowest risk 
group compared to the highest risk group, the highest risk group had failure earlier than 
the lowest risk group 73% of the time.  
 
An interactive spreadsheet to calculate risk group from model parameters given a 
baseline profile will be available online. 
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Sensitivity analyses 
Competing risks  
 The unadjusted Kaplan-Meier curve of cumulative incidence of failure will over-
estimate the actual risk of failure on first-line over time, since it assumes that censored 
patients who have died or switched to second line are losses to follow-up with a 
theoretical future first line failure time. In a side-by-side comparison of a crude Kaplan-
Meier estimate of the cumulative incidence of failure over 5.5 years on ART and 
cumulative incidence of failure adjusting for death and switch to second line as 
competing risks, it is clear that they have minimal impact on the estimate of failure over 
time (Appendix Figure A1D). 
 
Censored subjects 
 Subjects were censored when they died, switched to second line treatment 
before first line failure, transferred to another clinic, or were lost to follow-up. 
Associations between predictor variables and study censoring are displayed in Appendix 
Table A1E. A higher rate of censoring due to death and switch to second line was 
associated with sicker patients who had lower CD4 counts (Table A1E). Conversely, 
censoring due to transfer to another clinic for care was not strongly related to any 
predictors, but the lowest CD4 count group was less likely to transfer to another clinic. 
The group that is lost to follow-up is a mixture of patients with different outcomes, 
including death, transfer or leaving care. A large proportion of these patients may have 
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died or gone off treatment (90), and thus loss to follow-up is also considered to be a 
negative outcome.  
 The goal of the predictive model is to predict treatment failure among patients 
who remain in care, not among patients who may experience treatment failure after 
leaving the clinic. Thus, sensitivity analyses considering losses to follow-up as failures 
were not done. Patients who transferred did not differ greatly from patients who 
remained in the study. Since transfers could be represented by the patients remaining in 
care, this group was also not included in sensitivity analyses.  
Since switching to second line typically requires documented virologic failure, 
patients who switched to second line before treatment failure might be undocumented 
cases of treatment failure or suspected failures. In sensitivity analyses, switches to 
second line were considered to be treatment failures at the date of second line switch. 
Among patients who had a recorded death, 59% (1973/3369) of patients died while still 
in care, and the remainder died after loss to follow-up. Although not all deaths were 
necessarily related to treatment failure, in sensitivity analyses patients who died while 
in care were considered to be treatment failures at the date of death. In summary, the 
following models were considered in sensitivity analyses: 
 Model 0. Unadjusted data (for comparison) 
 Model 1. Assuming that switch to second line before documented failure was 
date of failure 
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 Model 2. Assuming that date of death for patients who remained in care was 
date of failure 
 Model 3. Models 1 and 2 combined 
 
 Appendix Figure A1E shows unadjusted Kaplan-Meier curves for the sensitivity 
analyses models. Model 2, which accounted for deaths as failures, had very little impact 
on overall survival. However, model 1, which accounted for switches to second line ART 
as failures, resulted in a substantially higher rate of failure. To evaluate the impact of 
treatment switches as undocumented treatment failures, the beta estimates in the 
predictive model were re-run to include date of switch to second line as date of failure. 
The model accounting for switch to second line as failure had similar hazard ratios 
compared to the hazard ratios for predictor variables in the predictive model (Appendix 
Table A1F). Since the beta estimates did not differ greatly, discrimination between 
patients would not be affected. 
In the last sensitivity analysis where person time was defined as time in 
treatment with regular viral load measurements, and patients without a viral load for 
more than one year were censored, hazard ratios remained consistent with predictive 
model which bases person time on time in care. The hazard ratios for CD4 count, NVP 
use, MCV, TB, hemoglobin, sex and age were the same in the model using person time 
based on viral load, but the effect of missed visits was attenuated toward the null (the 
adjusted hazard ratio was 1.28 (95% CI: 1.21, 1.36) compared to 1.41 in the final 
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predictive model; Appendix Table A1G). Definition of person time based on time of lab 
values rather than time in clinic did not alter the factors predictive of treatment failure, 
and only the magnitude of the parameter estimate for the missed visits variable was 
lessened, likely because patients with many missed visits were censored because of 
their missed viral load measurements. 
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DISCUSSION 
 
Overview of results 
 Through 5 years on ART, 15% of the patient population experienced treatment 
failure, which is consistent with previous estimates of treatment failure in South Africa. 
For example, a long term ART program in Khayelitsha, Cape Town, that was not part of 
this study population, has reported 14% of patients failing ART in 5 years (21). The 
survival curves for treatment failure indicated that the hazards of failure were fairly 
constant over time, with no sharp drops or inclines. The scale parameter in the Weibull 
model was slightly greater than 1 (1.16), indicating that the hazards of failure showed a 
slight decrease over time, and suggesting that the need for regular viral load monitoring 
over time does not decrease. 
 At a population level, this model goes beyond other studies’ long-term estimates 
for treatment failure over time by providing a model that can estimate long term need 
for second line ART among specific sub-populations. For example, the model parameters 
can be used to calculate risk of failure using population averages. If everyone in the 
population began ART at a CD4 count <25 cells/mm3, failure over 5 years would be 
predicted to be 19%, assuming all other predictor variables were at the average values 
for the population in this study. If values of other variables remained constant but the 
population average CD4 count at initiation increased to 201 – 350 cells/mm3, the risk of 
treatment failure would drop to 10%. The model developed in this study can give an 
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absolute estimate for how need for second line ART would change with a change in 
parameters at first line initiation. The model would only apply to patients who remain in 
care, and not account for potential failures or deaths after loss from care. As CD4 counts 
at ART initiation increase over time with earlier ART initiation, we can expect that long 
term failure rates will decline. Since CD4 count was one of the strongest predictors of 
treatment failure, this study highlights the importance of early initiation on ART at 
higher CD4 counts in order to reduce treatment failure and limit need for second line 
ART. 
 At the individual level, this model can be used by clinicians to identify patients at 
highest risk for treatment failure. Thus, clinicians can effectively target adherence 
counseling and interventions early, before virologic indication of treatment failure. In 
addition to CD4 count, age and sex were very strong predictors of treatment failure, 
indicating that young adult patients and males may have the worst adherence and 
greatest need for adherence interventions. Other individual predictors of ART failure 
identified in the model are described below. The detection of patients at highest risk of 
failure allows for targeted interventions among the high risk group and/or increased 
treatment monitoring. Interventions for optimizing patient adherence, in addition to 
adherence counseling, include SMS reminders and other mHealth initiatives that are still 
being developed. A review of the literature of HIV adherence interventions concluded 
that there is still limited evidence to inform strategies to improve ART adherence in sub-
Saharan Africa (91). Ideally, these interventions would prevent elevated viral loads in 
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patients at high risk of failure, which would in turn limit accumulation of drug resistance 
mutations, poor clinical outcomes, and the need for more expensive second line drugs. 
 
Predictors of treatment failure 
 The final predictive model included age, sex, NNRTI on first line, baseline CD4 
count, mean corpuscular volume, hemoglobin, history of tuberculosis, missed visits in 
the first 6 months on treatment, and an interaction between age and sex. The relative 
importance of each predictor is clear when looking at the hand-calculated prognostic 
score, where value of the score is equivalent to the magnitude of the model parameter 
estimate (Table 13). Sex / age group and CD4 count were the most influential baseline 
factors, and hemoglobin and history of TB were the least influential. The interaction 
term between age and sex showed that all young patients were at highest risk of failure, 
particularly young women, but the risk of failure decreased more substantially with 
older age for women than it did for men. Male gender and younger age have been 
shown in previous studies to be associated with higher failure rates (14,44). 
 Other predictors in this model have also been shown to be associated with 
treatment failure in previous studies. The predictive model showed that higher risk of 
failure was associated with low CD4 counts, patients with history of TB, low hemoglobin, 
which have been associated with treatment failure and death in prior studies 
(14,21,23,24,25,44,45). Failure has also been seen more commonly among patients with 
nevirapine in their regimen rather than efavirenz previously (21,44,45). Although 
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associations with treatment outcomes and hemoglobin are commonly seen, MCV did 
not appear as a predictor of treatment failure in previous studies. A model excluding 
MCV was considered in the cross validation analysis, but including MCV in the model 
offered slightly better model discrimination. MCV can become elevated with AZT use 
over time on treatment, however when the predictive model was stratified by NRTI 
used in first line, the association between elevated MCV and failure remained consistent 
for all patients irrespective of their NRTI in first line. Possible reasons for the association 
between MCV and failure are that MCV is a marker for alcoholism, folic acid deficiency 
or vitamin B12 deficiency.  
 Although year was not included in the predictive model, when looking at year of 
initiation as an individual predictor of failure, there was evidence that failure rates have 
increased over time for most clinics. Adjusting model parameters for year did not 
improve the model’s predictive ability, however, if trends towards increasing treatment 
failure continue, the model may under-estimate the proportion of patients failing ART. 
The reason for increased failure over time may be due to poorer patient management 
with more patients in care, or may be due to differences in laboratory procedures for 
viral load testing. Similarly, if patient retention improves over time, more treatment 
failures may occur prior to loss to follow-up, in which case this model would also under-
estimate the absolute need for second line ART.  
 Clinic was also not included in the final predictive model but for comparison 
purposes, clinic was added to the final model to determine the relative influence of 
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clinic in predicting failure. To compare the scale of the parameter estimates, the 
estimates were transformed to the same scale as the hand-calculated prognostic score 
parameters. In the hand calculated score, most clinics would receive a score ranging 
from 0 to 2, with 2 clinics receiving a score of 3, and Clinic E would receive a score of 5. 
With the exception of Clinic E, the beta estimates for clinic were less strong than the 
estimates for CD4, age, sex, and missed visits, implying that those factors were more 
important in determining if a patient fails than which clinic they attend. Attendance at 
most clinics was about as influential in determining failure as hemoglobin, MCV or 
history of TB. These results indicated that clinic was not the most important indicator of 
failure, implying that a model without clinic included as a predictor is still useful, but 
that clinic did play an important role in determining an individual’s success on 
treatment. 
 
Model generalizability 
 The goal of the predictive risk model is for it to be applied to other clinic 
populations in South Africa, so it is important that the study population is representative 
of other South African patients in care. The patient population in this study is similar to 
other HIV cohorts reported in research from South Africa. For example, one other large 
HIV patient cohort in South Africa (59) reported baseline characteristics with 64.4% 
female, median age of 34 years, median baseline CD4 count of 97 cells/mm3, while our 
study population (65% female, median age 36 years, median baseline CD4 count of 123 
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cells/mm3). Yet, it is important to note that this study cohort along with other cohorts 
for which clinical data is available for research are likely better resourced than cohorts 
not reported on in the literature.  Additionally, this study cohort was comprised of 
mainly urban or semi-urban populations, with only 2 rural clinics (Clinic E and Clinic C).  
In this study, any patient who was initiated on ART but did not return to the 
clinic after 6 months past their ART initiation date, and thus did not complete their first 
virologic monitoring visit, was excluded because there was no way to detect if these 
patients had failed, and because the goal of the predictive model was to identify failure 
among patients who remained in care for clinical purposes. Patients who were excluded 
due to having less than 6 months in care were more likely to be males and were sicker 
than patients who returned for visits after 6 months, with respect to TB history, 
underweight BMI, and low CD4 counts at baseline (Table 3). Although this finding does 
not affect the predictive model because these patients do not experience treatment 
failure while in the clinic, it is otherwise important to know from a public health 
perspective that males and sicker patients may be less likely to return to the clinic after 
initiation of treatment. 
 
Model performance 
 Cross validation of the candidate models ensured that the chosen model would 
be most useful with respect to identifying patients at high risk of failure when applied to 
external data. Many interaction terms were statistically significant in the model initially, 
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but did not offer improved model discrimination or calibration when applied to external 
data, with the exception of the interaction term between age and sex.  
The ability of the model to discriminate failure times between individual patients 
(Harrell’s C statistic) was lower than expected (60.1%), but the model had good 
calibration, with a 5 year predictive risk equivalent to the actual failure at 5 years. Risk 
groups of patients could be identified and failure estimates from the model by risk 
group matched the actual failure by risk group over time. 
 
Study strengths, weaknesses & future direction 
The main weakness of the study is the low discrimination score for the predictive 
model. The C statistic of 60.1% implies that the model correctly identifies that a patient 
is at higher risk than another patient 60.1% of the time. The clinic attended by a patient 
does play a role in failure rate and could potentially improve model discrimination, but 
could not be included in a predictive model intended for external use. The low 
discrimination score also indicates that treatment failure is a complex event, likely 
having determinants based on individual behavior and external circumstances, and thus 
could not be very precisely identified through a model of baseline clinic, lab and 
demographic variables. 
Additionally, the quality of data was a weakness of the study. Due to missing 
predictor values, multiple imputation was used so all patients could be included in the 
predictive model. Missing outcomes due to missing viral load measurements could 
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occur, and in order to investigate the impact of missing viral loads, a sensitivity analysis 
was performed in which person time was defined as time in treatment with regular viral 
load measurements, and patients without a viral load for more than one year were 
censored. This sensitivity analysis showed that our inclusion of patients with missing 
viral loads over time did not affect the predictors of treatment failure, and that when 
patients with missing viral loads were censored the importance of missed visits as a 
predictor of treatment failure was lessened. It is also likely that, due to infrequent viral 
load monitoring, time of patient failure occurs slightly earlier than it is detected. Late 
detection of treatment failure would slightly underestimate absolute risk of failure at 
each time point, but would not change risk group prediction. 
Lastly, a potential weakness of the model is that it may under-estimate absolute 
risk of failure. If failure rate is truly increasing in recent years, the 5 year estimate of 
failure for patients currently initiated on ART may be higher than the model predicts. 
Additionally, in sensitivity analyses, the failure rate was increased by about 5% over 5 
years when switches to second line ART without documented treatment failure were 
considered to be failures. However, this finding was not a major concern because the 
failure rate identified in the study was consistent with previously published studies in 
South Africa.  
The main strength of the model developed in this study is its ability to provide 
insight into the factors associated with risk of treatment failure and their relative 
influence, and to identify risk groups of patients who are most likely to fail. The model 
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also very closely mirrored actual failure rates over 5 years. The model allows for 
prediction of failure over 5 years and need for second line ART among specific 
populations initiating HIV treatment. Practically, the identification of high risk groups for 
treatment failure also has an important application in clinical settings, where patients 
who are at high risk of failing can be monitored more closely and receive treatment 
adherence counseling or other interventions. Both the hand calculator and interactive 
excel sheet can help identify patients at risk of failure.  
The large sample size was also a strength of this study. Analyses included 9 clinic 
sites from across South Africa, which allowed for modeling of interaction terms in the 
predictive model, and through the cross validation procedure, only terms that improved 
the ability to discriminate between failing patients were included in the final model. 
The current study is useful for individual prediction of risk and estimation of 
need of second line over time among patients in care. Future work should expand the 
model to account for patients who are lost for care. Estimating outcomes for all patients 
regardless of whether or not they stay in care would be helpful for public health 
planning. Additionally, further research into best practices for ART adherence 
interventions and adherence counseling is an important next step in order to effectively 
improve outcomes using the model’s identification of patients at highest risk of failure. 
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STUDY 1 TABLES & FIGURES 
 
Table 2. Subjects included in study 1, among all treatment naïve adults. 
  
Included in 
study 
(N, %) 
Less than 6 
months on 
ART (N, %) 
Error in visit 
dates or 
initiation 
date (N, %) 
ART started 
before 
2004 (N, %) Total 
Clinic A 20623 4376 138 210 25347 
81.36 17.26 0.54 0.83   
Clinic B 8714 2259 6 26 11005 
79.18 20.53 0.05 0.24   
Clinic C 4937 1144 5 11 6097 
80.97 18.76 0.08 0.18   
Clinic D 6290 920 7 5 7222 
87.09 12.74 0.1 0.07   
Clinic E 7420 1647 1 9 9077 
81.75 18.14 0.01 0.1   
Clinic F 8055 2772 4 31 10862 
74.16 25.52 0.04 0.29   
Clinic G 3998 768 1 6 4773 
83.76 16.09 0.02 0.13   
Clinic H 10721 1366 3 14 12104 
88.57 11.29 0.02 0.12   
Clinic I 1423 252 16 127 1818 
78.27 13.86 0.88 6.99   
Total 72181 15504 181 439 88305 
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Table 3. Differences between study population and those 
excluded due to short follow-up time. 
  
Included in 
analysis 
Excluded because 
patient did not 
return to clinic for 
viral load testing 
Female (%) 65.3 58.9 
Age category (%)     
< 25 7.0 7.6 
25–29.9 16.8 16.3 
30–34.9 23.1 21.3 
35–39.9 20.0 20.0 
40–44.9 14.1 14.3 
45–49.9 9.2 8.5 
50–54.9 5.3 5.8 
55+ 4.5 6.2 
TB at baseline (%) 14.8 18.2 
BMI (%)     
Underweight 17.0 27.7 
Normal 56.3 52.9 
Overweight 17.9 13.1 
Obese 8.8 6.3 
CD4 count at baseline (%)     
0–25 13.1 22.4 
25–50 10.5 14.1 
51–100 18.8 19.0 
101–200 37.8 27.0 
201–350 16.1 14.0 
>350 3.8 3.5 
Hemoglobin <10 (%) 25.4 40.7 
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Table 4. Outcomes at the end of follow-up time. 
  Frequency Percent Months to event  (median; IQR) 
Treatment failure 6889 9.54 13.6 (5.1, 28.6) 
Death 3431 4.75 11.8 (4.4, 26.1) 
Switch to second line 2504 3.47 18.9 (1.8, 36.6) 
Lost to follow-up 14220 19.7 14.5 (5.6, 29.3) 
Transfer 18098 25.07 20.1 (8.7, 37.6) 
Study end 27039 37.46 34.5 (16.8, 55.4) 
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Table 5. Percent of missing data for select predictor variables at baseline by clinic. 
Clinic CD4 Hemoglobin BMI 
A 15.7% 15.7% 20.3% 
B 24.8% 16.8% 27.4% 
C 19.3% 21.5% 34.8% 
D 31.6% 45.1% 64.4% 
E 22.4% 51.3% 35.9% 
F 34.5% 26.0% 27.8% 
G 33.1% 43.8% 52.3% 
H 28.3% 25.8% 56.5% 
I 29.9% 43.4% 66.5% 
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Table 6. Predictor variable values at ART initiation for all clinics. 
Baseline variable: Frequency Percent 
Female 46215 65.0 
Age     
< 25 4311 6.1 
25–29.9 11363 16.0 
30–34.9 16140 22.7 
35–39.9 14932 21.0 
40–44.9 10454 14.7 
45–49.9 6835 9.6 
50–54.9 3901 5.5 
55+ 3218 4.5 
Year of initiation     
2004 2009 2.8 
2005 3982 5.6 
2006 6574 9.2 
2007 7218 10.1 
2008 9426 13.3 
2009 11196 15.7 
2010 11104 15.6 
2011 8704 12.2 
2012 7257 10.2 
2013 3684 5.2 
TB positive 10477 14.7 
Peripheral neuropathy 1129 1.6 
History of alcohol use 4246 6.0 
History of smoking 3966 5.6 
Pregnant 2650 3.7 
NRTI in first line regimen     
TDF 24055 33.8 
AZT 4321 6.1 
D4T 42778 60.1 
NNRTI in first line regimen     
EFV 61791 86.8 
NVP 9363 13.2 
Missed visits in first 6 months on 
treatment     
Yes 16273 22.9 
No 54881 77.1 
WHO stage     
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Stage I 51355 72.2 
Stage II 933 1.3 
Stage III 15102 21.2 
Stage IV 3764 5.3 
BMI     
< 18.5 7737 10.9 
18.5–24.9 29688 41.7 
25–29.9 10522 14.8 
30 and up 5527 7.8 
Missing 17680 24.8 
CD4 count     
0–25 6673 9.4 
25–50 5392 7.6 
51–100 9610 13.5 
101–200 19032 26.7 
201–350 10707 15.0 
>350 2519 3.5 
Missing 17221 24.2 
Hemoglobin     
<10 11723 16.4 
>10 40059 56.2 
Missing 19372 27.2 
ALT     
<40 40243 56.5 
>40 9397 13.2 
Missing 21514 30.2 
AST     
<40 19896 27.9 
>40 11684 16.4 
Missing 39574 55.5 
TLC     
0–3.2 591 0.8 
3.2–8.1 5445 7.6 
8.1+ 896 1.3 
Missing 64222 90.1 
MCV     
<80 6707 9.4 
80–95 33196 46.6 
95+ 7924 11.1 
Missing 23327 32.7 
RBC     
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<4 19928 28.0 
4+ 25477 35.7 
Missing 25749 36.1 
Creatinine serum     
0 – 0.55 5254 7.4 
0.55–1.15 27323 38.3 
1.15+ 2215 3.1 
Missing 36362 51.0 
Creatinine clearance     
Severe (<30) 531 0.7 
Moderate (30–59) 1452 2.0 
Mild (60–89) 5725 8.0 
Normal (>=90) 24680 34.6 
Missing 38766 54.4 
Blood pressure     
Low 597 0.8 
Normal 19797 27.8 
Borderline high 18071 25.4 
Stage 1 hypertension 9016 12.6 
Stage 2 hypertension 4866 6.8 
Missing 18807 26.4 
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Table 7. Distribution of imputed missing variables after imputation. 
  Non-imputed Imputed 
Baseline variable: 
Percent among 
non-missing Percent 
BMI     
< 18.5 14.5 14.8 
18.5–24.9 55.5 53.6 
25–29.9 19.7 21.4 
30 and up 10.3 10.3 
CD4 count     
0–25 12.4 12.5 
25–50 10.0 11.5 
51–100 17.8 18.9 
101–200 35.3 32.5 
201–350 19.9 18.1 
>350 4.7 6.6 
Hemoglobin     
<10 22.6 23.0 
>10 77.4 77.0 
ALT     
<40 81.1 80.7 
>40 18.9 19.3 
MCV     
<80 14.0 15.4 
80–95 69.4 66.1 
95+ 16.6 18.5 
RBC     
<4 43.9 44.8 
4+ 56.1 55.2 
Blood pressure     
Low 1.1 1.8 
Normal 37.8 37.3 
Borderline high 34.5 34.4 
Stage 1 
hypertension 
17.2 17.8 
Stage 2 
hypertension 
9.3 8.8 
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Table 8. Study outcomes at the end of follow-up stratified by year of initiation. 
 
 
  
Outcome (N, %) 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Total 
Failure 264 519 682 703 868 980 926 593 300 21 5856 
13.1 13.0 10.4 9.7 9.2 8.8 8.3 6.8 4.1 0.6   
Death 196 389 627 553 561 472 346 162 59 4 3369 
9.8 9.8 9.5 7.7 6.0 4.2 3.1 1.9 0.8 0.1   
Switch to second 
line 
177 267 377 359 455 494 394 254 110 13 2900 
8.8 6.7 5.7 5.0 4.8 4.4 3.6 2.9 1.5 0.4   
Lost to follow-up 380 800 1348 1497 1975 2546 2465 1769 1225 320 14325 
18.9 20.1 20.5 20.7 21.0 22.7 22.2 20.3 16.9 8.7   
Transfer 602 1281 2348 2468 3164 3155 2595 1330 629 96 17668 
30.0 32.2 35.7 34.2 33.6 28.2 23.4 15.3 8.7 2.6   
Alive and in care 390 726 1192 1638 2403 3549 4378 4596 4934 3230 27036 
19.4 18.2 18.1 22.7 25.5 31.7 39.4 52.8 68.0 87.7   
Total 2009 3982 6574 7218 9426 11196 11104 8704 7257 3684 71154 
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Table 9. Adjusted Weibull model predictors using non-imputed and imputed data.  
Parameter   Estimate 95% Confidence Limits p-value HR 
Imputed 
HR 
Intercept     8.915 8.747 9.084 <.0001   
Age < 25   -0.442 -0.600 -0.284 <.0001 1.45 1.47 
  25–29.9   -0.229 -0.342 -0.115 <.0001 1.21 1.19 
  30–34.9   0.000 . . . Ref  
  35–39.9   0.128 0.020 0.237 0.020 0.90 0.89 
  40–44.9   0.196 0.073 0.319 0.002 0.85 0.87 
  45–49.9   0.247 0.101 0.393 0.001 0.81 0.84 
  50–54.9   0.160 -0.018 0.338 0.079 0.87 0.81 
  55+   0.373 0.160 0.586 0.001 0.73 0.78 
Sex Male   -0.3484 -0.4932 -0.2036 <.0001 1.34 1.25 
  Female   0.000 . . . Ref  
NNRTI NVP   -0.230 -0.427 -0.033 0.022 1.22 1.26 
  EFV   0.000 . . . Ref  
CD4 count 0–25   -1.001 -1.225 -0.777 <.0001 2.34 1.97 
  25–50   -0.851 -1.101 -0.601 <.0001 2.06 1.49 
  51–100   -0.609 -0.819 -0.399 <.0001 1.68 1.33 
  101–200   0.000 . . . Ref  
  201–350   0.146 -0.085 0.377 0.216 0.88 0.88 
  >350   0.251 -0.136 0.637 0.204 0.81 0.70 
Hemoglobin <12   -0.362 -0.502 -0.222 <.0001 1.36 1.17 
  12+   0.000 . . . Ref  
MCV <80   0.000 . . . Ref  
  80–95   -0.161 -0.272 -0.049 0.005 1.15 1.13 
  95+   -0.335 -0.474 -0.195 <.0001 1.33 1.24 
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Missed visits in first 6 
months on ART Yes   -0.349 -0.430 -0.267 <.0001 1.34 1.42 
 No   0.000 . . . Ref  
History of TB Positive   -0.093 -0.184 -0.002 0.045 1.08 1.08 
  Negative   0.000 . . . Ref  
NNRTI*CD4 NVP 0–25 -0.689 -1.007 -0.371 <.0001 1.79 1.31 
  NVP 25–50 -0.194 -0.574 0.186 0.316 1.18 1.09 
  NVP 51–100 -0.178 -0.493 0.137 0.268 1.16 1.03 
  NVP 101–200 0.000 . . . Ref  
  NVP 201–350 -0.018 -0.363 0.327 0.918 1.02 1.02 
  NVP >350 0.418 -0.207 1.043 0.190 0.70 1.01 
  EFV 0–25 0.000 . . . Ref  
  EFV 25–50 0.000 . . . Ref  
  EFV 51–100 0.000 . . . Ref  
  EFV 101–200 0.000 . . . Ref  
  EFV 201–350 0.000 . . . Ref  
  EFV >350 0.000 . . . Ref  
CD4*Hemoglobin 0–25 <12 0.542 0.317 0.766 <.0001 0.63 0.72 
  0–25 12+ 0.000 . . . Ref  
  25–50 <12 0.421 0.166 0.677 0.001 0.70 0.93 
  25–50 12+ 0.000 . . . Ref  
  51–100 <12 0.479 0.259 0.698 <.0001 0.67 0.80 
  51–100 12+ 0.000 . . . Ref  
  101–200 <12 0.000 . . . Ref  
  101–200 12+ 0.000 . . . Ref  
  201–350 <12 0.013 -0.246 0.273 0.920 0.99 1.01 
  201–350 12+ 0.000 . . . Ref  
  >350 <12 0.206 -0.308 0.720 0.432 0.84 0.95 
  >350 12+ 0.000 . . . Ref  
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Sex*CD4 Male 0–25 0.280 0.060 0.501 0.013 0.79 0.85 
  Male 25–50 0.355 0.105 0.605 0.005 0.74 0.87 
  Male 51–100 0.175 -0.048 0.397 0.124 0.86 0.96 
  Male 101–200 0.000 . .   Ref  
  Male 201–350 0.004 -0.272 0.281 0.976 1.00 0.97 
  Male >350 -0.394 -0.881 0.094 0.114 1.40 1.28 
  Female 0–25 0 . .   Ref  
  Female 25–50 0 . .   Ref  
  Female 51–100 0 . .   Ref  
  Female 101–200 0 . .   Ref  
  Female 201–350 0 . .   Ref  
  Female >350 0 . .   Ref  
Scale     1.179 1.149 1.210     
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Table 10. Results from the internal-external cross validation of candidate models. 
Model 
number Predictors AIC 
Harrell's 
C 
statistic 
Difference 
in 5 year 
survival 
prediction 
from actual 
survival 
Predicted 
5 year 
survival 
Actual 5 
year 
survival 
1 Age, sex, NNRTI, CD4, hemoglobin, MCV, missed 
visits, history of TB, interaction between NNRTI 
and CD4, interaction between CD4 and 
hemoglobin, interaction between sex and CD4 
57105.97 59.1 -0.1%     
  Clinic I   54.6 -3.5% 85.7% 89.2% 
  Clinic H    60.5 -2.3% 83.7% 86.0% 
  Clinic G    57.3 0.0% 83.8% 83.8% 
  Clinic F    56.2 -1.9% 83.8% 85.7% 
  Clinic E    61.4 8.1% 83.8% 75.7% 
  Clinic D    56.3 -2.3% 83.4% 85.7% 
  Clinic C    60.0 -3.2% 83.3% 86.5% 
  Clinic B   54.8 2.2% 86.3% 84.1% 
  Clinic A     61.7 -0.6% 83.7% 84.4% 
2 Model 1 with no interactions 57121.66 59.9 0.0%   
  Clinic I   53.8 -3.0% 86.3% 89.2% 
  Clinic H    61.7 -2.3% 83.7% 86.0% 
  Clinic G    59.1 0.6% 84.3% 83.8% 
  Clinic F    57.5 -1.6% 84.1% 85.7% 
  Clinic E    62.4 8.7% 84.4% 75.7% 
  Clinic D    59.1 -1.8% 84.0% 85.7% 
  Clinic C    61.6 -2.8% 83.7% 86.5% 
  Clinic B   59.3 1.1% 85.2% 84.1% 
  Clinic A     59.6 -0.3% 84.0% 84.4% 
3 Model 2 with sex*cd4 interaction 57117.53 59.9 0.0%   
  Clinic I   54.8 -3.0% 86.2% 89.2% 
  Clinic H    61.6 -2.3% 83.7% 86.0% 
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  Clinic G    58.8 0.6% 84.3% 83.8% 
  Clinic F    57.7 -1.6% 84.1% 85.7% 
  Clinic E    62.2 8.7% 84.4% 75.7% 
  Clinic D    59.3 -1.8% 84.0% 85.7% 
  Clinic C    61.8 -2.8% 83.7% 86.5% 
  Clinic B   59.0 1.1% 85.2% 84.1% 
  Clinic A     59.7 -0.3% 84.1% 84.4% 
4 Model 2 with hemoglobin*CD4 interaction 57112.47 58.6 0.0%   
  Clinic I   53.0 -3.3% 85.9% 89.2% 
  Clinic H    60.8 -2.1% 83.9% 86.0% 
  Clinic G    58.1 0.2% 84.0% 83.8% 
  Clinic F    56.4 -1.8% 83.9% 85.7% 
  Clinic E    61.0 8.2% 83.8% 75.7% 
  Clinic D    56.5 -2.3% 83.5% 85.7% 
  Clinic C    60.4 -3.1% 83.4% 86.5% 
  Clinic B   58.6 0.4% 84.6% 84.1% 
  Clinic A     58.0 0.5% 84.9% 84.4% 
5 Model 2 with NNRTI*CD4 interaction 57118.61 59.9 0.0%   
  Clinic I   53.9 -2.9% 86.3% 89.2% 
  Clinic H    61.6 -2.3% 83.7% 86.0% 
  Clinic G    59.2 0.6% 84.3% 83.8% 
  Clinic F    57.5 -1.6% 84.1% 85.7% 
  Clinic E    61.9 8.7% 84.4% 75.7% 
  Clinic D    59.2 -1.7% 84.0% 85.7% 
  Clinic C    61.6 -2.8% 83.7% 86.5% 
  Clinic B   59.3 1.0% 85.2% 84.1% 
  Clinic A     59.7 -0.3% 84.1% 84.4% 
6 Model 2 with age*sex interaction 57112.19 60.0 0.0%   
  Clinic I   54.4 -3.1% 86.2% 89.2% 
  Clinic H    62.1 -2.3% 83.7% 86.0% 
  Clinic G    58.9 0.5% 84.3% 83.8% 
  Clinic F    57.7 -1.7% 84.1% 85.7% 
  Clinic E    62.4 8.7% 84.4% 75.7% 
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  Clinic D    59.2 -1.8% 83.9% 85.7% 
  Clinic C    61.7 -2.8% 83.7% 86.5% 
  Clinic B   59.2 1.0% 85.2% 84.1% 
  Clinic A     59.6 -0.3% 84.0% 84.4% 
7 Model 2 with CD4*sex interaction 57117.53 59.9 0.0%   
  Clinic I   54.9 -3.0% 86.2% 89.2% 
  Clinic H    61.6 -2.3% 83.7% 86.0% 
  Clinic G    58.8 0.6% 84.3% 83.8% 
  Clinic F    57.7 -1.6% 84.1% 85.7% 
  Clinic E    62.2 8.7% 84.4% 75.7% 
  Clinic D    59.3 -1.8% 84.0% 85.7% 
  Clinic C    61.8 -2.8% 83.8% 86.5% 
  Clinic B   59.0 1.1% 85.2% 84.1% 
  Clinic A     59.7 -0.3% 84.1% 84.4% 
8 Model 2 with NNRTI*sex interaction 57121.81 59.9 0.0%   
  Clinic I   53.9 -3.0% 86.3% 89.2% 
  Clinic H    61.7 -2.3% 83.7% 86.0% 
  Clinic G    59.1 0.6% 84.3% 83.8% 
  Clinic F    57.5 -1.6% 84.1% 85.7% 
  Clinic E    62.4 8.7% 84.4% 75.7% 
  Clinic D    59.0 -1.8% 83.9% 85.7% 
  Clinic C    61.5 -2.8% 83.8% 86.5% 
  Clinic B   59.3 1.1% 85.2% 84.1% 
  Clinic A     59.6 -0.3% 84.1% 84.4% 
9 Model 6 adjusting for year and clinic 56680.61 59.9 3.8%   
  Clinic I   54.2 0.3% 89.5% 89.2% 
  Clinic H    62.1 1.5% 87.5% 86.0% 
  Clinic G    59.3 3.8% 87.6% 83.8% 
  Clinic F    57.7 1.4% 87.1% 85.7% 
  Clinic E    62.0 11.6% 87.3% 75.7% 
  Clinic D    59.4 1.5% 87.2% 85.7% 
  Clinic C    61.4 1.2% 87.7% 86.5% 
  Clinic B   59.0 4.0% 88.2% 84.1% 
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  Clinic A     59.5 4.6% 89.0% 84.4% 
10 Model 6 excluding Clinic I 56160.08 60.1 0.0%   
  Clinic H    62.1 -2.4% 83.6% 86.0% 
  Clinic G    58.9 0.4% 84.2% 83.8% 
  Clinic F    57.7 -1.7% 84.0% 85.7% 
  Clinic E    62.4 8.7% 84.3% 75.7% 
  Clinic D    59.1 -1.9% 83.8% 85.7% 
  Clinic C    61.7 -2.9% 83.7% 86.5% 
  Clinic B   59.1 1.0% 85.1% 84.1% 
  Clinic A     59.6 -0.4% 84.0% 84.4% 
11 Model 6 excluding Clinic E 52516.03 59.7 -0.4%   
  Clinic I    54.6 -2.5% 86.7% 89.2% 
  Clinic H    61.9 -1.8% 84.3% 86.0% 
  Clinic G    59.2 1.1% 84.9% 83.8% 
  Clinic F    57.9 -1.2% 84.5% 85.7% 
  Clinic D    59.6 -1.2% 84.6% 85.7% 
  Clinic C    61.8 -2.4% 84.1% 86.5% 
  Clinic B   59.2 1.6% 85.7% 84.1% 
  Clinic A     59.6 0.4% 84.8% 84.4% 
12 Model 10 without MCV 56186.79 59.9 0.0%   
  Clinic H    61.9 -2.3% 83.7% 86.0% 
  Clinic G    58.5 0.5% 84.3% 83.8% 
  Clinic F    57.5 -1.7% 84.0% 85.7% 
  Clinic E    62.4 8.6% 84.3% 75.7% 
  Clinic D    58.7 -2.0% 83.8% 85.7% 
  Clinic C    61.8 -3.0% 83.5% 86.5% 
  Clinic B   58.9 1.0% 85.1% 84.1% 
  Clinic A     59.4 -0.3% 84.1% 84.4% 
13 Model 10 with blood pressure 56156.95 60.1 0.0%   
  Clinic H    62.1 -2.4% 83.7% 86.0% 
  Clinic G    58.9 0.5% 84.3% 83.8% 
  Clinic F    57.7 -1.6% 84.1% 85.7% 
  Clinic E    62.3 8.5% 84.2% 75.7% 
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  Clinic D    59.0 -1.9% 83.8% 85.7% 
  Clinic C    61.9 -2.8% 83.7% 86.5% 
  Clinic B   59.2 1.0% 85.1% 84.1% 
  Clinic A     59.6 -0.4% 84.0% 84.4% 
14 Model 10 with BMI 56161.77 57.7 1.5%   
  Clinic H    60.1 -1.3% 84.8% 86.0% 
  Clinic G    55.7 1.7% 85.5% 83.8% 
  Clinic F    54.1 0.1% 85.8% 85.7% 
  Clinic E    60.6 10.1% 85.8% 75.7% 
  Clinic D    57.5 -0.5% 85.2% 85.7% 
  Clinic C    58.0 -0.6% 85.9% 86.5% 
  Clinic B   57.6 1.8% 85.9% 84.1% 
  Clinic A     57.0 1.4% 85.8% 84.4% 
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Table 11. Final predictive model estimates. 
Variable   Estimate 95% Confidence Limits p-value HR 
Intercept  9.97 9.83 10.11 <.0001 
 Age 18–24.9 -0.45 -0.58 -0.32 <.0001 1.47 
  25–29.9 -0.23 -0.33 -0.13 <.0001 1.22 
  30–34.9 0.00 . . . Ref 
  35–39.9 0.20 0.09 0.31 0.000 0.84 
  40–44.9 0.25 0.12 0.38 0.000 0.80 
  45–49.9 0.34 0.19 0.50 <.0001 0.74 
  50–54.9 0.29 0.10 0.49 0.004 0.78 
  55+ 0.36 0.13 0.59 0.003 0.73 
Sex Male -0.14 -0.26 -0.01 0.028 1.12 
  Female 0.00 . . . Ref 
NNRTI NVP -0.33 -0.41 -0.25 <.0001 1.33 
  EFV 0.00 . . . Ref 
CD4 count 0–25 -0.63 -0.73 -0.54 <.0001 1.73 
  25–50 -0.40 -0.50 -0.30 <.0001 1.41 
  51–100 -0.26 -0.35 -0.17 <.0001 1.25 
  101–200 0.00 . . . Ref 
  201–350 0.16 0.05 0.27 0.006 0.87 
  >350 0.37 0.15 0.59 0.002 0.73 
MCV <80 0.00 . . . Ref 
  80–95 -0.15 -0.24 -0.06 0.002 1.14 
  95+ -0.28 -0.41 -0.14 0.000 1.27 
Hemoglobin <12 -0.11 -0.18 -0.04 0.001 1.10 
  12+ 0.00 . . . Ref 
History of TB Yes -0.06 -0.13 0.02 0.131 1.05 
  No 0.00 . . . Ref 
Missed visits Yes -0.40 -0.46 -0.33 <.0001 1.41 
  No 0.00 . . . Ref 
Sex*age Female & 18–25 0.00 . . . Ref 
  Female & 25–30 0.00 . . . Ref 
  Female & 30–35 0.00 . . . Ref 
  Female & 35–40 0.00 . . . Ref 
  Female & 40–45 0.00 . . . Ref 
  Female & 45–50 0.00 . . . Ref 
  Female & 50–55 0.00 . . . Ref 
  Female & >55 0.00 . . . Ref 
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  Male & 18–25 0.20 -0.12 0.53 0.224 0.84 
  Male & 25–30 0.15 -0.05 0.35 0.144 0.88 
  Male & 30–35 0.00 . . . Ref 
  Male & 35–40 -0.14 -0.31 0.03 0.099 1.13 
  Male & 40–45 -0.19 -0.38 0.00 0.048 1.18 
  Male & 45–50 -0.33 -0.55 -0.10 0.004 1.33 
  Male & 50–55 -0.12 -0.41 0.16 0.393 1.11 
  Male & >55 -0.17 -0.49 0.16 0.314 1.16 
Scale   1.16         
 
 
 
 
 
 
 
Table 12. Percent of patients predicted to fail treatment over each year on ART. 
 
Risk group 
Range for the 
summation of model 
beta estimates 
Years on ART 
1 2 3 4 5 
High <9.105 3.8% 10.1% 15.4% 20.1% 24.4% 
Medium-
high 
9.105 – 9.382 
2.7% 7.3% 11.2% 14.7% 18.0% 
Medium 9.838 – 9.625 2.2% 5.9% 9.1% 12.1% 14.8% 
Medium-
low 
9.626 – 9.866 
1.8% 4.9% 7.5% 10.0% 12.3% 
Low >9.866 1.4% 3.7% 5.7% 7.6% 9.4% 
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Table 13. Approximation of risk group score based on final model parameters. Score is 
calculated by adding points in each category 1–7 for an individual’s baseline profile. 
Score calculation     
 
Score Risk group 
1. Sex & age:     
 
>17 High 
Females: Age:   
 
 14–17 Medium-high 
  18–24.9 +8 
 
 12–13 Middle 
  25–29.9 +6 
 
 9–11 Medium-low 
  30–34.9 +4 
 
 0–8 Low 
  35–39.9 +2 
     40–44.9 +1 
     45+ +0 
   Males: Age:   
     18–24.9 +7 
     25–29.9 +6 
     30–34.9 +5 
     35–49.9 +4 
     50+ +3 
         
   2. NNRTI: NVP +3 
     EFV +0 
         
   3. CD4 count: 0–25 +10 
     25–50 +8 
     51–100 +6 
     101–200 +4 
     201–350 +2 
     >350 +0 
         
   4. MCV: <80 +0 
     80–95 +1 
     95+ +3 
         
   5. Hemoglobin: <12 +1 
     12+ +0 
         
   6. History of TB: Yes +1 
     No +0 
         
   7. Missed visits during first 6 
months on treatment: 
Yes +4 
   No +0 
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Figure 1. Kaplan-Meier curve for overall survival over 5.5 years of follow-up.  
 
 
 
Figure 2. Kaplan-Meier curve showing survival stratified by clinic. 
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Figure 3. Actual failure over time by risk group for all individuals in study population. 
 
 
 
Figure 4. Predicted failure over time by risk group for all individuals in study population. 
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Figure 5. Confidence intervals surrounding risk group for the study population. 
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STUDY 2: EFFECT OF DELAYS IN SECOND LINE TREATMENT INITIATION ON SECOND 
LINE OUTCOMES 
 
OBJECTIVE 
While according to national treatment guidelines switch to second line ART 
should occur as soon as two consecutive failing viral loads on first line ART are detected, 
in practice many patients are switched late or not at all (92). Previous studies have 
shown that switch to second line occurs most quickly among patients who have contact 
with the clinic in the 4 months prior to switch, patients with high viral load, low CD4 
count, and that rates of switching differed by clinic, likely due to different interpretation 
of treatment guidelines (93). Clinicians may also be reluctant to switch patients who are 
clinically well to second line ART, due to the cost and lack of possible future regimens 
(92,94).  
Studies have emphasized, since protease inhibitor based second line regimens 
can resuppress HIV even in the presence of drug resistance mutations, that it is 
preferable to be sure that a patient is failing due to drug resistance and not adherence 
problems to avoid unnecessary switches to second line ART (41,63). One study found 
that during the first 6 months of viremia, accumulation of TAMs was minimal, and 
suggested waiting 3 to 6 months before switching to second line to make sure a patient 
did not resuppress (63). Yet, there is also concern that delaying second line ART and 
leaving patients on treatment with long periods of viremia could be detrimental to 
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second line regimen activity (55,56,92,95). NRTI resistance mutations accumulate more 
rapidly among sick and failing patients (36,31,95,96), and a meta-analysis of time to 
switch to second line ART has suggested that the current rate of switch to second line 
ART in sub-Saharan Africa is too slow given the amount of drug resistance mutations 
that accumulate over time on failing regimens (92). 
The objective of this study is to explore the impact of delaying second line ART 
initiation after first line treatment failure on rates of virologic failure over multiple years 
on second line ART. Research has shown that delays in switching could be associated 
with poorer outcomes on second line with the accumulation of NRTI resistance 
mutations and potentially substantial decline in CD4 count. Alternatively, worse 
outcomes on second line ART could be explained by physicians deciding to switch non-
adherent patients later, and these patients may continue to have poor adherence on 
second line. The importance of how soon after first line failure switching to second line 
occurs and the actual impact of a delay in switch on second line activity is not well 
understood. We will explore possible reasons for delays in second line ART and impacts 
of these delays on death and virologic failure after second line.  
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METHODS 
 
Data source and study population 
This study is a retrospective analysis of an observational cohort using 
prospectively collected routine medical record data. This study uses the same data 
source as study 1, the Right to Care HIV treatment cohort, which is a compilation of 
clinical HIV treatment cohorts from nine HIV clinics across South Africa. 
The population for this study included adult patients (≥ 18 years old) who were 
treatment naïve and started on a standard first line ART regimen in 2004 or later, and 
had documented confirmed virologic failure of first line ART. As in study 1, a standard 
first line regimen was defined as two nucleoside reverse transcriptase inhibitors (NRTIs) 
(either stavudine (d4T), zidovudine (AZT) or tenofovir (TDF) plus lamivudine (3TC) or 
emtricitabine (FTC)) and one non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
(either efavirenz (EFV) or nevirapine (NVP)). Failure on first line ART was defined as two 
consecutive failing viral load values >1,000 copies/mL between two weeks and 12 
months apart, any time after the first three months on first line ART. Patients who 
switched to a second line regimen before failing treatment were excluded in all 
analyses. Treatment interruptions and switches to regimens that were not second line 
regimens were ignored. All patients had to have at least one year of potential follow-up 
time after first line failure, to allow for time to switch to second line. The dataset closed 
in April 2014, so all subjects had failure dates that occurred before April 2013.  
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Study variables 
Exposure 
 The exposure of interest is time from first line failure until initiation of a second 
line regimen. Switch to a second line regimen was defined as initiation of a new NRTI 
not present in the regimen the patient was on at the time of treatment failure, plus the 
addition of a protease inhibitor (PI). Time was categorized into intervals (<1.5 months, 
1.5 to 3 months, 3 to 6 months, 6 to 12 months, and >12 months) from first line failure 
to start of second line regimen. Time of first line failure was the date of the second viral 
load measurement >1000 copies/mL.  
 
Outcomes 
The main outcome of interest was rate of confirmed treatment failure on second 
line ART after switch to second line (defined as for first line failure, two consecutive 
failing viral loads >1,000 copies/mL between 2 weeks and 12 months apart). Secondary 
outcomes included rate of a single viral load >1,000 copies/mL on second line ART, and 
rate of suppression on second line ART (viral load <400 copies/mL). In descriptive 
analyses, the proportion suppressed at one year on second line, and the proportion 
suppressed at two years on second line among the subset of patients with two years of 
potential follow-up time, were included.  
  Since none of these virologic outcomes on second line treatment were 
applicable to patients who virologically failed first line but did not switch to second line, 
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when including patients who did not switch in the analysis, death and rate of 
suppression (single viral load <400 copies/mL) any time after first-line failure were used 
as outcomes.  
 When examining rates of virologic failure and suppression on second line, 
person-time began at the date of start of the second line regimen. Person-time ended at 
the outcome of interest or when a patient failed to follow routine virologic monitoring 
on second line, since outcomes on second line could not be assessed when patients did 
not have virologic monitoring. Failure to follow virologic monitoring on second line was 
defined as having ≥12 months without a viral load measurement, as has been done 
elsewhere (97).  
 
Covariates 
The following variables were considered as potential confounders: clinic, year of 
ART initiation, year of first line failure, sex, age at ART initiation, age at failure, WHO 
stage at ART initiation, history of TB, duration from first line ART initiation to first line 
failure, proportion of visits missed by >7 days before failure, time between consecutive 
failing viral loads on first line, value of first and second failing viral load on ART, and 
measurements at baseline and at time of first line failure of BMI, CD4 count, viral load, 
and hemoglobin. Having any missed visits in the first 6 months following first line failure, 
number of scheduled and actual visits between failure and second line switch, missed 
visits between failure and second line switch, time until next viral load after switch, and 
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time until next viral load after failure were covariates used in descriptive analyses to 
explore how frequency of visits differed by time to switch group. Time dependent 
covariates including CD4 count, viral load, hemoglobin level and BMI could be time 
dependent confounders if they occurred after failure but before second line initiation 
(they would be both predictors of second line initiation and intermediates on the 
pathway between time to second line initiation and second line treatment outcomes), 
yet they were not included as confounders because so few measurements occurred in 
this time period. 
 
Analytic plan 
 First, the population at time of first line ART failure was described and median 
time to switch from first line failure, and median time on second line ART were 
calculated. Potential confounders and effect measure modifiers of the relationship 
between delayed switch and second line failure were examined at first line failure by 
time to switch group, and associations between time to switch group and covariates 
were explored. Trends in covariates over time were also examined. 
 
Predictors of time to switch 
 To better understand why delays from first line ART failure to switch to second 
line regimen occurred (i.e. patient vs. provider delays), variables related to clinic 
attendance and disease progression were explored to determine which, if any, was 
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more likely to explain delays in second line switch. Cox proportional hazards models 
were used to model predictors of time to switch to second line following first line 
failure. Crude and adjusted hazards ratios were examined.  
 
Outcomes on second line 
 Crude outcomes on second line were examined by time to switch group, 
including number of subjects with virologic failure and suppression, as well as amount of 
person time, incidence rate and crude incidence rate ratios. Additionally, Kaplan-Meier 
curves were used to visually examine the relationship between time to switch group and 
all other covariates with rate of failure on second line.  
 In multivariate models, Cox proportional hazards regression models were used 
to examine the relationship between time to switch group and hazards of all outcomes 
on second line, as well as to control for confounding. Models were stratified by several 
variables including CD4 count and viral load at first line failure, gender, peak CD4 count 
on first line treatment until time of first line failure, drop in peak on treatment CD4 
count to CD4 count at failure, viral suppression on first line ART, and proportion of 
missed visits before failure, to determine if results differed among subsets of the study 
population and to investigate any relative effect measure modification. To determine if 
results differed by site, models were run separately for each of the three largest sites 
and were run excluding one clinic that appeared to be an outlier due to the high rate of 
failure. 
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Patients who did not switch after failure 
 A description of patients who failed first-line therapy but did not switch to 
second line, and thus would be excluded from models of outcomes on second line, was 
included to better understand why some patients did not begin second line treatment. 
The proportion of patients who died, were lost to follow up, experienced additional 
failing viral loads after date of failure, were virologically suppressed and in care one year 
after failure, and the proportion who had changes to their ART regimens were 
examined. To include these patients in adjusted models, Cox proportional hazards 
models were run for both death and virologic suppression any time after treatment 
failure. In these analyses the group of patients that did not switch were included as their 
own exposure group (never switched, switch in 0–1.5 months, switch in 1.5–3 months, 
switch in 3–6 months, switch in 6–12 months, and switch in >12 months).  
 
Marginal structural models 
 In addition to Cox models for death and suppression, marginal structural models 
were used for these outcomes (97,98,99). Marginal structural models allowed all 
patients, including patients who did not switch, to contribute person time to each of the 
time to switch exposure groups until they failed to follow the definition of that exposure 
group, at which time they were censored. As a result, outcomes for non-switchers could 
be incorporated into the analysis and survivor bias could be addressed. Outcomes in the 
marginal structural models included death and suppression any time after first line 
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failure since non-switchers were included in analysis. This method also adjusts for 
confounders over time. 
The detailed steps for creating the marginal structural models are as follows. 
Observations for each subject were created in half-month units of time. Observations 
began at the date of first line ART failure and ended at the earliest date of loss to follow-
up, the outcome of interest, or the end of the study period. Loss to follow-up was 
considered to be 12 months following the last viral load measurement, since viral load 
values were not carried forward more than 12 months. Each observation was matched 
to the closest date of time-dependent covariates including BMI, hemoglobin, CD4 count 
and viral load, within a -6 month to 1 year range. The dataset was then expanded to 
make 6 copies of each individual’s follow-up time for each of the 5 exposure groups plus 
a group for those who never switched. Within each copy, individuals were censored 
when they did not follow the definition of the exposure group. For example, for the 
copy of each individual for exposure group 2 (switch in 1.5 to 3 months), subjects were 
censored at date of switch to second line ART if they switched before 1.5 months after 
failure, and subjects were censored at 3 months if they did not switch or if they 
switched after 3 months because in either case they did not follow the definition of the 
exposure group as of the time of censoring. If they switched between 1.5 and 3 months 
they were censored at the end of follow-up time since they never stopped following the 
definition of this exposure group. Thus, individuals contributed some person time to 
every exposure group.  
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An example of how 4 hypothetical individuals contribute person time to the 6 
exposure groups is displayed in Figure 6. Person 1 switches in 1 month, and contributes 
all of their person time to exposure group switch in 0 – 1.5 months. At 1 month they fail 
to follow the definition of the other exposure groups and their follow-up time is 
censored. Person 2 never switches, person 3 switched in 8 months, and person 4 
switches in 4 months. In each case person time was censored for each exposure group 
based on the time at which an individual switched to second line. 
Artificial censoring allows patient to contribute time to all exposure groups, but 
creates selection bias that must be accounted for using weighting by the inverse 
probability of remaining uncensored. In these models, probability of remaining 
uncensored is equivalent to the inverse probability of starting second line treatment 
(97). Probabilities of initiation of second line treatment were calculated in the 
unexpanded data, using person time until the half month of second line treatment 
initiation, if it occurred. Stabilized weights were calculated for each person-half-month 
of data. Weights were created by fitting two pooled logistic regression models and 
calculating the probability of initiating second line treatment. The first model 
(numerator) estimated the probability a subject had his/her observed exposure given 
baseline confounder values and exposure history. The second model (denominator) 
estimated the probability a subject had his/her observed exposure given baseline and 
time varying values of confounders and exposure up until time of treatment initiation.  
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Parameters of a marginal structural Cox model were estimated by fitting a 
weighted pooled logistic regression to predict death or virologic suppression by time of 
switch to second line group. Robust standard errors were used to account for weighting. 
Confounders were included if they altered the hazard ratio for time group by 10% or 
more. 
 
Sensitivity analyses 
Several variations of the study outcomes were analyzed in sensitivity analyses to 
determine if the results were dependent on the definition of the study outcome. First, 
the patient population was restricted to subjects who had at least 12 months of follow-
up time on second line ART. Second, the patient population was restricted to subjects 
who had at least 24 months of follow-up time on second line ART. These analyses 
ensured that patients had sufficient follow-up time for a failure or suppression outcome 
to be detected. Third, for rates of failure, follow-up time was altered to begin at 12 
weeks after the switch to second line to avoid detecting failing viral loads before a new 
regimen was able to suppress the virus. Fourth, the rate of virologic failure analysis was 
limited to patients who experienced viral suppression with person time beginning at 
suppression instead of switch.  
Models were also run limited to individual sites that had large enough patient 
populations, and excluding sites with especially high or low failure rates, to detect 
differences by site.  
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RESULTS 
 
Sample size 
There were 88,305 adult patients initiated on first line ART, and 8.3% of these 
patients (7,265) ever failed treatment with 2 consecutive viral loads >1,000 copies/mL. 
Of the patients who failed treatment, 81% were included in the analysis (Table 14). 
Other patients who failed had already switched to second line ART (5%), had an error in 
the date of second line ART initiation (0.1%), or had less than 1 year of potential follow-
up after failure (14%).  
 The majority of the 5,895 patients (35%) came from Clinic A, the largest clinic 
and the site with the fewest missing data. The break-down of the study sample from 
each of the 9 clinics is displayed below (Table 15).  
 
Description of population at first line failure 
Median time on first line until treatment failure was 17.4 months (IQR 10.2–30.9 
months). Among the 5,895 patients with first line failure included in the study, 2,189 
(37%) never switched to second line treatment after failing first line ART. At Clinic A, 
only 28% of patients never switched to second line. Among the 3,706 patients who 
switched to second line, the median time to switch after first line failure was 3.4 months 
(IQR: 1.1–8.7 months). Median follow-up time on second line ART among patients who 
switched was 1.4 years (IQR: 0.71–2.41 years).  At the end of follow-up time, 64% of 
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patients were in care without confirmed virologic failure, 27% of patients were lost from 
the clinic, and 9% of patients experienced confirmed virologic failure on second line 
ART. 
Basic descriptor variables of the population at time of first line failure by time to 
switch group are displayed in Table 16. Time to switch groups was similar with respect 
to age, sex, BMI and hemoglobin level (60.6% – 64.8% female, median age 36.4 – 37.2 
years, median BMI 23.8 – 24.3, and median hemoglobin 12.9 – 13.1 g/dL). Patients who 
switched to second line more quickly had higher viral loads at first line failure. Patients 
who did not switch or switched after 12 months tended to have higher CD4 counts and 
lower viral loads (median CD4 count 221 cells/mm3 (IQR: 118 – 346) and median viral 
load count 9,400 copies/mL (IQR: 2,720 – 58,244) among non-switchers; median CD4 
count 207 cells/mm3 (IQR: 122–326) and median viral load 12,000 copies/mL (IQR: 
3,381–52,355) among patients switching in >12 months; and median CD4 count 185 
cells/mm3 (IQR: 103–299) and median viral load 19,000 copies/mL (IQR: 5,000–80,000) 
among patients switching in <1.5 months). These trends indicate that some of these 
patients were healthier and clinicians may have decided to delay switch to second line, 
possibly to optimize adherence and preserve first line ART. Median viral load for 
patients who did not switch was 9,400 copies/mL (IQR: 2720–58344), while it was 
14,000 (IQR: 4043–55649) among patients switching in 6 to 12 months, and 19,000 (IQR: 
5000–80000) among patients who switched in <1.5 months. Patients who did not switch 
had lowest viral load and highest CD4 values at failure. There was some indication that a 
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later time to switch was also patient driven, since the percent of people who missed 
visits on first line before treatment failure increased with a longer time to switch 
(patients who switched in <1.5 months had 6.1% of pre-failure visits missed, while 
patients who switched in >12 months had 9.1% of pre-failure visits missed). 
 
Trends in CD4 count over time 
 CD4 count at first line failure was very low for all switch groups. Figure 7 displays 
trends in population median CD4 count over time among patients who failed treatment. 
Median CD4 count at first line failure was 157 cells/mm3, and was higher than the 
median CD4 count at ART initiation of 123 cells/mm3.  
 
Predictors of time to switch 
 One of the biggest differences between the different time to switch groups was 
the viral load at time of failure. Patients with a higher failing viral load were more likely 
to switch to second line ART more quickly. Other predictors of time to second line 
switch were investigated with crude and adjusted Cox models (Table 17). Time to switch 
to second line after failure differed by clinic, especially for Clinic E, which had a relatively 
low hazard of switching to second line ART. Due to this difference in clinics, the adjusted 
proportional hazards model for time to switch to second line was stratified by clinic.  
Patients with high viral loads and low CD4 counts were more likely to be 
switched to second line faster. In adjusted analyses, missing fewer visits on first line was 
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also associated with shorter time to switch. These models indicate that switching to 
second line depends only partly on patient behavior (delay in switch was associated with 
history of missed visits on first line). Physician decisions also determined how quickly 
patients were switched. Even in the longer time to switch groups, the majority of 
patients did not miss visits in the 6 months following first line failure (Table 16), and the 
sickest patients were switched most quickly (Table 17). The percent of patients who 
missed visits in the first 6 months following treatment failure was lowest among 
patients who switched most quickly (69.7%), was 56.7% among patients who switched 
in >12 months, and was 58.2% among patients who never switched. The adjusted 
hazard ratio for switching to second line ART after first line failure was 1.34 (95%CI: 
1.21, 1.49) for patients with a failing viral load of 60,000+ copies/mL compared to 
patients with a failing viral load of 1,000–9,999 copies/mL, and the adjusted hazard ratio 
for switching to second line was 1.32 (95% CI: 1.14, 1.52) for patients with a CD4 count 
at failure of 0–49 cells/mm3 compared to a failing CD4 count >250 cells/mm3. There was 
no relative interaction between CD4 count and missed visits in models predicting time 
to switch. 
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Outcomes on second line 
 
Crude outcomes by time to switch group 
 Crude outcomes by time to switch group are displayed in Table 18. Rates of all 
outcomes on second line (confirmed treatment failure, single failing viral load, 
suppressed viral load) were similar across time to switch groups. The proportion with 
failing viral loads at 1 year and 2 years on second line was also similar across time to 
switch groups, but was slightly lower among the later time to switch groups (10.1% for 
switch in >12 months and 13.0% for switch in <1.5 months at one year after failure) 
(Table 18).  
 Several variations of the outcomes were analyzed in sensitivity analyses to 
determine if the results were dependent on the definition of the outcome (Appendix 
Table A2A). Analyses restricted to patients with at least 12 months or at least 24 months 
of potential follow-up time on second line showed that overall results remained the 
same. There was a slightly faster rate of detecting a single failing viral load among the 
longer time to switch groups in the analysis that changed follow up time to begin 12 
weeks after switch to second line (crude IRR for switch in 6–12 months compared to 
switch in 0–1.5 months = 1.13). The analysis examining rate of failure after a single 
suppressed viral load on second line (among patients who experienced viral 
suppression) reduced the sample size the most, and showed that the crude incidence 
rate ratio for failure was lower among the longer time to switch groups. 
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Crude predictors of failure on second line 
 In addition to time to switch group, associations between other variable values 
at first line failure and virologic outcomes on second line were assessed. In unadjusted 
analyses, high viral load, low CD4 count, and being underweight at first line failure were 
associated with increased hazards of failure on second line. Gender, proportion of visits 
missed on first line ART, and time between failing viral loads on first line ART were not 
associated with treatment failure on second line. Kaplan Meier curves for each of these 
predictors are displayed in Appendix Figure A2A. 
 
Multivariate models of outcomes on second line 
 In multivariate Cox proportional hazards models with all patients, time to switch 
to second line group did not predict failure on second line (Table 19). There was some 
evidence that the longer time to switch groups were associated with less failure on 
second line, which was likely due to residual confounding by indication (the sickest 
patients were switched most quickly) and survivor bias (patients in the late switch 
groups had to survive and remain in care for a certain amount of time in order to be in 
the late switch groups by definition). The adjusted hazard ratio for virologic failure on 
second line ART for switch in >12 months compared to switch in <1.5 months was 0.82 
(95% CI: 0.61, 1.095). Higher viral load at failure, younger and older age, CD4 count of 
50–99 at failure, low hemoglobin and being underweight were associated with 
increased rates of failure on second line in the adjusted Cox model (Table 19). An 
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interaction term between missed visits and viral load at failure was tested in the model 
but was not statistically significant at the 0.2 level, and did not alter the hazard ratios for 
the time to switch groups. 
Outcomes by time to switch group did not differ by site. Results remained the 
same when they were restricted to Clinic A only, Clinic H only, and Clinic B only, and 
when excluding Clinic E.  
 
Stratified multivariate models for outcomes on second line 
 Results also did not differ when stratified by sex or by proportion of missed visits 
before first line failure. However, results for the effect of time to switch on outcomes on 
second line did differ when the study sample was stratified by CD4 count at first line 
failure, peak CD4 count on first line before failure, and decline from peak CD4 count to 
CD4 count at failure, or viral load at first line failure.  
 Among the sickest patients with lowest CD4 count at failure (≤100 cells/mm3), 
patients whose CD4 count did not decline from peak value until value at failure, and 
patients with a low peak CD4 count (≤100 cells/mm3) on treatment until time of failure, 
delaying switch to second line resulted in worse outcomes with respect to failure on 
second line than switching within 1.5 months after failure. Stratifying by viral load 
showed similar trends, where patients who had evidence of an elevated viral load on 
first line ART prior to failure also had worse outcome on second line ART.  
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 The trend was most clearly observed when stratifying by peak CD4 count on 
treatment through time of first line failure (Table 20). For patients with a peak CD4 
count ≤100 cells/mm3, even a small to moderate delay in initiating second line ART after 
failure led to worse outcomes on second line ART. For example, waiting 3–6 months led 
to a 2-fold increase in rate of failure on second line (aHR = 2.13; 95% CI = 1.01, 4.47) 
compared to those who switched immediately (in less than 1.5 months). The confidence 
intervals were fairly large in this analysis due to a small sample size when restricting to 
patients to peak CD4 ≤100 cells/mm3. Likely due to survivor bias, this harmful effect of 
delay was attenuated as time to switch group became longer.  Among patients with a 
peak CD4 count ≤100 cells/mm3, the adjusted hazard ratio for failure for patients 
switching in >12 months compared to patients switching in <1.5 months was 1.35 (95% 
CI: 0.49, 3.73) (Table 20). On the other hand, when limiting the sample to patients with a 
peak CD4 count before failure of >100 cells/mm3, delaying switch to second line was 
associated with slightly reduced failure on second line or no effect of delaying second 
line. The adjusted hazard ratio for failure on second line among patients switching in 
>12 months compared to switching in <1.5 months was 0.73 (95% CI: 0.52, 1.02) (Table 
20). In this stratum, there was also a trend toward longer time to switch groups being 
associated with relatively less failure on second line ART. 
 Crude Kaplan-Meier curves among patients with CD4 count ≤100 cells/mm3 at 
first line failure provide evidence that patients who were switched most quickly had the 
lowest rates of failure on second line (Figure 8), despite no adjustment for confounding. 
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This association was not seen among patients with a failing CD4 count >100 cells/mm3 
(Figure 9), demonstrating that the effect of time to switch group is dependent on CD4 
count at first line failure. 
 
Patients who do not switch after failure 
 Out of all patients in the study who failed first line ART, 37% did not switch to 
second line, and their outcomes on second line could not be assessed. On average, 
these patients remained at the clinic for a median of 1.16 years after failure (IQR: 0.37 – 
2.13 years), and 20% of patients were lost from care with their last visit within 3 months 
of failure. Within one year after failure, 43% of these patients were lost from care and 
5.7% had died. Table 21 displays the time at which the never-switch group was lost from 
care after first line failure. A substantial proportion of non-switching patients were lost 
from care within the first 1.5 months after treatment, particularly among patients with a 
very low peak CD4 count (≤100 cells/mm3). 
 Viral loads of patients who never switched after failure were examined to see 
how many had evidence of re-suppression. 564 patients (26%) had no viral loads taken 
at any time after failure, suggesting they did not return to the clinic. 1,059 patients (49% 
of patients who failed but did not switch) had a recorded viral load >1,000 copies/mL at 
any time after first line failure. 883 patients (41% of patients who failed but did not 
switch) had a recorded suppressed viral load (<400 copies/mL) at any time after first line 
failure, suggesting these patients’ adherence was optimized and they were able to 
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remain on their first line regimen. Median time to virologic suppression for these 
patients was 4.6 months (IQR: 2.8–8.1 months). At one year after failure 28% of patients 
were still in care with their most recent viral load suppressed.  
 Most patients who did not switch had no change to their ART regimen. However, 
192 (9%) had an NRTI switched, and 83 (4%) had started a PI without a change in NRTI 
within the year following first line failure.  
 
Marginal Structural Models 
 To account for patients who did not switch to second line ART but were part of 
the population that failed first line ART, to minimize survivor bias, marginal structural 
models were used. The probability of treatment used for the inverse probability of 
treatment weighting was calculated for the denominator using time (in half-month 
units), time squared, clinic, year of failure, gender, age, dichotomized WHO stage, viral 
load at failure, CD4 at failure, BMI at failure, hemoglobin at failure, time on first line 
treatment, time between failing viral loads on first line, and updated values over time 
for viral load, CD4 count, BMI and hemoglobin. To stabilize the weights, the probability 
of treatment was calculated for the numerator of the weights using time, time squared, 
year of failure, gender, age, failing viral load level, and CD4 count at failure as 
predictors. The resulting weights had a minimum of 0.145 and a maximum of 20.9. The 
highest weight values were truncated at the 99th percentile so no data points would be 
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overly influential. The final weights had a minimum of 0.145, a maximum of 7.42, and a 
mean of 1.31.  
 
Time to death 
When examining death as the outcome of interest, 298 (5.1%) patients had 
follow-up time end at time of death. Other patients were lost to follow up (3,555, 
60.3%), or remained in care at the end of follow-up time (2,042, 34.6%). Any patient 
death that occurred after being lost to follow-up was considered a lost to follow-up 
outcome, not death. Death occurred among 152 of 3,555 patients (4.3%) of patients 
after they were lost to follow-up. A Cox proportional hazards model was also run for 
death as a comparison to the marginal structural model results (Table 22). The marginal 
structural model demonstrated that the longer time to switch groups had slightly 
elevated hazards of death (aHR for switch in 6–12 months compared to 0–1.5 months = 
1.31; 95% CI: 0.96, 1.79). The trend in the Cox models for second line treatment failure 
of relative harm of switching decreasing with longer time to switch group was no longer 
present in the marginal structural models. 
In comparison to the Cox proportional hazards models, where non-switchers 
could only be included in a separate group, the longest time to switch group had the 
lowest hazards of death relative to immediate switch in both strata, demonstrating that 
the estimates for death are likely affected by survivor bias when the outcomes for the 
non-switchers are not included. Patients who did not switch had the greatest hazards of 
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death in the Cox proportional hazards model outcome (aHR for no switch compared to 
switch in 0–1.5 months = 2.42; 95% CI: 1.73, 3.38).  
When stratifying by peak CD4 count, the harmful effect of delaying switch to 
second line on hazards of death was more pronounced among patients with a peak CD4 
count ≤100 cells/mm3 (aHR for switch in 6–12 months compared to 0–1.5 months = 
1.49; 95%CI = 0.91, 2.42). Among patients with a higher peak on-treatment CD4 count 
(>100 cells/mm3), delayed switch to second line was only harmful among the longest 
time to switch groups, while patients switching any time in less than 6 months after first 
line failure had similar hazards of death as patients who switched immediately (in <1.5 
months).  
In both marginal structural models and Cox models, the oldest age group and 
patients with the highest viral loads and lowest CD4 counts at first line failure were at 
greatest risk for death. Males tended to have a slightly higher risk of death. 
 
Time to viral suppression 
 When examining suppression after first line ART failure as the outcome of 
interest, 3,400 (57.7%) patients had follow-up time end at viral suppression. The 
remaining patients had follow up time end at loss to follow-up (1,222; 20.7%) or 
remained in care until the end of follow-up time (1,273; 21.6%). Both the marginal 
structural models and the Cox models to predict time until suppression indicated that 
patients who switched to second line most quickly had the highest rates of viral 
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suppression. In the marginal structural model, patients who switched in 6–12 months 
had an adjusted hazard ratio of death of 0.67 (95% CI: 0.60, 0.74) compared to patients 
who switched in 0–1.5 months, while in the Cox model the adjusted hazard ratio of 
death for this group was 0.58 (95% CI: 0.50, 0.68). Overall, delaying switch led to the 
greatest relative reduction in suppression rates among patients with a low peak CD4 
count on first line ART (≤100 cells/mm3).  Patients who had no additional viral load 
measurements taken after first line failure were excluded from this analysis since 
suppression would not have been detected among these patients if it had occurred. 
Restricting the analysis to patients with future viral load measurements also limited 
surveillance bias, where higher rates of viral suppression may have been observed 
among patients who switched to second line more quickly because of more frequent 
viral load monitoring. Results for the time to suppression after first line failure analysis 
are in Appendix Table A2B. 
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DISCUSSION 
 
Overview of results 
 This study provides evidence that even short delays in switch to second line ART 
are associated with poor outcomes on second line, among the sickest patients. For 
patients with a peak CD4 count prior to failure of ≤100 cells/mm3, delaying switch by 1.5 
to 3 months was associated with an adjusted hazard ratio of virologic failure on second 
line of 2.26 (95% CI: 1.12, 4.55). This increased failure was not seen for patients with 
CD4 counts on first line ART >100 cells/mm3. Similarly, even small delays in second line 
initiation were associated with increased hazards of death in the marginal structural 
models among patients who had a peak CD4 count prior to failure of ≤100 cells/mm3. 
The adjusted hazard ratio for death for delay of 1.5 to 3 months was 1.39 (95% CI: 0.85, 
2.27), and increased to 1.55 (95% CI: 0.95, 2.53) for patients who never switched to 
second line. Among patients with a peak CD4 count >100 cells/mm3, delay in treatment 
was only associated with increased hazard of death for a delay of >6 months (hazard 
ratio for death for switch in 6–12 months compared to switch in <1.5 months was 1.22 
(95% CI: 0.82, 1.79)).  
 
Time to switch to second line 
 Results were consistent with previous studies with regard to the proportion of 
patients failing first line ART over time and time to switch among those who failed first 
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line ART (21,61). While a substantial proportion of patients did not switch to second line 
ART after failure (37%), this result was consistent with previous cohort studies in South 
Africa (44,92,93). Analyzing predictors of time to switch to second line ART in this study 
gave insight into who switched to second line most quickly. Patients who switched most 
quickly had a median CD4 count of 185 (IQR: 103–299) and a median viral load of 19,000 
(IQR: 5,000 – 80,000), compared to patients who never switched, who had a median 
CD4 count of 221 (IQR: 118–346) and a median viral load of 9,400 (IQR: 2,720 – 58,344). 
This finding was consistent with a previous study that showed that switch to second line 
occurred most quickly among patients who had low CD4 counts and high viral load 
levels (93). This previous study found that, while patients with higher viral loads 
switched to second line most quickly, patients with the highest viral loads at first line 
failure had a slight reduction in rate of switch to second line, likely due to physicians’ 
hesitancy to switch patients who they believe are non-adherent (93). Our study was not 
consistent with this finding, where even patients with viral loads >60,000 copies/mL at 
failure had an increased hazard ratio of switch to second line compared to patients with 
a failing viral load of 1,000 to 10,000 (1.34 (95% CI: 1.21, 1.49), Table 16).  
 Our study further investigated timing of missed visits after first line failure. Most 
patients, even those who never switched, did not miss visits during the 6 months 
following failure on first line ART, which indicated that delay in switching some patients 
was at least partly due to physician decisions. This was consistent with previous 
research showing that patients typically are switched to second line in their 3rd or 4th 
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visit following first line failure (93). Our finding suggests that, even among patients who 
took the longest to switch to second line, there is opportunity to intervene at the 
provider-level to switch patients to second line earlier.  
 Our findings suggest that delayed switch to second line is both physician driven 
and related to patient behavior. Physicians had the opportunity to switch patients with a 
long delay to second line earlier, and the correlation between high viral load and fast 
rate of switch suggests that physicians are more likely to switch patients with high viral 
loads more quickly. Although most patients did not miss visits after switch to second 
line, patients who switched later did have more evidence of missed visits. The median 
proportion of missed visits prior to first line failure was 6.1% for patients who switched 
immediately, and was 9.1% for patients who switched in >12 months (Table 16). While 
physicians may believe patients with missed visits are more likely to have problems with 
adherence and purposely delay switch to second line among this group, this finding 
suggests that patient behavior (lack of visit adherence) also influenced delaying switch 
to second line. 
 Among the patients who never switched, we found that 28% were in care with a 
suppressed viral load after a year on after failure, and thus were likely not true failures 
or had failure attributed to lack of adherence. Still, a substantial proportion of patients 
who failed but never switched were lost from care during the first year after failure. 25% 
of patients in this group never returned to the clinic after failure, and at 12 months on 
ART 43% of patients had been lost to follow-up and likely did not switch to second line 
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because they were lost from care. When examining the patients who did not switch to 
second line stratified by peak CD4 count on treatment, it was clear that the patients 
who were sickest over time were lost most quickly, which emphasizes the need to 
switch sickest patients quickly, before they are lost from care. The loss of the sickest 
patients before they could switch to second line ART also likely caused biased outcomes 
in the Cox models. Selection bias would occur when analyzing outcomes on second line 
ART by time to switch group because the longer time to switch groups were limited to 
healthier patients. 
 
Outcomes on second line 
 Cox proportional hazards models for outcomes on second line ART among all 
patients who switched to second line showed no difference or slightly reduced rates of 
failure on second line associated with delay in second line initiation, in crude and 
adjusted results. Both residual confounding due to sicker patients being in the shorter 
time to switch groups, and survivor bias due to healthier patients being in the later time 
to switch groups by definition are likely explanations for this result. Due to statistical 
adjustment for health indicators such as TB history and CD4 count, BMI, and viral load at 
first line failure, confounding by indication should be minimized.  
 Despite these biases, when results were stratified by peak CD4 count prior to 
first line failure, delaying switch to second line was associated with more failure on 
second line among the sickest patients, as summarized in the overview of results. The 
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trend toward delay in second line being harmful for the sickest patients was seen 
consistently for patients with a low peak CD4 count (≤100 cells/mm3), patients with a 
low CD4 count at first line ART failure, patients with no change from peak CD4 count 
until CD4 count at failure, and patients with previous high viral load (>1,000 copies/mL) 
on first line ART. The harmful effect of delaying switch to second line ART among these 
patients was attenuated as time to switch increased, for example, compared to patients 
who switched in <1.5 months, the hazard ratio for failure on second line was 2.26 
(95%CI: 1.12, 4.55) for patients who switched in 1.5 to 3 months, but was 1.54 (95% CI: 
0.68, 3.46) for patients who switched in 6 to 12 months. This attenuation of the harmful 
effect of delay in switch to second line among the longer time to switch groups may be 
explained by the increasing strength of survivor bias as time to switch increased or 
residual confounding. Among less sick patients (CD4 >100 cells/mm3) Cox proportional 
hazards models indicated that delaying switch to second line did not affect rates of 
failure on second line, and that the longest time to switch group, which included the 
healthiest patients, had improved outcomes on second line (aHR for failure on second 
line for those who switched in >12 months compared to switch in <1.5 months = 0.73 
(95% CI: 0.52, 1.02). 
 Marginal structural models allowed us to include person-time and outcomes for 
patients who were lost from care before switching to second line. Since the longest time 
to switch groups were no longer composed entirely of people who had to survive long 
enough to enter those exposure groups, we expect survivor bias was minimized in these 
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models. The marginal structural models were intended to mimic a clinical trial where 
time to switch group was randomly assigned to all patients with documented failure on 
second line ART at time of failure. Although outcomes on second line could not be 
assessed because not all patients switched to second line, the marginal structural 
models for death after first line failure indicated that delaying switch to second line was 
harmful for all patients, not only those with a low peak CD4 count on first line ART. This 
finding was consistent with a previous study in South Africa investigating impact of 
delaying second line ART on death (66).  
 In the marginal structural models for death that were stratified by peak CD4 
count before failure, among the sickest patients with CD4 counts ≤100 cells/mm3, 
delaying second line ART increased the rate of death after first line failure by 
approximately 30% for a 6 month delay, and approximately 50% for a delay of 6 months 
or longer. Among the relatively healthier patient population at first line failure, delaying 
switch to second line by up to 6 months did not influence the rate of death, but a longer 
delay or never switching to second line ART increased the rate by approximately 20%. In 
these models that attempt to account for selection bias, the trend in the Cox models 
where the harmful effect of delaying second line was attenuated with a longer delay 
until switch was no longer present. 
 Marginal structural models and Cox models for suppression any time after failure 
both showed that patients who switched to second line the most quickly were 
suppressed the most quickly after first line failure (Appendix Table A2B). These results 
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confirmed that switching to a PI-based regimen can successfully suppress patients’ viral 
load levels more quickly than remaining in first line ART. 
 
Possible mechanisms 
The association between delay in second line initiation and poor outcomes on 
second line ART can either be explained by a biologic mechanism related to decline in 
health and accumulation of drug resistance mutations, or because physicians purposely 
delay switching patients with adherence problems who continue to have poor 
adherence on second line. 
 For the poor adherence hypothesis, if physicians decide to delay treatment 
switch for patients with known adherence problems, delaying switch may be associated 
with failure on second line because patients with poor adherence on first line would be 
more likely to have poor adherence on second line. Although this scenario was 
proposed in a prior study of predictors of switch to second line, where patients with the 
highest viral loads at first line failure had a slightly lower rate of switch (93), we did not 
observe the same trend. We found that overall, patients with the highest viral loads 
were switched to second line most quickly, likely because physicians are reluctant to 
switch patients who are clinically well because of limited future regimen options (92,94). 
While delayed switching due to poor adherence may play a role in this study, the high 
rate of switch to second line among patients with the highest viral loads suggests that 
there are motivating factors other than adherence for the time at which patients are 
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switched to second line. 
 Additionally, in order for the adherence hypothesis to explain our study results, 
physicians would have to delay second line switch for poor adherers among sicker 
patients more frequently than among patients who are relatively healthier. It is possible 
that physicians do not believe that very sick patients who have poor adherence need to 
be switched to a second line regimen because they never took first line ART 
consistently, but we would also expect that physicians would safely delay switch to 
second line for patients who are relatively healthier but known to have adherence 
problems. Lastly, we attempted to control for adherence as a confounder by including 
proportion of missed visits prior to failure and time between failing viral load 
measurements as confounders in our adjusted models. Although residual confounding 
from adherence is likely present due to proportion of missed visits being an inexact 
measurement of treatment adherence over time, lack of adherence is probably not the 
sole explanation for the observed results. 
 Alternatively, the poor outcomes among patients who have delayed switch to 
second line may be explained by accumulation of drug resistance mutations among the 
sickest patients who fail first line and decline in immune system function and overall 
health of the sickest patients who remain on a failing regimen for a long time. All types 
of NRTI resistance mutations that can compromise second line ART have been shown to 
accumulate over time while patients remain on failing regimens (31,32,55,56,63,73,96). 
TAMs have been shown to accumulate rapidly while patients are on a failing first line 
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NNRTI-based regimen (63,73,92), and prolonged time on failing regimens has been 
associated with the presence of ≥3 TAMs (31), which would potentially limit the 
effectiveness of d4T, AZT and TDF on second line. 
 Our study results, where the sickest patients had the worst outcomes associated 
with delay of second line ART, are consistent with the accumulation of drug resistance 
mutations over time on second line ART, because NRTI resistance mutations have been 
shown to accumulate more rapidly or appear more often among sickest patients. 
Hosseinipour et al. found that the emergence of the K65R and the K70E mutations, 
which limit the activity of TDF, occurred most often among patients with a CD4 count 
<100 cells/mm3 at failure (55). Other types of NRTI resistance mutations, including 
TAMs, have occurred more frequently among sickest patients (32,96). Among the 
patients in our study with a peak CD4 count prior to failure ≤100 cells/mm3, drug 
resistance mutations may have begun to accumulate prior to detection of first line 
failure because these patients were never fully suppressed while on first line ART. 
Patients with even low levels of detectable viral loads on first line ART are more likely 
than patients who are fully suppressed to develop drug resistance mutations over time 
on treatment (27,100). It is possible that among the sickest patients in care, delaying 
switch to second line allowed for significantly more NRTI resistance mutations to 
develop and multiply, potentially limiting the effectiveness of NRTIs in second line ART. 
 Despite the limited effectiveness of NRTIs that develops over time on a failing 
regimen, particularly among the sickest patients, suppression on a second line regimen 
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is possible in the presence of NRTI resistance mutations (37,63,101). While drug 
resistance can still play a role in the effectiveness of second line ART (55,56), it is 
possible that damage to the immune system that occurs while HIV is not suppressed can 
account for the poor outcomes on second line. Among the patients in this study with an 
already weak immune system (CD4 counts ≤100 cells/mm3), remaining on a failing 
regimen would cause further immune system damage. Previous studies have shown 
that damage to the immune system can influence second line outcomes, with one study 
demonstrating that an AIDS defining event prior to second line switch was associated 
with worse outcomes on second line (70).  
 It is likely that each of these mechanisms plays a role in the study outcomes, and 
that allowing very sick patients with CD4 counts ≤100 cells/mm3 to remain on a failing 
regimen for even a few months, and allowing relatively healthier patients to remain on a 
failing regimen for 6 months to over a year can cause both substantial immune system 
damage and accumulation of drug resistance mutations that limit the effectiveness of 
second line. Without drug resistance genotyping available in this study, we cannot 
determine which mechanism is operating. 
 
Potential biases 
Residual confounding 
 In addition to residual confounding due to poor adherence, it is apparent that 
confounding by indication was present in the crude models, where switches to second 
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line occurred most quickly for sickest patients, and sickest patients (with low BMI, low 
CD4 count, and high viral load) had highest rates of death and failure on second line 
ART. While these covariates were controlled for in adjusted analyses, residual 
confounding may remain. Clinic was also a potential confounder but was adjusted in the 
analyses. When restricting the models to patients at Clinic A only, which was the only 
clinic large enough to run the models independently, associations between time to 
switch group and failure on second line among all patients and among the sickest 
patients were consistent with the Right to Care cohort as a whole, suggesting that the 
results could not be explained by confounding by site. 
 
Time dependent confounding 
 Lab values and BMI values can be time dependent confounders if they occurred 
after first line treatment failure but before second line switch (Figure 10). Since very few 
values were available in this time window, and since lab values at time of first line 
treatment failure, which would be closely related to subsequent values before second 
line switch were controlled for, time dependent confounding was not a significant 
concern. Results from the marginal structural models for death and suppression would 
also control for any time dependent confounders.  
 
Differential surveillance 
 Differential surveillance could be a concern if patients who were switched most 
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quickly had failure on second line identified most quickly because of increased 
treatment monitoring following switch to second line ART. However, the median time to 
next viral load following switch to second line was very consistent across groups, 
ranging from 119 days to 123 days, except for the switch in >12 month group which had 
a slightly longer time to virologic monitoring following second line switch (140 days). 
Additionally, results in the marginal structural models for death, where differential 
treatment monitoring would not alter results, also showed delaying second line was 
associated with increased hazards of death. 
 
Survivor bias 
Survivor bias was present in the Cox models for outcomes on second line ART. 
This bias could be addressed with marginal structural models for death following first 
line treatment. The marginal structural models introduced a new bias from artificial 
censoring, which could be un-done by inverse probability of treatment weighting, which 
was equivalent to the inverse probability of censoring. The extent to which artificial 
censoring bias could be reversed was dependent on the ability to predict second line 
treatment switch, but the direction of this bias is unpredictable. The logistic regression 
model predicting second line treatment switch was fairly accurate, with a C-statistic of 
0.72. 
Marginal structural model results were consistent with the presence of survivor 
bias in Cox models. Marginal structural models showed that longer time to switch 
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groups were associated with worse outcomes on second line, while Cox models showed 
relatively less failure on second line ART among the longest time to switch groups. 
 
Study strengths, weaknesses & future direction 
This study addresses an important question for clinical practice by providing 
some insight into the effect of delaying second line treatment. The main weaknesses of 
this study is the inability to address survivor bias in models for virologic failure outcomes 
on second line ART, and the inability to determine with certainty whether the poor 
outcomes associated with delay in switch to second line can be attributed to residual 
confounding or adherence rather than immune system damage and drug resistance. 
Additionally, when stratifying by peak CD4 count, the smaller sample size led to poor 
precision for the effect estimates. 
The main strength of this study was that the population on second line ART was 
large enough to look at several specific time to switch groups to try to determine at 
what point delaying switch is harmful to patients, which is an important but poorly 
understood question. While some have suggested delaying switch to second line by 3 to 
6 months to after failure to ensure switch to second line is necessary (63), this study 
shows that even a short delay in switch should be avoided for patients who are very sick 
(peak CD4 count ≤100 cells/mm3).  
Although suppression is possible with the presence of NRTI resistance mutations, 
patients who were very sick and remained on a failing regimen for a long time had poor 
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outcomes on second line. We could not rule out poor adherence as a cause of failure, so 
immediate regimen switch among the sickest patients failing ART is especially important 
for patients who do not have problems with adherence. While it is always important to 
maximize patient adherence to medication and visits, especially for patients who are 
failing treatment, this study also demonstrated that intervening at the physician level to 
switch patients to second line more quickly would be useful, because even patients with 
a long delay until second line switch did not miss visits after failure. 
Future studies could explore delaying switch by 3 to 6 months for patients who 
are relatively healthier at first line failure, since we found no evidence that delay in 
switch was associated with poor outcomes among these patients if they switched within 
6 months of treatment failure. Also, to better understand the mechanisms at work in 
this study, it would be ideal to track reasons why a physician would delay switch to 
second line to try to better understand the role that poor adherence played in delaying 
second line ART. Additionally, obtaining data on drug resistance among patients 
switching to second line would be helpful to understand if poor outcomes among the 
sickest patients were associated with drug resistance mutations.   
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STUDY 2 TABLES & FIGURES 
 
 
Table 14. Patients included in analysis among all patients who failed ART. 
  N % 
Included in analysis 5,895 81.2 
Switch to second line occurred before failure 370 5.1 
Less than 1 year of follow-up after failure 991 13.6 
Error in date of second line start 9 0.1 
 
 
 
 
Table 15. Study 2 sample size by clinic. 
Clinic N % 
A 2091 35.48 
B 613 10.40 
C 408 6.92 
D 484 8.21 
E 563 9.55 
F 534 9.06 
G 298 5.05 
H 813 13.79 
I 91 1.54 
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Table 16. Description of study population at time of first line failure by time to switch group. 
 
  no switch 0 to 1.5 mo 1.5 to 3 mo 3 to 6 mo 6 to 12 mo >12 mo 
N (%) 2189 (37.1%) 1114 (18.9%) 669 (11.4%) 688 (11.7%) 593 (10.1%) 642 (10.9%) 
Gender (% female) 63.1 64.8 60.8 60.6 61.9 64.6 
Age (median, IQR) 36.9  
(31.6–43.1) 
37.2  
(32.0–44.1) 
37.0  
(31.8–43.7) 
37.0  
(32.1–43.5) 
37.1  
(32.0–43.5) 
36.4  
(30.7–42.8) 
Viral load (median, IQR) 9400  
(2720–58344) 
19000  
(5000–80000) 
15862  
(4500–66000) 
12741 
(4100–53000) 
14000 
(4034–55649) 
12000 
(3381–52355) 
CD4 (median, IQR) 221  
(118–346) 
185  
(103–299) 
191  
(107–312) 
197 
(108–287) 
182.5 
(100–286.5) 
207 
(122–326) 
BMI (median, IQR) 23.8  
(20.9–27.6) 
24.2  
(21.2–27.9) 
24.0 
(21.5–27.9) 
23.8 
(21.1–27.6) 
24.3 
(21.5–28.2) 
24.3 
(21.4–27.9) 
Hemoglobin (median, 
IQR) 
13.0 
(11.6–14.1) 
13.1  
(11.7–14.2) 
13.0 
(11.8–14.2) 
13.0 
(11.8–14.2) 
13.0 
(11.7–14.2) 
12.9 
(11.6–14.4) 
Median percent of 
missed visits on before 
failure 
6.9% 6.1% 6.7% 7.7% 8.4% 9.1% 
Year of ART initiation (% 
per switch category) 
            
2004 3.8 5.5 4.6 4.7 4.2 7.5 
2005 7.7 9.3 10.2 8.9 11.3 12.2 
2006 11.0 14.5 12.7 12.5 11.3 14.8 
2007 11.7 11.8 14.1 12.8 10.0 16.8 
2008 13.6 17.3 14.8 14.8 13.8 17.1 
2009 17.7 16.5 16.7 16.6 15.9 13.4 
2010 19.3 15.9 14.8 16.0 17.5 12.3 
2011 11.7 7.6 9.4 10.9 12.8 5.5 
2012 3.5 1.6 2.7 2.9 3.2 0.5 
Percent with no missed 
visits in first 6 months 
after failure 
58.2% 69.7% 68.4% 61.6% 56.8% 56.7% 
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Table 17. Adjusted and unadjusted Cox proportional hazard model estimates for time to 
switch to second line after first line failure. 
Variable Crude HR 
HR 95% 
LCL 
HR 95% 
UCL 
Adjusted
* HR 
Adj. HR 
95% 
LCL 
Adj. HR 
95% 
UCL 
Viral load at first line failure             
  1000–9999 Ref           
  10000–59999 1.35 1.25 1.46 1.44 1.31 1.58 
  60000+ 1.34 1.24 1.45 1.34 1.21 1.49 
CD4 count at first line failure             
  0–49 1.52 1.34 1.73 1.32 1.14 1.52 
  50–99 1.37 1.20 1.55 1.16 1.01 1.32 
  100–250 1.26 1.16 1.38 1.18 1.08 1.30 
  >250 Ref           
Age               
  < 25 0.87 0.76 1.00 0.96 0.82 1.13 
  25–29.9 0.99 0.90 1.09 1.05 0.93 1.18 
  30–34.9 Ref           
  35–39.9 1.01 0.91 1.11 1.06 0.95 1.19 
  40–44.9 1.00 0.90 1.12 0.96 0.84 1.09 
  45–49.9 1.02 0.90 1.16 1.05 0.90 1.21 
  50–54.9 0.92 0.78 1.09 0.93 0.77 1.13 
  55+ 1.19 0.99 1.44 1.27 1.01 1.60 
Sex 
 
            
  Female Ref           
  Male 1.04 0.97 1.11 0.92 0.84 1.00 
Time on first line ART             
  0–1 year 1.16 1.04 1.31 0.95 0.82 1.12 
  1–2 years 0.98 0.87 1.10 0.99 0.85 1.16 
  2–3 years 0.93 0.82 1.06 0.99 0.84 1.16 
  3–4 years 0.90 0.78 1.04 0.96 0.79 1.15 
  >4 years Ref           
Percent of visits missed before failure             
  0–5% missed 1.02 0.93 1.11 1.21 1.08 1.35 
  5–10% missed 1.03 0.93 1.15 1.32 1.16 1.50 
  10–20% missed 1.09 0.98 1.20 1.22 1.08 1.38 
  >20% missed Ref           
Time between failing viral loads on 
first line             
  0–1.5 months 1.43 1.27 1.62 0.91 0.79 1.04 
  1.5–3 months 1.59 1.46 1.73 1.06 0.96 1.18 
  3–6 months 1.31 1.20 1.43 0.98 0.87 1.11 
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  >6 months Ref           
Hemoglobin level at failure             
  0–10 0.94 0.82 1.07 0.87 0.74 1.01 
  >10 Ref           
BMI at failure             
  underweight 0.93 0.81 1.07 0.82 0.70 0.97 
  normal Ref           
  overweight 0.99 0.91 1.07 1.00 0.91 1.10 
  obese 1.07 0.97 1.17 1.10 0.98 1.23 
TB history             
  positive 1.09 1.00 1.18 0.99 0.90 1.09 
  negative Ref           
Year of failure             
  2004 1.11 0.27 4.55 0.90 0.20 4.15 
  2005 1.55 1.16 2.09 1.17 0.77 1.78 
  2006 1.27 0.98 1.65 0.96 0.65 1.41 
  2007 1.68 1.33 2.12 1.43 0.99 2.06 
  2008 1.66 1.31 2.11 1.59 1.10 2.31 
  2009 1.85 1.47 2.32 1.77 1.23 2.55 
  2010 1.61 1.29 2.01 1.52 1.06 2.18 
  2011 1.60 1.29 1.99 1.40 0.98 2.00 
  2012 1.43 1.15 1.78 1.24 0.86 1.78 
  2013 Ref           
Clinic 
 
      
  
  
  Clinic C 1.30 1.15 1.47 
  
  
  Clinic H 0.78 0.71 0.87 
  
  
  Clinic G 0.64 0.54 0.76 
  
  
  Clinic I 0.63 0.47 0.84 
  
  
  Clinic D 1.46 1.30 1.64 
  
  
  Clinic F 0.70 0.62 0.79 
  
  
  Clinic E 0.17 0.14 0.20 
  
  
  Clinic A Ref     
  
  
  Clinic B 0.72 0.64 0.80       
* stratified by clinic, adjusted for year of failure, time between first line viral loads, age, sex, 
CD4, viral load 
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Table 18. Crude rates and proportions of outcomes on second line by time to switch 
group. 
  Time to switch groups: 
  0 to 1.5 mo 1.5 to 3 mo 3 to 6 mo 6 to 12 mo >12 mo 
N 1114 669 688 593 642 
Confirmed failure on second line 
Number failed 182 107 109 71 61 
Total person-days 742459 456759.5 414960.5 320907 287149 
Total person-years 2034 1251 1137 879 787 
Rate (failures per 100 
person years) 8.9473 8.5505 9.5877 8.0755 7.7538 
Crude IRR Ref 0.96 1.07 0.90 0.87 
            
Single failure on second line 
Number failed 446 267 271 214 181 
Total person-days 604453.5 371070 335935.5 257615 242499.5 
Total person-years 1656 1017 920 706 664 
Rate (failures per 100 
person years) 26.932 26.263 29.445 30.320 27.243 
Crude IRR Ref 0.98 1.09 1.13 1.01 
            
Single suppressed viral load 
Number suppressed 792 483 482 403 362 
Total person-days 228062 142696 145793.5 112389.5 122397.5 
Total person-years 625 391 399 308 335 
Rate (suppressions per 
100 person years) 126.76 123.55 120.67 130.88 107.95 
Crude IRR Ref 0.97 0.95 1.03 0.85 
            
N with at least 1 year 
of potential follow-up 
time 
1106 646 623 477 424 
Virologic outcomes at 1 year after second line, among patients with at least 1 year of 
potential follow-up time 
Failure (>1,000 
copies/mL) 
11.6% 13.0% 13.3% 11.5% 10.1% 
400–1000 copies/mL 3.4% 2.9% 2.6% 1.9% 5.7% 
Suppression (<400 
copies/mL) 
54.5% 55.7% 54.4% 58.7% 53.3% 
Lost to follow-up 30.5% 28.3% 29.7% 27.9% 30.9% 
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N with at least 2 years 
of potential follow-up 
time 
934 519 469 312 286 
Virologic outcomes at 2 years after second line, among patients with at least 2 years of 
potential follow-up time 
Failure (>1,000 
copies/mL) 
6.5% 6.7% 6.4% 5.4% 5.9% 
400–1000 copies/mL 2.6% 2.1% 1.9% 2.6% 2.8% 
Suppression (<400 
copies/mL) 
40.7% 46.4% 39.4% 40.7% 36.4% 
Lost to follow-up 50.2% 44.7% 52.2% 51.3% 54.9% 
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Table 19. Adjusted hazards ratios predicting time to failure on second line, among all 
patients who switched to second line after first line failure. 
Variable   Adj. HR 
HR 95% 
LCL 
HR 95% 
UCL 
Months to switch category         
  0 to 1.5 mo Ref     
  1.5 to 3 mo 0.962 0.757 1.221 
  3 to 6 mo 1.04 0.82 1.318 
  6 to 12 mo 0.865 0.657 1.138 
  >12 mo 0.819 0.613 1.095 
First line failing viral load level         
  1000–9999 0.52 0.423 0.639 
  10000–59999 0.701 0.567 0.867 
  60,000+ Ref     
Age         
  < 25 1.332 0.912 1.947 
  25–29.9 1.524 1.166 1.992 
  30–34.9 Ref     
  35–39.9 1.264 0.968 1.65 
  40–44.9 1.32 0.982 1.774 
  45–49.9 1.296 0.923 1.821 
  50–54.9 1.339 0.859 2.087 
  55+ 1.442 0.874 2.379 
Sex         
  Female 0.944 0.792 1.124 
  Male Ref     
First line failing CD4 count         
  0–49 0.528 0.346 0.805 
  50–99 Ref     
  100–249 0.647 0.487 0.86 
  250+ 0.574 0.428 0.771 
Hemoglobin         
  0–10 1.265 0.909 1.76 
  >10 Ref     
First line failing BMI         
  underweight 1.652 1.201 2.274 
  normal Ref     
  overweight 0.878 0.713 1.081 
  obese 0.769 0.59 1.002 
Time on first line ART         
  0–1 year 0.985 0.724 1.34 
  1–2 years 0.886 0.649 1.211 
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  2–3 years 1.118 0.8 1.561 
  3–4 years 0.865 0.574 1.305 
  >4 years Ref     
Percent missed visits on first line 
ART         
  0–5% missed 0.947 0.739 1.213 
  5–10% missed Ref     
  10–20% missed 1.054 0.803 1.383 
  20% missed + 0.874 0.652 1.172 
Time between failing viral loads 
on first line ART         
  0–1.5 months 1.158 0.849 1.58 
  1.5–3 months 1.065 0.845 1.344 
  3–6 months 1.13 0.879 1.452 
  >6 months Ref     
TB history         
  negative 0.896 0.73 1.102 
  positive Ref     
Year of failure         
  2004 – 2005 2.263 0.666 7.69 
  2006 3.292 1.022 10.605 
  2007 2.223 0.696 7.097 
  2008 2.307 0.719 7.405 
  2009 2.72 0.859 8.612 
  2010 2.069 0.652 6.567 
  2011 1.681 0.533 5.301 
  2012 1.657 0.519 5.292 
  2013 Ref     
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Table 20. Cox proportional hazards ratios of confirmed failure on second line ART 
stratified by peak CD4 count on treatment before time of first line failure. 
  Peak CD4 ≤ 100 cells/mm3 Peak CD4 > 100 cells/mm3 
N in model 496 2939 
Months to 
switch 
category 
N aHR* 95% LCL 95% UCL N aHR* 95% LCL 95% UCL 
0 to 1.5 mo 156 Ref - - 884 Ref - - 
1.5 to 3 mo 99 2.26 1.12 4.55 524 0.87 0.67 1.14 
3 to 6 mo 101 2.13 1.01 4.47 552 1.03 0.78 1.35 
6 to 12 mo 87 1.54 0.68 3.46 460 0.87 0.63 1.20 
>12 mo 53 1.35 0.49 3.73 519 0.73 0.52 1.02 
*Adjusted for gender, age, viral load level at failure, BMI at failure, year of failure, missed 
visits before failure, time on first line ART, clinic 
 
 
 
 
 
Table 21. Time remaining in clinic after first line failure among patients who did not 
switch to second line ART. 
 All Peak CD4 <= 100 Peak CD4 > 100 
  Frequency Percent Frequency Percent Frequency Percent 
0 to 1.5 month 273 12.6 67 22.79 206 10.97 
1.5 to 3 months 146 6.7 33 11.22 113 6.02 
3 to 6 months 194 8.9 36 12.24 158 8.42 
6 to 12 months 300 13.8 48 16.33 252 13.43 
>12 months 1258 58.0 110 37.42 1148 61.16 
Total 2171 100.0 294 100.00 1877 100.00 
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Table 22. Marginal structural model and Cox model results for hazards of death after first line failure. 
 All patients Peak CD4 ≤ 100 Peak CD4 >100 
  Marginal structural model Cox model 
Marginal structural 
model Cox model 
Marginal structural 
model Cox model 
 HR 
HR 
95% 
LCL 
HR 
95% 
UCL 
HR 
HR 
95% 
LCL 
HR 
95% 
UCL 
HR 
HR 
95% 
LCL 
HR 
95% 
UCL 
HR 
HR 
95% 
LCL 
HR 
95% 
UCL 
HR 
HR 
95% 
LCL 
HR 
95% 
UCL 
HR 
HR 
95% 
LCL 
HR 
95% 
UCL 
Time to 
switch:                   
No 
switch 1.31 0.96 1.78 2.42 1.73 3.38 1.55 0.95 2.53 2.68 1.54 4.65 1.20 0.82 1.76 2.26 1.51 3.38 
0–1.5 
months Ref   Ref   Ref   Ref   Ref   Ref   
1.5–3 
months 1.13 0.84 1.52 0.97 0.61 1.53 1.39 0.85 2.27 1.12 0.54 2.34 0.93 0.64 1.34 0.75 0.42 1.33 
3–6 
months 1.12 0.83 1.51 1.04 0.66 1.63 1.31 0.81 2.15 0.78 0.33 1.80 0.98 0.68 1.42 1.05 0.63 1.76 
6–12 
months 1.31 0.96 1.79 0.80 0.49 1.31 1.49 0.91 2.42 0.96 0.41 2.23 1.22 0.82 1.79 0.70 0.38 1.28 
>12 
months 1.22 0.90 1.66 0.27 0.13 0.53 1.52 0.94 2.46 0.26 0.06 1.13 1.11 0.77 1.62 0.26 0.12 0.56 
Gender:                   
Female Ref   Ref   Ref      Ref   Ref   
Male 1.10 0.80 1.53 1.17 0.92 1.49 0.81 0.46 1.42 1.19 0.78 1.80 1.37 0.92 2.02 1.20 0.90 1.60 
Age:                   
18–25 0.93 0.47 1.84 1.10 0.70 1.72 0.92 0.37 2.29 1.14 0.56 2.32 0.87 0.31 2.38 1.06 0.59 1.90 
25–30 1.00 0.60 1.66 1.07 0.75 1.53 0.76 0.34 1.68 1.12 0.63 2.00 1.22 0.64 2.33 1.18 0.76 1.81 
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30–35 Ref   Ref   Ref   Ref   Ref   Ref   
35–40 0.91 0.57 1.45 0.81 0.57 1.15 0.58 0.23 1.46 0.70 0.37 1.31 1.26 0.73 2.16 0.91 0.59 1.39 
40–45 0.69 0.40 1.21 0.95 0.65 1.37 0.39 0.15 0.99 0.61 0.30 1.23 1.02 0.53 1.97 1.22 0.78 1.90 
45–50 0.78 0.40 1.54 0.87 0.54 1.41 0.65 0.23 1.84 1.11 0.48 2.56 0.91 0.40 2.08 0.81 0.45 1.45 
50–55 1.52 0.75 3.08 1.18 0.72 1.95 1.06 0.35 3.22 1.04 0.43 2.54 1.75 0.70 4.37 1.35 0.74 2.43 
55+ 1.12 0.46 2.71 1.17 0.62 2.21 0.65 0.19 2.24 1.17 0.41 3.37 1.53 0.55 4.25 1.13 0.53 2.42 
Failing 
viral 
load: 
                  
1000–
9999 0.55 0.36 0.85 0.58 0.43 0.77 0.39 0.19 0.80 0.53 0.30 0.93 0.51 0.31 0.84 0.53 0.38 0.75 
10,000–
59,999 0.64 0.43 0.97 0.68 0.51 0.90 0.82 0.42 1.63 0.85 0.54 1.34 0.57 0.35 0.95 0.61 0.43 0.88 
60,000+ Ref   Ref   Ref   Ref   Ref   Ref   
CD4 
count at 
failure: 
                  
0–49 2.51 1.59 3.96 1.47 1.04 2.06       2.46 1.20 5.04 1.13 0.64 1.98 
50–99 Ref   Ref         Ref   Ref   
100–250 0.74 0.47 1.15 0.56 0.41 0.77       0.72 0.41 1.28 0.46 0.31 0.68 
>250 0.39 0.21 0.71 0.30 0.20 0.44       0.42 0.20 0.85 0.26 0.16 0.42 
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Figure 6. Hypothetical person time contributed to each of the 6 exposure groups in 
marginal structural models, for an individual who switches to second line ART in 1 
month (person 1), never (person 2), in 8 months (person 3), and in 4 months (person 4). 
Time of switch to second line is represented by a red line. 
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Figure 7. Trends in median clinic population CD4 count, relative to ART initiation, failure 
date, and switch date. 
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Figure 8. Kaplan-Meier curves of single failing viral load after 12 week delay from 
starting second line, among patients with very low (0–99 cells/mm3) CD4 count at first 
line failure. 
 
Figure 9. Kaplan-Meier curves of single failing viral load after 12 week delay from 
starting second line, among patients with CD4 count >100 cells/mm3 at first line failure. 
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Figure 10. Potential time dependent confounding by lab values and BMI values after first 
line failure and before switch to second line ART. 
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STUDY 3: EFFECT OF CHANGE IN NRTI FROM FIRST TO SECOND LINE ART ON SECOND 
LINE OUTCOMES 
 
OBJECTIVE 
Although drug resistance is rare at antiretroviral therapy (ART) initiation, most 
patients who fail first line ART have some resistance to nucleoside reverse transcriptase 
inhibitors (NRTIs) that are also used in second line regimens (30,35,37). In order to 
optimize the efficacy of NRTIs in second line, national treatment guidelines recommend 
that patients switch at least one NRTI when switching to second line ART (8,9,18,19,20). 
However, in practice switch in NRTI does not always occur, usually due to 
contraindications to specific NRTIs.  
Studies have shown that second line ART can successfully suppress HIV in the 
presence of NRTI drug resistance mutations (34,67,68,37,69,101), yet the number of 
NRTIs switched from first line to second line ART has been found to be associated with 
improved outcomes on second line ART (72). Patients on a failing regimen containing 
zidovudine (AZT) frequently have accumulation of thymidine analogue mutations 
(TAMs) that can cause reduced activity to AZT and stavudine (d4T). High numbers of 
accumulated TAMs (≥3) will also cause activity of tenofovir (TDF) to be limited (40). 
Patients on a failing regimen containing d4T also accumulate TAMs but usually at a 
slower rate, and have a less predictable pattern of drug resistance accumulations than 
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patients failing on AZT (35,56,62). Patients on a failing regimen containing TDF 
accumulate resistance mutations K65R and K70E, which cause the activity of TDF to be 
limited (62). These TDF specific resistance mutations have also been found among 
patients on AZT or d4T first line regimens, but at lower rates (41). The impact of switch 
to specific NRTIs in second line has not been explored to determine when switching 
NRTIs is influential with respect to outcomes on second line ART. 
The objective of this study is to analyze whether switching NRTIs from first to 
second line ART improves outcomes on second line ART. Specifically, this study will 
investigate whether switching from AZT in first line to a different NRTI in second line 
improves outcomes on second line among all patients on second line ART who were 
initiated on AZT, and among patients with renal failure who have fewer options for 
NRTIs in second line due to contraindications to TDF (9). Under current treatment 
guidelines in South Africa, patients with renal failure should be initiated on AZT rather 
than TDF, and these patients also cannot switch to TDF in second line ART. A switch in 
the second NRTI of the regimen will not be examined. As a comparison and to further 
investigate if NRTI resistance plays a role in second line outcomes, switch to a different 
NRTI at second line start among patients initiated on a first line regimen containing d4T 
and among patients initiated on a first line regimen containing TDF will also be 
considered. 
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METHODS 
Data Source 
This study uses data from the International Epidemiologic Databases to Evaluate 
AIDS Southern Africa (IeDEA-SA) cohort. IeDEA is a worldwide initiative for pooling data 
to address epidemiologic research questions surrounding HIV treatment, and is funded 
by the National Institutes of Health (http://iedea-sa.org). The Southern Africa cohort 
was established in 2006 and is one of seven regional cohorts within the IeDEA network. 
The Southern Africa database includes data on approximately 300,000 adults on ART 
from participating clinics in six southern African countries (Lesotho, Malawi, 
Mozambique, South Africa, Zambia and Zimbabwe). The IeDEA dataset was used in this 
analysis rather than the Right to Care Cohort used in the other studies because patients 
from outside of South Africa had more variability in the first line NRTI prescribed, and 
the database was large enough to allow restriction to specific NRTIs used in first line 
ART. This allowed us to ask specific questions about changes in drugs from first to 
second line (e.g. if a patient is initiated on first line with AZT and the patient fails first 
line what is the effect of switching to a second line regimen containing TDF vs. 
remaining on AZT?) 
Electronic data from the clinics are manipulated and formatted into a standard 
template used by IeDEA, and combined across sites. Data is collected for patients at the 
start of ART and at each follow-up visit. Data is compiled at the University of Cape Town 
in South Africa and the University of Bern in Switzerland. Clinic information includes 
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basic patient information such as date of birth, sex, height, weight, date of visits, lab 
values, diagnoses, and HIV treatment regimens. Use of viral load monitoring differs 
based on country-specific guidelines and size or resources of clinics. Viral load 
monitoring is standard in South Africa but very limited elsewhere. Seven of the thirteen 
participating sites are located in South Africa. 
 
Study design 
This study is a retrospective observational cohort study using prospectively 
collected clinical data. The study population includes adult patients initiated on a 
standard first line regimen (triple therapy including 2 NRTIs plus a non-nucleoside 
reverse transcriptase inhibitor (NNRTI), Introduction Table 1) who later switched to a PI 
containing second line regimen after treatment failure. All patients who had no NRTI 
identified at the start of their second line regimen were excluded from this analysis. To 
be included in the analysis, patients also must have some evidence of failure on first line 
ART: either a viral load >1,000 copies/mL among South African patients, or 2 
consecutive CD4 counts <100 or a 30% drop in peak CD4 level on first line ART among 
patients outside of South Africa where virologic monitoring is not done (80). Treatment 
interruptions were ignored, where once patients started on a drug they were assumed 
to stay on that drug while in treatment until a regimen switch was recorded.  
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Exposure variable 
The exposure for this study is switching NRTIs from first line to second line ART. 
NRTI used at second line initiation was categorized into AZT, d4T, TDF, abacavir (ABC), or 
other. The reference group was no change in NRTI from first line to second line ART. This 
exposure was evaluated in several ways: 
(1) Among patients initiated on AZT 
(2) Among patients initiated on AZT who had evidence of renal failure at baseline, 
defined as creatinine clearance <60 mL/min 
(3) Among patients initiated on d4T 
(4) Among patients initiated on TDF 
 
Outcome variables 
 Treatment failure on second line ART is the primary outcome for this study. 
Failure was defined differently depending on the clinic’s use of viral load monitoring. 
CD4 based definitions for treatment failure are not as accurate as viral load 
measurements. CD4 testing has a low sensitivity and high specificity for identifying 
treatment failure (102). In South Africa, where viral load monitoring was available the 
following definitions were used: 
(1) Confirmed virologic failure on second line ART, defined as the date of the second 
of two consecutive viral loads >1,000 copies/mL between two weeks and one 
year apart, any time after second line initiation. 
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(2) Single failing viral load measurement on second line ART, defined as any viral 
load measurement >1,000 copies/mL after the start of second line ART. 
 
For settings without viral load monitoring, standard immunologic definitions of 
treatment failure were used (103,104). These definitions are also in the Zambian 
National Treatment Guidelines. They are: 
(3) A 30% drop in CD4 count from the baseline CD4 value any time after the start of 
second line. For outcomes on second line, the baseline CD4 value is considered 
to be the CD4 value closest to second line ART initiation. 
(4) A 50% drop from the peak CD4 count on treatment any time after the start of 
second line ART. 
 
Covariates 
 Covariates considered in adjusted Cox models for each of the above outcomes 
included: year of ART initiation, country, clinic, age, sex, duration on first line ART, 
NNRTI in first line, time on first line ART, values of CD4 count, viral load, hemoglobin, 
creatinine clearance and WHO stage at first line ART initiation, and values of CD4, viral 
load, hemoglobin and creatinine clearance over time on first line and at second line 
initiation. Viral load levels were not available at all sites.  
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Analytic plan 
Descriptive analyses 
Stratified tables were used to examine the distribution of patient characteristics 
by switch compared to no switch in NRTI from first to second line regimen. Confounding 
by indication was assessed by comparing baseline values of creatinine clearance, 
hemoglobin, CD4 count, viral load, and WHO stage, and values at second line initiation 
of CD4, viral load, hemoglobin, and creatinine clearance, and adjusting if necessary in 
multivariate analyses. The proportion of subjects switching to each type of NRTI on 
second line was also examined, as well as trends in NRTI use over time.  
Overall crude rates of each outcome on second line by switch in NRTI from first 
line to second line were also examined. Rates were calculated using person-time, and 
examined graphically with Kaplan-Meier curves. Results were also be stratified by 
country.  
 
Multivariate analyses 
Cox proportional hazards models were used to analyze hazards of failure 
outcomes on second line over time and to adjust for confounding. Confounders at ART 
initiation and at second line switch were considered. Confounders were selected if they 
were identified as potential confounders using DAGs (Figure 11) and altered the hazard 
ratio for the exposure of interest by 10% or more. Models were also examined stratified 
by country, sex, viral load level at second line switch, and year of ART initiation to look 
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for modification among these variables. 
The models to compare remaining on AZT to switch from AZT to a different NRTI 
in second line were also run on a subset of patients with renal failure, who should not 
be put on TDF in second line (9). Renal failure was defined as creatinine clearance levels 
<60 mL/min.  
To maximize sample size in the adjusted analyses, a missing category was 
created missing covariates. For comparison, multiple imputation was also used to 
impute missing covariates and adjusted hazards models were also run using imputed 
data and proc mianalyze in SAS (46,83,84).  
Lastly, propensity scores were used in adjusted analyses to make the non-
randomized treatment groups comparable, and to maximize statistical efficiency (109). 
Propensity scores were calculated separately for South Africa and Zambia using logistic 
regression to predict switch to individual second line NRTIs in a series of dichotomous 
comparisons, from imputed covariates at ART initiation and at start of second line ART 
(Figure 11). For example, to compare switch to TDF compared to remaining on AZT for 
patients initiated on AZT, a logistic regression model predicting switch in NRTI was 
calculated among all patients who initiated on AZT and were prescribed either TDF or 
AZT in second line. The predicted probability of switching to TDF was then output, and a 
histogram was created to compare overlap in propensity scores. If the histogram 
showed some overlap in scores, the propensity score was used as a single covariate for 
adjustment in survival models predicting outcomes on second line ART. 
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Sensitivity analyses  
Several variations of the models were run in sensitivity analyses.  
(1) Models were run in the Right to Care cohort in South Africa to ensure that 
results were not specific to the prescribing patterns at the clinics in the IeDEA 
data set. 
(2) Among South African patients, the population was further limited to patients 
who had 2 consecutive viral loads >1000 copies/mL, to help ensure that 
switching to a PI-based regimen was due to failure on first line. 
(3) Possible switches to a PI-based regimen due to pregnancy or desire to get 
pregnant were accounted for by excluding female patients who were on EFV 
and did not have a switch in NRTI at second line, also to help ensure that 
regimen switch was due to failure on first line. 
(4) Models were run for outcomes within 1 and 2 years after second line 
initiation, among patients who had at least 1 or 2 years of potential follow-up 
time on second line ART, to account for differing follow-up time related to 
which drug was used in second line. Outcomes examined in these models 
included a single failing viral load (>1000 copies/mL) or a single suppressed 
viral load (<400 copies/mL) among South African patients, and a single low 
CD4 count (<100 copies/mm3) among Zambian patients.  
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RESULTS 
 
Study sample 
 The IeDEA-SA dataset includes patients from 13 cohorts in South Africa, Zambia, 
Zimbabwe, Mozambique and Malawi. Overall there were 293,339 adult patients started 
on first line ART across these sites. Clinic sites outside of Zambia and South Africa had so 
few patients switched to PI containing second line regimens that they were not included 
in the analysis. In South Africa and Zambia, there were 255,841 patients initiated on first 
line ART (Table 23). The CIDRZ cohort in Zambia was comprised of 104 individual clinic 
sites, with patient populations ranging from 1 to 10,781 individuals.  
 The sample for analysis was limited to patients who switched to a PI-based 
second line regimen. In South Africa, 7,520 patients on second line were identified (9.4% 
of patients ever initiated on first line ART), and in Zambia 3,673 patients on second line 
were identified (2.1% of patients ever initiated on first line ART). In order to ensure that 
second line switches were treatment failure related, the sample was further limited to 
patients who had evidence of poor treatment outcomes on first line ART. In South 
Africa, patients who had at least one elevated viral load >1000 copies/mL on first line 
ART were included in the analysis (4,614 out of 7,520, or 61.4% of patients that were on 
a PI-based regimen). In Zambia, 56.1% of patients had evidence of immunologic failure 
on first line ART (2,061 out of 3,673 patients that were on a PI-based regimen) and were 
included in analysis. Lastly, patients without visits after date of switch to second line 
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(2.5%) and patients who did not have any NRTI identified in the regimen at time of 
second line initiation (3.1%) were excluded. The total sample for analysis included 6,303 
patients (4,275 in South Africa and 2,028 in Zambia).  
 
Description of population 
 Among the 6,303 patients in analysis, 91% had a switch in NRTI at the time of 
second line initiation. A description of the study population is shown in Table 24. 
Patients were similar with respect to CD4 count at ART initiation and age. More patients 
who did not switch NRTIs at second line initiation were Zambian patients. The group of 
patients who did not switch second line also had fewer missing lab values, which may be 
an indication that patients who did not switch NRTIs were being monitored for a 
contraindication to certain NRTIs. It appeared that some patients who switched NRTIs at 
second line were slightly sicker on first line ART. South African patients who switched 
NRTIs were more likely to have confirmed virologic failure on first line ART (77%) 
compared to patients who remained on the same NRTI (44%), and less likely to have 
evidence of viral suppression on first line ART (59%) compared to patients who 
remained on the same NRTI (72%). Time on first line ART was very similar for both 
groups. The median duration on first line was 27.8 months for patients who did not 
switch NRTI at second line, and 27.7 months for patients who did switch NRTIs at second 
line. 
 Most patients initiated on d4T on first line ART (63%), while other patients 
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initiated on AZT on first line (22%) or TDF in first line (15%). Very few patients (<1%) 
initiated on ABC or a different NRTI on first line ART. Initiation on TDF has become much 
more common in recent years with the updated treatment guidelines. Zambia began 
using TDF more recently than South Africa, so the proportion of patients switching to 
TDF in second line was higher among Zambian patients overall (Table 25).  Similarly, 
initiation on d4T has become less common over time, while the proportion of patients 
initiating on AZT has remained more constant. Very few patients switched to a d4T-
containing regimen in second line. The NRTIs in second line by year are displayed in 
Figure 12, and shows very few patients had d4T in second line at any time. Numbers of 
patients switching to each NRTI at second line by NRTI initiated in first line and stratified 
by country are displayed in Table 25.  
Follow-up time on second line depended on the outcome of interest and the 
stratum of NRTI used in first line ART. For example, patients initiated on d4T in first line 
had the longest follow-up time, and patients initiated on TDF in first line had the 
shortest follow-up time available due to national treatment guideline policy (Table 26). 
When follow-up time was examined by NRTI used in second line, patients on ABC or TDF 
in second line had the least follow-up time available overall. For the virologic failure on 
second line outcome in South Africa, patients on ABC in second line had 15.2 months 
(IQR: 8.7–18.7) of follow up time, patients on TDF had 17.0 months (IQR: 14.2–22.9), 
patients on AZT had 19.8 months (IQR: 13.6–34.4), and patients on d4T in second line 
had 23.9 months (IQR: 15.6–37.1) of follow up time on second line. In Zambia, this trend 
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was not as strong, and unlike in South Africa, patients on ABC in second line had the 
longest amount of follow-up time on second line ART. As can be seen in Figure 12, ABC 
was the most common second line NRTI in Zambia in earlier years. It was used less 
frequently in South Africa, and was also more commonly prescribed in earlier years for 
patients switching from AZT. For the 50% drop in CD4 count outcome in Zambia, 
patients on AZT in second line had 15.0 months (IQR: 5.8–23.2), patients on d4T had 
17.7 months (IQR: 9.7–23.7), patients on TDF had 18.1 months (IQR: 8.1–30.7), and 
patients on ABC had 18.5 months (IQR: 8.8 – 34.4) of follow-up time on second line ART.   
 
Outcomes on second line ART 
Among patients initiated on AZT in first line 
 Among patients initiated on AZT in first line, very few patients switched to d4T in 
second line ART (Table 25, Figure 12). Outcomes for switch from AZT could only be 
compared for patients who switched to ABC or TDF compared to those who remained 
on AZT.  
 For patients in South Africa, crude and adjusted results showed an association 
between switching from AZT to TDF and reduced failure on second line compared to 
staying on AZT. In crude analyses ABC use in second line was associated with increased 
failure on second line compared to staying on AZT, but this association was due to 
confounding by clinic, where Clinics A&B had increased use of ABC and higher rates of 
failure. When this clinic was excluded from the crude analysis switching from AZT to ABC 
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in second line was associated with slightly decreased failure rates in second line vs 
remaining on AZT, yet the confidence intervals were very wide. When Clinics A&B were 
excluded from analysis, there were not enough patients switching to ABC in second line 
(5 patients total) for the comparison to be meaningful. 
 In adjusted analyses that controlled for clinic site, sex, age category, baseline 
hemoglobin, CD4 count, and creatinine clearance, where missing values were included 
as a separate category, switching from AZT to TDF also appeared to be beneficial 
compared to remaining on AZT, for both confirmed virologic failure on second line ART 
(aHR: 0.54; 95% CI: 0.21, 1.35) and a single failing viral load on second line (aHR: 0.58; 
95% CI: 0.33, 1.03) (Table 27). When using multiple imputation to impute missing 
covariates rather than a separate category for missing, results showed similar 
associations (the aHR for confirmed virologic failure on second line ART for switching to 
TDF vs. remaining on AZT was 0.51 (95% CI: 0.21, 1.23), and the aHR for a single failing 
viral load on second line ART for switching to TDF vs. remaining on AZT was 0.55 (95% 
CI: 0.31, 0.97), Table 28). While these models adjusted for confounders at first line ART 
initiation only, the propensity score analysis was able to account for more variables, 
including values of creatinine clearance, hemoglobin, and CD4 count at the start of 
second line ART, without losing precision in the confidence intervals.  Adjusting for 
propensity scores also showed consistent results for lower hazards of failure on second 
line ART among those who switched to TDF rather than remain on AZT (aHR: 0.43; 95% 
CI: 0.16, 1.18) (Table 28). The similarity in hazard ratios indicates that there is limited 
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confounding from variables at the start of second line ART, or that those variables were 
poorly measured. The overlap in propensity scores for switch to TDF compared to 
staying on AZT is shown in the Appendix (Figure A3A; Part 1).  
It was unclear if switching to ABC was beneficial compared to remaining on AZT. 
Very few patients in South Africa were switched to ABC outside of Clinics A&B, and the 
propensity scores for switch to ABC compared to remaining on AZT showed no overlap 
(Appendix Figure A3A; Part 3), indicating that the patients switched to ABC in second 
line were not comparable to patients remaining on AZT. The hazard ratio for confirmed 
failure on second line ART for switching to from AZT to ABC compared to remaining on 
AZT showed no difference (aHR: 1.08; 95% CI: 0.26, 4.58), yet the confidence interval 
was wide. The hazard ratio for a single failing viral load similarly showed a HR close to 1, 
but some evidence of reduced failure on second line (aHR: 0.74; 95% CI: 0.29, 1.88) 
(Table 27).  
 For patients in Zambia, both crude and adjusted results show that switching to 
from AZT to either ABC or TDF compared to remaining on AZT was beneficial. The 
adjusted hazard ratio for 50% drop in peak CD4 count while on second line ART for 
patients switching to ABC compared to remaining on AZT was 0.70 (95% CI: 0.38, 1.32) 
and for switching to TDF compared to remaining on AZT was 0.66 (95% CI: 0.37, 1.16) 
(Table 27). Models using multiple imputation and propensity score adjustment showed 
consistent results (Table 28). Unlike in South Africa, there was some overlap in 
propensity score for switch to ABC compared to remaining on AZT in Zambia (Appendix 
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Figure A3A), and there were more patients in Zambia who switched to ABC in second 
line.  
 
Sensitivity analyses 
 In sensitivity analyses, switches to second line that may be due to pregnancy 
(women on EFV who switched to a PI but with no change in NRTI) were excluded, and 
models were run among South African patients with confirmed failure on first line ART. 
Neither of these analyses altered the results. 
One-year and two-year outcomes on second line ART among patients with at 
least 1 year and at least 2 years of potential follow-up time on second line ART were 
examined to account for differing lengths of follow-up time depending on which NRTI 
was used in second line. The one-year outcomes for South Africa still showed reduced 
second line failure for patients switched from AZT to TDF (aHR: 0.75; 95% CI: 0.38, 1.48), 
and switching from AZT to ABC compared to remaining on AZT still showed a hazard 
ratio close to 1 (aHR: 0.90; 95% CI: 0.30, 2.72). Similarly among patients in Zambia, 
hazards of having a CD4 count drop below 100 cells/mm3 were still highest among 
patients who remained on AZT rather than switching to a different NRTI. For patients 
switching to ABC, the HR for a low CD4 count on second line ART was 0.55 (95% CI: 0.24, 
1.23), and for patients switching from AZT to TDF the HR for a low CD4 count on second 
line ART was 0.46 (95% CI: 0.22, 0.96). These hazard ratios for a low CD4 count were 
further reduced when looking at 2-year outcomes for patients with at least 2 years of 
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follow-up time on second line ART. 
Finally, when the same outcomes were run within the Right to Care cohort, the 
protective effect of switching to TDF compared to remaining on AZT was reduced (aHR: 
0.89; 95% CI: 0.52, 1.51). In the Right to Care cohort there were too few patients who 
switched to ABC to analyze outcomes among patients on ABC in second line. Rates of 
outcomes over 1 and 2 years on second line were also examined in the Right to Care 
cohort, and also showed the protective effect of TDF was reduced (aHR for failure on 
second line: 0.92; 95% CI: 0.66, 1.29). 
 
Among patients with renal failure 
 Patients with renal failure have fewer options on second line since they cannot 
switch from AZT to TDF on second line. Among all patients initiated on AZT on first line, 
197 had moderate to severe creatinine clearance levels (< 60 mL/min) at ART initiation, 
190 of whom were in Zambia. The models could only be run among Zambian patients 
when limiting the population to those with renal failure. Zambian ART guidelines started 
using TDF, which requires renal sufficiency testing, earlier than South Africa. 
Overall, results showed that patients who switched from AZT to a different NRTI 
did better on second line than among those who remained on AZT (Table 29). Hazard 
ratios for poor immunologic outcomes on second line ART for switch to ABC were close 
to 1, but showed some evidence that switching to ABC may improve outcomes on 
second line ART (aHR for 50% drop in CD4 count on second line ART: 0.58; 95% CI: 0.20, 
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1.70). Results consistently showed that switching to TDF in second line was associated 
with less immunologic failure compared to remaining on AZT (aHR for 50% drop in CD4 
count on second line ART: 0.23; 95% CI: 0.09, 0.62).  
 
Among patients initiated on d4T in first line 
Among patients initiated on d4T in first line, crude analyses of patients in South 
Africa showed that switching from d4T to TDF was associated with reduced hazards of 
failure on second line ART than remaining on d4T (Table 30). In adjusted analyses, 
hazard ratios indicated that switching NRTIs was associated with reduced failure on 
second line ART, and these hazard ratios appeared stronger when limiting the patient 
sample in South Africa to patients who had documented failure on first line ART. Among 
these patients, switching to TDF compared to remaining on d4T in second line was 
associated with less failure on second line ART (aHR: 0.63; 95% CI: 0.38, 1.03).  
Switching to ABC was less common and was associated with wide confidence 
intervals, but there was some evidence of reduction in hazard ratios for failure on 
second line ART among patients switching to ABC as well (aHR: 0.65; 95% CI: 0.37, 2.18). 
Again, in the propensity score analysis, there was very little overlap in propensity 
between switching to ABC compared to remaining on d4T, indicating that the group of 
patients prescribed ABC in second line in South Africa is so different that they are not 
comparable to the patients on d4T. In all of the models, including models using imputed 
baseline variables and adjustment for propensity scores, there was no association 
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between outcomes on second line and switching to AZT compared to remaining on d4T 
in second line ART (aHR: 0.97; 95% CI: 0.61, 2.26) (Table 30, Table 28). As in the models 
for switch from AZT, propensity scores also adjusted for confounders at start of second 
line ART.  
Among Zambian patients, a similar result was seen for reduction in hazards of a 
50% drop in CD4 count on second line associated with switching from d4T to ABC (aHR: 
0.56; 95% CI: 0.28, 1.10) or TDF (aHR: 0.78; 95% CI: 0.44, 1.39). There was also no 
association between switching from d4T to AZT compared to staying on d4T in second 
line and drop in CD4 count on second line ART among Zambian patients (aHR: 0.97; 95% 
CI: 0.50, 1.86) (Table 30). 
 
Sensitivity analyses 
One-year outcomes on second line ART among patients with at least 1 year of 
follow-up time on second line ART also indicated that there may be a reduction in failure 
on second line when switching from d4T to ABC or to TDF. Among patients with 1 year 
of follow-up time in South Africa, hazards of failure on second line were close to null for 
all NRTIs used in second line ART. Among patients who had at least 2 years of follow-up 
time on second line ART, switching to TDF compared to remaining on d4T appeared to 
be associated with reduction of virologic hazards (aHR: 0.83; 95% CI: 0.63, 1.11). For 
Zambian patients, patients with at least 1 year of potential follow-up time on second 
line ART who switched to TDF had reduced hazards of a low CD4 count on second line 
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ART (aHR 0.75; 95% CI:  0.27, 2.12), and who switched to ABC had reduced hazards of a 
low CD4 count on second line ART (aHR: 0.70; 95% CI: 0.28, 1.99). Among the Zambian 
patients, confidence intervals became quite wide due to restricting the patient 
population and the low number of patients who remained on d4T in second line ART.  
When the models for switch from d4T to a different NRTI in second line ART 
were run in the Right to Care cohort, a reduction in hazards was seen among patients 
who switched to TDF in second line ART (aHR: 0.77; 95% CI: 0.45, 1.34), yet a switch to 
any other NRTI (AZT or ABC) was not associated with a change in rate of failure on 
second line ART.  
 
Among patients initiated on TDF in first line 
 Follow-up time was more limited for patients initiating on TDF in first line ART 
because the drug was introduced into national program later than d4T and AZT, and the 
sample size was smaller. The majority of patients initiated on TDF switched to AZT in 
second line, but overall in South Africa and Zambia combined 17% of these patients still 
remained on TDF in second line (Table 25). For patients in South Africa, results for 
switching from TDF to a different NRTI in second line were inconsistent. Hazard of 
confirmed failure appeared to be reduced for all NRTIs in second line compared to 
remaining on TDF, for both crude and adjusted results (aHR for switching to AZT 
compared to remaining on TDF: 0.32; 95% CI: 0.12, 0.91). Confidence intervals for a 
single failing viral load on second line were wide, and hazard ratios were all close to 1 or 
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>1, indicating that switching from TDF to a different NRTI at second line initiation would 
offer no benefit on second line ART (Table 31). Models using imputed covariates and 
propensity scores similarly showed that switching to AZT in second line compared to 
remaining on TDF was associated with decreased confirmed failure on second line ART 
(aHR: 0.44; 95%CI: 0.14, 1.42), but was not associated with a decrease in the rate of a 
single failing viral load on second line ART (aHR: 1.10; 95%CI: 0.40, 3.02) (Table 28). 
Among Zambian patients, rates of a 50% drop in peak CD4 count on second line ART 
were increased for patients switching to a different NRTI at second line initiation. For 
patients switching to AZT, in adjusted models, the HR for 50% drop in CD4 count on 
second line ART was 1.98 (95% CI: 0.96, 4.06) (Table 31).  
 
Sensitivity analyses 
Among patients with at least 1 year of follow-up time on second line ART, most 
models indicated that switching NRTIs at second line initiation compared to remaining 
on TDF was associated with higher rates of failure on second line ART, yet the sample 
size for this analysis was very small (351 in South Africa and 222 in Zambia). Among 
South African patients, 1-year outcomes for a failing viral load all hazard ratios were 
close to 1. In the 1-year outcomes for a low CD4 count among Zambian patients, 
compared to remaining on TDF in second line ART, switching to AZT was associated with 
a hazard ratio of 1.41 (95% CI: 0.75, 2.64), switching to ABC was associated with a 
hazard ratio of 0.63 (95% CI: 0.28, 1.42), and switching to d4T was associated with a 
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hazard ratio of 1.93 (95% CI: 0.89, 4.17).  
In the Right to Care cohort, results also indicated slightly elevated hazards of 
failure on second line associated with switching to an NRTI rather than remaining on 
TDF in second line ART, with very wide confidence intervals. The hazard ratios were 
mostly elevated for a switch to d4T (aHR: 7.59; 95% CI: 2.18, 26.44).  
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DISCUSSION 
 
Previous research has shown that protease inhibitor (PI) based second line ART 
can successfully suppress HIV in the presence of drug resistance mutations and that lack 
adherence is a likely cause of failure on second line (52,71), yet this study suggests that 
the NRTI used in second line ART does influence outcomes on second line treatment. 
We saw that, especially among patients on AZT in first line, switching to TDF in second 
line ART was associated with less virologic and immunologic failure on second line. 
About 81% to 90% of patients who fail first line have NRTI resistance at first line failure 
(30,35,36,37), and at the time of failure of second line ART in South Africa, 
approximately 29% of patients have been shown to have NRTI drug resistance 
mutations, yet only 6% of patients had resistance to PIs (40). Thus, it is possible that 
NRTI resistance plays a role in failure of second line ART and that switching NRTIs could 
be beneficial, even if NRTI resistance is a less important factor than lack of treatment 
adherence.  
 
Patients initiated on AZT 
 Among patients on AZT in first line ART, most models showed that switching to 
TDF on second line was beneficial compared to remaining on AZT (propensity score-
adjusted HR for failure on second line among South African patients for switching to TDF 
compared to remaining on AZT = 0.43; 95% CI = 0.16,1.18; Table 28). Among Zambian 
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patients, switching to ABC also appeared to be beneficial with respect to immunologic 
failure, but it was unclear among South African patients if switching to ABC led to less 
virologic failure on second line, or if it did not change second line outcomes compared 
to remaining on AZT. Lack of overlap in propensity scores between patients switched to 
ABC rather than remaining on AZT indicated that these groups were not comparable in 
South Africa.  
Initiating first line ART on AZT is not standard practice in South Africa, and would 
typically only have been prescribed over d4T (under the 2004 treatment guidelines) 
when patients have pre-existing peripheral neuropathy or if patients were at greater risk 
of hyperlactatemia. Once TDF became available in first line ART in South Africa in 2010, 
patients typically only are initiated on AZT over TDF if they have renal failure. In Zambia, 
AZT was a more common regimen option in first line ART, and was part of national 
guidelines before 2010.  
Among patients initiated on AZT who had evidence of renal failure, the sample 
size was quite small and models could only be run among Zambian patients. Zambia 
began using TDF in standard regimens earlier than in South Africa, so creatinine testing 
became standard earlier in Zambia because TDF is contraindicated among patients with 
renal failure. Severity of renal failure was not adjusted in this analysis because almost all 
patients had moderate-level renal failure. Results suggested that patients switching to 
TDF did better than those remaining on AZT (aHR for 50% drop in peak CD4 count for 
patients who switch to TDF compared to patients who remain on AZT = 0.23; 95% CI = 
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0.09, 0.62; Table 29). Yet, this finding may be confounded by severity of renal disease at 
second line ART initiation, where patients with the most severe renal failure would 
remain on AZT rather than switching to TDF, assuming that patients with less severe 
renal failure have better outcomes on second line ART. The group of patients that 
switched to ABC on second line, which can include patients with renal failure, also was 
associated with a lower rate of a 50% drop in peak CD4 count on second line, despite 
wide confidence intervals (aHR for 50% drop in peak CD4 count for patients who switch 
to ABC compared to patients who remain on AZT = 0.58; 95% CI = 0.20, 1.70; Table 29).  
These results are consistent with the possibility that drug resistance mutations 
accumulated over time with a failing AZT regimen inhibit the activity of AZT in a second 
line regimen. The TAMs that are commonly accumulated on a failing AZT regimen may 
limit activity of AZT in second line ART, but TAMs would need to be present in high 
number to limit the activity of TDF, and may not affect activity of ABC (40,62). TAMs also 
limit the activity of d4T, but since it was very uncommon to switch to d4T in second line, 
a comparison between switch to d4T and remaining on AZT could not be interpreted.  
 
Patients initiated on d4T 
First line initiation on d4T was the standard, most commonly prescribed NRTI 
through 2010 in South Africa and prior to 2007 in Zambia. Patients initiated on d4T 
commonly switched to AZT, and in later years to TDF in second line ART. Use of d4T in 
second line ART was not part of standard regimens other than in Zambia in 2004–2006 
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when it was used in addition to didanosine (ddI) in second line ART. Compared to 
remaining on d4T in second line, models in this study indicated that switching to ABC or 
TDF in second line was associated with improved outcomes, overall. Switching from d4T 
to TDF rather than remaining on d4T was associated with reduced virologic and 
immunologic failure. The propensity score adjusted HR for confirmed virologic failure 
among South African patients for switch to TDF compared to remaining on d4T was 0.77 
(95% CI: 0.51, 1.16) (Table 28). The propensity score adjusted HR for 50% drop from 
peak CD4 count among Zambian patients for switch to TDF compared to remaining on 
d4T was 0.82 (95% CI: 0.44, 1.51) (Table 28). Most models for Zambian patients 
indicated a trend toward reduced immunologic failure associated with switch to ABC 
compared to remaining on d4T as well, yet again among South African patients those 
who switched to ABC were not comparable to those remaining on d4T, with little to no 
overlap in propensity scores (Appendix Figure A3A).  
Switching from d4T to AZT, however, did not influence second line outcomes, 
with most models for switch to AZT showing a HR close to 1 (aHR for confirmed virologic 
failure on second line ART = 1.17; 95% CI: 0.84, 1.62; Table 28). This result was 
consistent in Zambia models and among sensitivity analyses. Since TAMs accumulate 
over time on a failing d4T regimen, and limit the activity of AZT but only limit activity of 
TDF in high numbers (40,62), switching from d4T to AZT in second line ART may be less 
beneficial because of these resistance mutations. 
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Patients initiated on TDF 
 Fewer patients on second line ART had been initiated on TDF in first line ART, 
since TDF was only available in more recent years (in Zambia after 2007 and in South 
Africa after 2010). Due to the smaller sample size, particularly in South Africa, 
confidence intervals for some outcomes were quite wide, and results were inconsistent. 
For the confirmed failure on second line ART outcome among South African patients, 
virologic failure was reduced when the NRTI was switched from TDF (aHR for confirmed 
virologic failure on second line ART for switch to AZT compared to remaining on TDF= 
0.44, 95%CI: 0.14, 1.42), yet other outcomes showed no difference or increased failure 
associated with switch in NRTI among patients initiated on TDF.  
 Drug resistance mutations that accumulate over time on TDF could potentially 
limit the activity of TDF in second line ART, but these results do not show a substantial 
limitation in the activity of TDF in second line. Mutations specific to TDF (K65R and 
K70E) are not as common as TAMs, and have been found in 46% of patients failing a first 
line TDF regimen (106).   
 
Study strengths, weaknesses & future direction 
 The main weakness of this study is that it is difficult to determine if patients who 
remain on the same NRTI in second line are comparable to patients who switch NRTIs. In 
general, patients should switch NRTIs at second line ART initiation if they do not have 
contraindications to the NRTI specified in guidelines, such as anemia (a toxicity 
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associated with AZT), renal failure (a toxicity associated with TDF), or peripheral 
neuropathy, lipodystrophy, or lactic acidosis (toxicities associated with d4T). Otherwise, 
patients may be put on a PI-based regimen without a change in NRTI if they are 
switching for a reason other than failure, such as side effects associated with an NNRTI, 
or women on EFV who are pregnant or are trying to become pregnant. Patients who 
remain on the same NRTI because of complications that do not allow them to take 
certain second line drugs may have worse outcomes on second line ART due to these 
contraindications, or the severity of their contraindications. On the other hand, patients 
who switch to a different NRTI on second line may include more patients who truly 
failed first line ART, and these patients may also have worse outcomes on second line 
ART. In descriptive analyses, patients who switched NRTIs in second line were more 
likely to have stronger evidence of first line failure and less evidence of suppression on 
first line ART (Table 24). Lastly, patients may not switch to the preferred NRTI on second 
line ART due to drug availability. For example, in early 2012 there was a shortage of TDF 
in South Africa and patients were initiated on alternative regimens. 
 We attempted to control for differences between patients who switched NRTIs 
on second line and those who did not in several ways. First, to ensure patients were true 
failures and not switching for pregnancy related reasons, we limited the patient 
population to those with some evidence of virologic or immunologic failure on first line. 
We also performed sensitivity analyses in which patients who were possible switches for 
pregnancy (women most recently on EFV without a switch in NRTI) were excluded, and a 
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sensitivity analysis in which we limited South African patients to those who had 
confirmed virologic failure on first line ART (rather than just one failing viral load on first 
line, which was required for inclusion in the study). These sensitivity analyses generally 
did not alter outcomes, with the exception of the analysis for switch from d4T to TDF 
among South African patients, where restricting the population to those with confirmed 
virologic failure on first line strengthened the protective effect of switch in NRTI (Table 
30), likely due to residual confounding. 
 In multivariate models, statistical control for confounders minimized 
confounding by indication. Variables at ART initiation and at second line switch were 
potential confounders, such as CD4 count, hemoglobin, and creatinine clearance (Figure 
11). In multivariate models, age, sex, and baseline confounders were controlled for, 
while in propensity score adjusted models, confounders at the start of second line ART 
were also controlled for. Due to the large number of confounders and sometimes small 
group sizes, propensity scores were used to minimize confounding while maximizing 
statistical efficiency. Overall, models adjusted using propensity scores had the same or 
slightly narrower confidence intervals, but adjusted for more potential confounders. 
Adjusting survival models for propensity scores allowed for two non-randomized 
treatment groups (ie. switch to “X” NRTI vs. remain on the same NRTI) to be comparable 
to each other with respect to all covariates that created the propensity score (105). 
Also, by examining histograms of propensity scores we could visually inspect whether 
the groups that were compared had enough overlap for the comparison to be logical. 
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There was no overlap in propensity scores for South African patients who switched to 
ABC compared to South African patients who remained on the same NRTI (in each of the 
analyses for remaining on AZT, remaining on d4T, or remaining on TDF), as a result, the 
outcomes for switch to ABC among South African patients should not be given much 
weight. 
 Another potential study weakness was the differing follow-up time associated 
with each NRTI used in second line ART. For example, patients on TDF in second line 
tended to have less follow-up time, particularly in South Africa. In sensitivity analyses 
that restricted the patient population to those with 1 year or 2 years of potential follow-
up time after switch to second line ART, results were mostly consistent with the 
unrestricted models. 
 Missing data was a potential study weakness as well. Both creating a category 
for missing covariate values and multiple imputation of missing covariate values were 
used as approaches to be able to include all patients in adjusted analyses. Both 
approaches produced similar results. There is also likely misclassification of the study 
outcomes, particularly in models for Zambia using immunologic failure, because low 
CD4 count is a poor predictor of virologic failure. Outcomes for models for Zambian 
patients tended to be consistent with outcomes for South African patients, with the 
exception of the switch from TDF to AZT compared to staying on TDF, where South 
African models indicated a benefit or no change in second line outcomes associated 
with switching and Zambian models indicated more immunologic failure on second line 
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ART associated with switching to AZT.  
The strength of this study is the ability to analyze changes to specific NRTIs used 
in second line ART stratified by NRTI in first line ART. Numbers of patients for some 
strata were too small for models to run precisely, yet the variation in NRTIs prescribed, 
particularly in Zambia, and access to both the IeDEA and Right to Care dataset allowed 
us to look at this question in detail in terms of specific NRTIs prescribed. Since previous 
studies have shown mixed results when investigating the role that NRTI resistance plays 
in second line effectiveness, we were able to determine when NRTI resistance may play 
a role in second line outcomes. On one hand, studies indicate that PIs are so powerful 
that patients on regimens that are partially inactive due to NRTI resistance do not have 
worse outcomes than patients with fully active regimens (52,70,71). Yet, other studies 
have shown that failure rates depend on the number of NRTIs switched from first to 
second line ART (72). Outcomes in this study showed that switching to TDF tended to be 
associated with the most improved outcomes on second line, which may be due to TDF 
being associated with better treatment outcomes among the South African population 
overall (107). Yet, the results were still consistent with NRTI resistance, especially TAMs, 
playing a role in second line outcomes. After the M184V mutation associated with 3TC 
and FTC, TAMs are the most common type of NRTI resistance mutation at first line ART 
failure in South Africa (41).  
Our study suggests that higher rates of failure on a second line regimen 
containing AZT may be associated with TAMs that are accumulated over time on failing 
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first line AZT and d4T regimens, but this result should be interpreted cautiously due to 
potential residual confounding. For patients initiated on AZT, switching to TDF was 
associated with decreased failure rates, switching to ABC could only be evaluated in 
Zambia but was also associated with decreased failure rates, and too few patients 
switched to d4T in second line for switch to d4T to be evaluated. Results for switch from 
d4T in first line were also consistent with TAMs being harmful in second line ART for 
patients on AZT. TAMs also accumulate on a failing d4T regimen, and switch from d4T to 
TDF in second line was beneficial, but switch to AZT in second line was not. Since many 
patients were initiated on d4T in the past, this result highlights the importance of 
switching to TDF in second line rather than AZT when possible for patients failing d4T. 
Switching from TDF to a different NRTI in second line was associated with mixed results, 
but we had limited follow-up time on second line for patients initiated on TDF in first 
line. Still, there was no clear trend that TDF in second line was beneficial for patients 
initiated on TDF, which supports the theory that TDF was better in second line than AZT 
in second line for patients who failed AZT or d4T on first line due to the presence of 
TAMs. 
To investigate the potential for TAMs to be harmful to second line regimens 
containing AZT in the future, we would ideally collect information on drug resistance 
genotype at first line failure, as well as more detail about renal failure or other 
contraindications to NRTIs and reason for switch or no switch in NRTI. Further follow-up 
of patients on AZT with renal failure who fail first line and further follow-up of patients 
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initiated on TDF who fail first line and switch NRTIs in second line is needed as the 
number of patients and the amount of follow-up on TDF regimens increases. 
Our results indicate that outcomes on second line ART are not completely 
dependent on the protease inhibitor, and that the NRTI in second line plays a role in 
treatment outcomes. This study supports the need for more research regarding NRTI 
choices for patients with renal failure who fail AZT first line regimens, and suggests that 
switching to a different NRTI may be more beneficial than remaining on AZT in second 
line. Further investigation into NRTI choice in second line is worthwhile, particularly 
when some NRTIs cannot be prescribed due to contraindications.  
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STUDY 3 TABLES & FIGURES 
 
Table 23. Number of patients initiated on first line ART, among 
the cohorts included in the study analysis. 
Country Clinic 
N, % of 
patients on 
first line 
South Africa 
Clinic A 
13372 
5% 
Clinic B 
5630 
2% 
Clinic C 
5753 
2% 
Clinic D 
23314 
9% 
Clinic E 
4718 
2% 
Clinic F 
23187 
9% 
Clinic G 
3934 
2% 
Zambia Cohort H (multiple clinics) 
175933 
69% 
  
Total 
255841 
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Table 24. Study 3 patient population on second line ART. 
Variable Did not switch NRTI Switched NRTI All patients 
N 
 
552 5751 6303 
Female (%)   62.86 60.88 61.05 
Age (%) 18–29 26.99 27.96 27.88 
  30–39 44.38 44.46 44.46 
  40–49 21.20 20.66 20.70 
  50+ 7.43 6.92 6.96 
Country (%) 
South 
Africa 37.14 70.77 67.82 
  Zambia 62.86 29.23 32.18 
Year of initiation (%) 2004 10.33 12.4 12.22 
  2005 15.04 19.39 19.01 
  2006 18.30 19.93 19.78 
  2007 19.02 15.41 15.72 
  2008 18.66 12.24 12.80 
  2009 11.59 8.99 9.22 
  2010 5.07 6.89 6.73 
  2011 1.63 3.93 3.73 
  2012 0.36 0.83 0.79 
NNRTI on first line 
ART EFV 46.74 51.16 50.77 
  NVP 53.26 48.84 49.23 
WHO stage (%) 1 23.55 23.74 23.72 
  2 13.95 10.68 10.96 
  3 46.92 41.78 42.23 
  4 12.14 13.98 13.82 
  Missing 3.44 9.82 9.27 
CD4 count (%) 0–50 23.19 22.54 22.59 
  50–100 14.86 14.43 14.47 
  100–200 21.56 19.87 20.02 
  200–350 8.88 7.89 7.98 
  350+ 2.72 1.77 1.86 
  Missing 28.80 33.49 33.08 
Hemoglobin (%) <12 45.83 34.48 35.48 
  12+ 26.81 22.66 23.02 
  Missing 27.36 42.86 41.5 
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Creatinine clearance 
(%) Normal 9.60 4.96 5.36 
  Mild 25.91 14.80 15.77 
  Moderate 13.22 8.82 9.20 
  Severe 0.36 0.43 0.43 
  Missing 50.91 71 69.24 
ALT (%) <40 53.99 44.04 44.92 
  40+ 11.96 9.91 10.09 
  Missing 34.06 46.04 44.99 
Frequency of visits on ART per year 
(Median, IQR) 
5.5  
(3.8, 8.0) 
7.3 
(4.1, 10.1) 
7.1  
(4.1, 9.9) 
Months on first line (Median, IQR) 27.8  (18.0, 43.3) 
27.7 
(17.1, 42.1) 
27.7  
(17.2, 
42.2) 
Months of follow-up on second 
line (Median, IQR) 
15.5  
(7.0, 26.8) 
19.5 
(10.3, 33.7) 
19.2  
(9.8, 
33.0) 
Peak CD4 count on first line 
(Median, IQR) 
287  
(156, 432) 
286  
(177, 424) 
286 
(176, 
425) 
Had 50% drop in peak CD4 count 
on treatment during first line ART 
(%) 
45.11 35.61 36.44 
Had viral suppression on first line 
(% among SA patients only) 72.2 58.8 59.44 
Had virologic failure on first line (% 
among SA patients only) 43.9 76.98 75.39 
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Table 25. NRTI in second line regimen stratified by first line NRTI and 
country. 
NRTI initiated in first 
line ART 
NRTI at second 
line initiation 
South Africa 
(N, %) Zambia (N, %) 
Initiated on AZT AZT 74 12.52 42 5.18 
  TDF 253 42.81 598 73.74 
  ABC 185 31.30 154 18.99 
  d4T 3 0.51 15 1.85 
  other 76 12.86 2 0.25 
  TOTAL 591   811   
Initiated on d4T d4T 294 9.41 37 4.47 
  TDF 1088 34.84 572 69.17 
  ABC 64 2.05 110 13.30 
  AZT 1677 53.70 108 13.06 
  other 0 0 0 0 
  TOTAL 3123   827   
Initiated on TDF TDF 32 5.70 124 32.89 
  AZT 474 84.49 138 36.60 
  ABC 15 2.67 81 21.49 
  d4T 38 6.77 34 9.02 
  other 2 0.36 0 0 
  TOTAL 561   377   
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Table 26. Months of follow-up time on second line ART for Study 3. 
    South Africa Zambia 
  
Outcome on second 
line Median Q1 Q3 Median Q1 Q3 
Switch from AZT VL failure 16.6 12.2 23.5       
  Single failing VL 14.6 4.6 21.2     
  30% drop from baseline 18.5 15.2 26.5 27.1 17.2 37.0 
  50% drop from peak 17.7 13.1 24.7 20.1 7.8 33.5 
  VL Suppression 6.1 3.7 15.5       
Switch from d4T VL failure 19.3 14.7 30.1     
  Single failing VL 16.1 7.4 25.4     
  30% drop from baseline 22.5 16.4 35.8 22.8 14.8 32.0 
  50% drop from peak 20.5 14.7 33.3 17.0 7.7 28.1 
  VL Suppression 5.3 3.7 12.4     
Switch from TDF VL failure 14.3 11.0 17.7       
  Single failing VL 12.9 7.4 16.1     
  30% drop from baseline 15.6 13.0 19.8 17.5 10.6 23.2 
  50% drop from peak 15.6 13.0 19.6 16.0 8.4 23.0 
  VL Suppression 4.6 3.2 9.2       
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Table 27. Outcomes on second line ART for patients initiating on AZT in first line 
ART. 
  
Country 
NRTI in 
second 
line 
N in 
group 
Hazard 
Ratio 
95% Hazard Ratio 
Confidence Limits 
        
Hazards of confirmed failure on 
second line 
Crude South 
Africa 
AZT 54 Ref     
    ABC 169 1.97 1.11 3.49 
    TDF 194 0.27 0.13 0.58 
    d4T 1 0.00 0.00 . 
    other 67 0.66 0.32 1.37 
Crude excluding 
Clinics A&B 
South 
Africa 
AZT 43 Ref     
    ABC 5 0.87 0.11 6.71 
    TDF 178 0.27 0.12 0.61 
    d4T 1 0.00 0.00 . 
    other 46 0.66 0.28 1.54 
Adjusted South 
Africa 
AZT 43 Ref     
    ABC 169 1.08 0.26 4.58 
    TDF 193 0.54 0.21 1.35 
    d4T 1 0.00 0.00 . 
    other 50 1.43 0.44 4.62 
        
Hazards of single failing viral load 
on second line 
Crude South 
Africa 
AZT 54 Ref     
    ABC 169 1.90 1.26 2.86 
    TDF 194 0.42 0.26 0.66 
    d4T 1 0.00 0.00 . 
    other 67 0.46 0.26 0.81 
Crude excluding 
Clinics A&B 
South 
Africa 
AZT 43 Ref     
    ABC 5 0.69 0.16 2.92 
    TDF 178 0.39 0.23 0.64 
    d4T 1 0.00 0.00 . 
    other 46 0.48 0.25 0.91 
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Adjusted South 
Africa 
AZT 43 Ref     
    ABC 169 0.74 0.29 1.88 
    TDF 193 0.58 0.33 1.03 
    d4T 1 0.00 0.00 . 
    other 50 0.54 0.24 1.19 
        
Hazards of confirmed failure on 
second line in Right to Care cohort 
Adjusted South 
Africa 
AZT 
217 Ref     
    ABC 9 0.00 0.00 . 
    TDF 388 0.89 0.52 1.51 
    d4T 8 2.48 0.30 20.85 
    other 11 1.16 0.14 9.35 
        
50% drop from peak on-treatment 
CD4 count  
Crude Zambia AZT 36 Ref     
    ABC 135 0.75 0.41 1.40 
    TDF 524 0.67 0.38 1.19 
    d4T 14 0.50 0.14 1.75 
    other 2 3.04 0.69 13.49 
Adjusted Zambia AZT 36 Ref     
    ABC 135 0.70 0.38 1.32 
    TDF 524 0.66 0.37 1.16 
    d4T 14 0.47 0.13 1.67 
    other 2 2.49 0.54 11.47 
        
Outcome at one year after second 
line: Single failure on second line 
Adjusted 
South 
Africa AZT 54 Ref     
    ABC 154 0.90 0.30 2.72 
    TDF 173 0.75 0.38 1.48 
    d4T 1 0.00 0.00 . 
    other 67 0.61 0.23 1.60 
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Outcome at one year after second 
line: Single failure on second line, 
among Right to Care cohort 
Adjusted 
South 
Africa AZT 213 Ref     
    ABC 4 0.00 0.00 . 
    TDF 358 0.92 0.66 1.29 
    d4T 7 0.41 0.06 2.96 
    other 9 0.50 0.12 2.10 
        
Outcome at one year after second 
line: CD4 < 100 cells/mm3 on 
second line 
Adjusted Zambia AZT 36 Ref     
    ABC 136 0.55 0.24 1.23 
    TDF 524 0.46 0.22 0.96 
    d4T 15 0.49 0.10 2.35 
    other 2 0.00 0.00 . 
* Adjusted models adjust for age, sex, baseline CD4, hemoglobin, and creatinine clearance 
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Table 28. Hazards of outcomes on second line for adjusted models using imputed covariates, and using propensity scores 
created from imputed covariates. 
        
Adjusted for imputed 
covariates * 
Adjusting for propensity 
score created from imputed 
covariates ** 
First line 
NRTI Outcome Country 
Second line 
NRTI HR 
Lower 
95% CL 
Upper 
95% CL HR 
Lower 
95% CL 
Upper 
95% CL 
AZT Confirmed virologic 
failure 
South Africa 
 
            
      ABC 1.02 0.23 4.58       
      TDF 0.51 0.21 1.23 0.43 0.16 1.18 
      d4T  --   --   --        
AZT Single failing viral load South Africa 
      
  
  
  
ABC 0.68 0.26 1.77 
  
  
  
  
TDF 0.55 0.31 0.97 0.56 0.31 1.03 
  
  
d4T 
     
  
AZT 50% drop from peak 
on-treatment CD4 
count  
Zambia 
 
            
      ABC 0.73 0.38 1.39 0.69 0.38 1.23 
      TDF 0.72 0.40 1.30 0.74 0.41 1.32 
      d4T 0.55 0.15 1.99       
AZT Virologic suppression South Africa 
      
  
  
  
ABC 1.30 0.61 2.76 
  
  
  
  
TDF 1.15 0.77 1.72 1.19 0.80 1.79 
      d4T 0.64 0.08 5.03       
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d4T Confirmed virologic 
failure 
South Africa 
 
            
      ABC 1.09 0.46 2.57       
      AZT 1.13 0.81 1.59 1.17 0.84 1.64 
      TDF 0.76 0.52 1.10 0.77 0.51 1.16 
d4T Single failing viral load South Africa 
      
  
  
  
ABC 1.06 0.57 1.97 
  
  
  
  
AZT 1.13 0.89 1.43 1.17 0.92 1.48 
  
  
TDF 0.94 0.73 1.21 0.88 0.67 1.16 
d4T 50% drop from peak 
on-treatment CD4 
count  
Zambia 
 
            
      ABC 0.58 0.28 1.17 0.62 0.25 1.57 
      AZT 0.94 0.47 1.86 1.27 0.52 3.07 
      TDF 0.78 0.43 1.42 0.82 0.44 1.51 
d4T Virologic suppression South Africa 
      
  
  
  
ABC 1.12 0.76 1.64 
  
  
  
  
AZT 0.94 0.81 1.09 0.89 0.76 1.05 
      TDF 1.07 0.91 1.25 1.09 0.92 1.29 
TDF Confirmed virologic 
failure 
South Africa 
 
            
      ABC 0.58 0.09 3.84       
      AZT 0.33 0.10 1.10 0.44 0.14 1.42 
      d4T 0.59 0.13 2.73       
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TDF Single failing viral load South Africa 
      
  
  
  
ABC 3.00 0.86 10.43 
  
  
  
  
AZT 1.12 0.42 2.96 1.10 0.40 3.02 
  
  
d4T 1.86 0.58 5.98 
  
  
TDF 50% drop from peak 
on-treatment CD4 
count  
Zambia 
 
            
      ABC 1.06 0.39 2.93 1.09 0.38 3.10 
      AZT 2.31 1.05 5.06 2.14 0.99 4.59 
      d4T 0.52 0.11 2.51       
TDF Virologic suppression South Africa 
      
  
  
  
ABC 0.90 0.40 2.05 
  
  
  
  
AZT 1.23 0.70 2.19 1.16 0.65 2.07 
      d4T 0.98 0.47 2.08       
* Adjusted models adjust for age, sex, baseline CD4, hemoglobin, and creatinine clearance 
** Propensity score adjusted models adjust for age, sex, baseline CD4, hemoglobin, and creatinine clearance, and second line initiation 
CD4, hemoglobin and creatinine clearance 
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Table 29. Switch from AZT on first line among Zambian patients with moderate or severe renal 
failure at first line initiation. 
    
50% drop in peak CD4 count on 
second line 
CD4 count <100 cells/mm3 during 
first year on second line 
  
Second 
line NRTI N HR 95% LCL 95% UCL N HR 95% LCL 95% UCL 
Crude ABC 23 0.641 0.232 1.775 21 1.109 0.287 4.29 
  TDF 132 0.345 0.145 0.823 128 0.373 0.109 1.28 
  d4T 4 0.340 0.041 2.836 4       
                    
Adjusted ABC 23 0.579 0.198 1.695 21 0.949 0.225 3.997 
  TDF 132 0.234 0.088 0.617 128 0.265 0.07 1.013 
  d4T 4 0.190 0.021 1.760 4       
* Adjusted models adjust for age, sex, baseline CD4, hemoglobin, and creatinine clearance 
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Table 30. Outcomes on second line ART for patients initiating on d4T in 
first line ART. 
   
Country 
NRTI in 
second 
line 
N in 
group 
Hazard 
Ratio 
95% Hazard Ratio 
Confidence Limits 
        
Hazards of confirmed failure on 
second line 
Crude South 
Africa 
d4T 254 Ref     
    ABC 49 1.43 0.70 2.93 
    AZT 1414 1.52 1.11 2.08 
    TDF 875 0.80 0.56 1.15 
              
Adjusted South 
Africa 
d4T 254 Ref     
    ABC 49 1.07 0.46 2.48 
    AZT 1414 1.21 0.87 1.68 
    TDF 875 0.78 0.54 1.13 
              
Adjusted, among 
patients with 
confirmed failure 
on first line ART 
South 
Africa 
d4T 170 Ref 
    
    ABC 34 0.65 0.19 2.26 
    AZT 1064 0.97 0.61 1.55 
    TDF 697 0.63 0.38 1.03 
              
        
Hazards of confirmed failure on 
second line in Right to Care cohort 
Adjusted South 
Africa 
d4T 72 
Ref     
    ABC 41 1.02 0.41 2.54 
    AZT 1456 1.13 0.66 1.94 
    TDF 1186 0.77 0.45 1.34 
    other 107 0.90 0.46 1.78 
        
50% drop from peak on-treatment 
CD4 count  
Crude Zambia d4T 31 Ref     
    ABC 92 0.56 0.29 1.10 
    AZT 89 0.90 0.47 1.71 
    TDF 476 0.76 0.43 1.34 
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Adjusted Zambia d4T 31 Ref     
    ABC 92 0.56 0.28 1.10 
    AZT 89 0.97 0.50 1.86 
    TDF 476 0.78 0.44 1.39 
              
        
Outcome at one year after second 
line: Single failure on second line 
Adjusted 
South 
Africa d4T 246 Ref     
    ABC 41 1.11 0.56 2.20 
    AZT 1368 1.13 0.86 1.48 
    TDF 800 0.92 0.69 1.23 
              
        
Outcome at two years after 
second line: Single failure on 
second line 
Adjusted 
South 
Africa d4T 216 Ref     
    ABC 22 1.22 0.54 2.76 
    AZT 1172 1.05 0.82 1.34 
    TDF 382 0.83 0.63 1.11 
              
        
Outcome at one year after second 
line: Single failure on second line, 
among Right to Care cohort 
Adjusted 
South 
Africa d4T 194 Ref     
    ABC 34 1.21 0.65 2.27 
    AZT 1381 1.16 0.88 1.54 
    TDF 1069 1.03 0.77 1.37 
    other 141 1.14 0.76 1.70 
        
Outcome at one year after second 
line: CD4 < 100 cells/mm3 on 
second line 
Adjusted Zambia d4T 32 Ref     
    ABC 95 0.75 0.27 2.12 
    AZT 82 1.18 0.43 3.21 
    TDF 458 0.70 0.28 1.77 
* Adjusted models adjust for age, sex, baseline CD4, hemoglobin, and creatinine clearance 
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Table 31. Outcomes on second line ART for patients initiating on TDF in first line 
ART. 
  
Country 
NRTI in 
second 
line 
N in 
group 
Hazard 
Ratio 
95% Hazard Ratio 
Confidence Limits 
        
Hazards of confirmed failure on 
second line 
Crude South 
Africa 
TDF 18 Ref     
    ABC 14 0.53 0.10 2.73 
    AZT 288 0.37 0.14 0.97 
    d4T 24 0.78 0.21 2.93 
    Other 2       
Adjusted South 
Africa 
TDF 18 Ref     
    ABC 14 0.53 0.10 2.93 
    AZT 288 0.32 0.12 0.91 
    d4T 24 0.63 0.17 2.43 
    Other 2       
        
Hazards of single failing viral load 
on second line 
Crude South 
Africa 
TDF 18 Ref     
    ABC 14 2.19 0.69 6.92 
    AZT 288 0.96 0.39 2.39 
    d4T 24 1.71 0.57 5.11 
    Other 2       
Adjusted South 
Africa 
TDF 18 Ref     
    ABC 14 3.17 0.94 10.71 
    AZT 288 1.13 0.44 2.91 
    d4T 24 1.81 0.59 5.56 
    Other 2       
        
Hazards of confirmed failure on 
second line in Right to Care cohort 
Adjusted South 
Africa 
TDF 
70 Ref     
    ABC 34 1.53 0.27 8.86 
    AZT 662 2.16 0.75 6.24 
    d4T 50 7.59 2.18 26.44 
    Other 3 0.00 0.00 . 
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50% drop from peak on-treatment 
CD4 count  
Crude Zambia TDF 81 Ref     
    ABC 58 1.06 0.43 2.63 
    AZT 105 2.15 1.07 4.31 
    d4T 28 0.51 0.11 2.31 
              
Adjusted Zambia TDF 81 Ref     
    ABC 58 1.02 0.40 2.62 
    AZT 105 1.98 0.96 4.06 
    d4T 28 0.48 0.10 2.24 
              
        
Outcome at one year after second 
line: Single failure on second line 
Adjusted 
South 
Africa TDF 21 Ref     
    ABC 12 5.22 1.38 19.66 
    AZT 294 1.36 0.47 3.89 
    d4T 22 2.07 0.55 7.76 
    other 2 0.00 0.00 . 
        
Outcome at one year after second 
line: Single failure on second line, 
among Right to Care cohort 
Adjusted 
South 
Africa TDF 64 Ref     
    ABC 21 1.84 0.69 4.87 
    AZT 582 1.55 0.83 2.90 
    d4T 47 4.62 2.16 9.89 
    other 6 1.42 0.17 12.12 
        
Outcome at one year after second 
line: CD4 < 100 cells/mm3 on 
second line 
Adjusted Zambia TDF 68 Ref     
    ABC 47 0.63 0.28 1.42 
    AZT 79 1.41 0.75 2.64 
    d4T 28 1.93 0.89 4.17 
              
* Adjusted models adjust for age, sex, baseline CD4, hemoglobin, and creatinine clearance 
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Figure 11. DAG showing potential confounders for the relationship between change in 
NRTI and outcomes and second line ART in Study 3. 
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Figure 12. NRTI in second line by year of second line start, stratified by country and NRTI 
in first line ART.  
Zambia: NRTI in second line after switch from AZT: 
 
Zambia: NRTI in second line after switch from d4T: 
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South Africa: NRTI in second line after switch from AZT: 
 
South Africa: NRTI in second line after switch from d4T: 
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CONCLUSION 
 
 These three studies advance the understanding of HIV treatment in South Africa, 
with findings that have clinical importance and lead to further research questions 
surrounding second line ART. The predictive model in Study 1 both identifies predictors 
associated with first line treatment failure, and identifies populations and individuals at 
high risk for treatment failure. The predictive model can thus be used to help inform 
strategies to minimize failure on second line at a population level (e.g. highlighting the 
importance of earlier initiation of ART at higher CD4 values), and at an individual level 
(e.g. identifying individuals at high risk for treatment failure in clinical practice, and 
implementing adherence interventions or increased monitoring for these patients).  
 Studies 2 and 3 investigate factors that influence outcomes on second line 
treatment. Study 2 shows that a delay in second line initiation after first line failure, 
which has been seen to occur consistently throughout sub-Saharan Africa, has the 
potential to be very harmful with respect to second line outcomes for patients who 
never do well on first line ART, even if the delay is small. Since most of the patients in 
our population who had a delay in second line initiation had the potential to switch to 
second line earlier, intervening at the clinic or clinician level to highlight the importance 
of immediate switch for very sick patients could improve outcomes on second line. This 
study also suggests that among relatively healthier patients, outcomes on second line 
may worsen after a long delay in second line initiation of (6–12 months or longer). 
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 The mechanism for why delayed switch to second line is associated with worse 
outcomes on second line could not be determined in this study with certainty, but upon 
this study finding, merits further research. It is possible that increased NRTI drug 
resistance mutations among the sickest patients were associated with worse outcomes 
on second line when second line treatment was delayed. While previous research has 
shown mixed results with respect to the importance of active NRTIs in a second line 
regimen, showing that the potency of PIs in second line can overcome NRTI resistance, 
both Study 2 and Study 3 demonstrate that this question warrants further investigation.  
Although bias from residual confounding by indication could not be excluded as 
an explanation for the findings in Study 3, results clearly showed that outcomes on 
second line differed depending on switching to a new NRTI in the second line regimen. 
For patients with renal failure who cannot take TDF, which is included in the current ART 
guideline recommendations in South Africa and Zambia, remaining on AZT from first line 
to second line ART may not be optimal. We observed that among patients failing a first 
line regimen containing AZT, remaining on AZT on second line rather than switching to a 
different NRTI was associated with worse outcomes on second line. Our finding is 
consistent with the presence of TAMs decreasing the effectiveness of AZT-containing 
second line regimens, and we believe that second line options for patients with renal 
failure should be explored further. Due to the more recent use of TDF in regimens, data 
on outcomes for patients who switched to second line after TDF in first line were more 
limited, but also should be examined further as time on TDF increases. 
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 Understanding the role of NRTI drug resistance mutations in the findings from 
Study 2 and 3 will help inform how these studies can influence clinical practice moving 
forward, and is an important next step for research. The limited availability of third line 
drugs in South Africa and resource-limited settings and expense of second and third line 
drugs emphasize the importance of minimizing first line failure and maximizing 
successful second line outcomes at a population level. 
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APPENDIX TABLES 
Table A1A. Select predictor variable values at ART initiation for all clinics by year of initiation. 
  2004 2005 2006 2007 2008 
N 2,009 3,982 6,574 7,218 9,426 
Baseline variable: N % N % N % N % N % 
Female 1376 68.5 2709 68 4291 65.3 4767 66 6274 66.6 
Age                     
< 25 95 4.7 216 5.4 366 5.6 427 5.9 568 6 
25–29.9 349 17.4 662 16.6 974 14.8 1138 15.8 1470 15.6 
30–34.9 506 25.2 982 24.7 1598 24.3 1738 24.1 2108 22.4 
35–39.9 424 21.1 852 21.4 1350 20.5 1528 21.2 2015 21.4 
40–44.9 291 14.5 595 14.9 1049 16 1057 14.6 1400 14.9 
45–49.9 185 9.2 350 8.8 621 9.5 656 9.1 890 9.4 
50–54.9 98 4.9 196 4.9 356 5.4 399 5.5 523 5.6 
55+ 61 3 129 3.2 260 4 275 3.8 452 4.8 
TB positive 503 25 859 21.6 945 14.4 867 12 1170 12.4 
NRTI in first line regimen                     
TDF 14 0.7 35 0.9 101 1.5 223 3.1 445 4.7 
AZT 168 8.4 268 6.7 423 6.4 513 7.1 691 7.3 
D4T 1827 90.9 3679 92.4 6050 92 6482 89.8 8290 88 
NNRTI in first line regimen                     
EFV 1741 86.7 3506 88.1 5716 87 6015 83.3 7564 80.3 
NVP 268 13.3 476 12 858 13.1 1203 16.7 1862 19.8 
Missed visits in first 6 months 
on treatment 121 6 404 10.2 1025 15.6 1370 19 1920 20.4 
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WHO stage                     
Stage I 1270 63.2 2549 64 4474 68.1 4802 66.5 6268 66.5 
Stage II 33 1.6 59 1.5 99 1.5 114 1.6 256 2.7 
Stage III 627 31.2 1169 29.4 1523 23.2 1633 22.6 2112 22.4 
Stage IV 79 3.9 205 5.2 478 7.3 669 9.3 790 8.4 
BMI                     
< 18.5 243 12.1 540 13.6 789 12 898 12.4 1058 11.2 
18.5–24.9 831 41.4 1642 41.2 2543 38.7 2741 38 4011 42.6 
25 – 29.9 232 11.5 431 10.8 701 10.7 858 11.9 1306 13.9 
30 and up 109 5.4 169 4.2 298 4.5 373 5.2 642 6.8 
Missing 594 29.6 1200 30.1 2243 34.1 2348 32.5 2409 25.6 
CD4 count                     
0–25 241 12 522 13.1 845 12.9 823 11.4 995 10.6 
25–50 206 10.3 382 9.6 579 8.8 643 8.9 800 8.5 
51–100 372 18.5 553 13.9 968 14.7 1104 15.3 1408 14.9 
101–200 435 21.7 1074 27 1669 25.4 2140 29.6 2925 31 
201–350 90 4.5 212 5.3 368 5.6 534 7.4 974 10.3 
>350 24 1.2 51 1.3 111 1.7 186 2.6 256 2.7 
Missing 641 31.9 1188 29.8 2034 30.9 1788 24.8 2068 21.9 
Hemoglobin                     
<10 281 14 642 16.1 1116 17 1290 17.9 1570 16.7 
>10 1124 55.9 2022 50.8 3332 50.7 3599 49.9 4985 52.9 
Missing 604 30.1 1318 33.1 2126 32.3 2329 32.3 2871 30.5 
Creatinine clearance                     
Normal (>=90) 36 1.8 117 2.9 297 4.5 800 11.1 2247 23.8 
Mild (60–89) 22 1.1 75 1.9 176 2.7 368 5.1 737 7.8 
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Moderate (30–59) 10 0.5 37 0.9 66 1 85 1.2 169 1.8 
Severe (<30) 6 0.3 10 0.3 30 0.5 24 0.3 61 0.6 
Missing 1935 96.3 3743 94 6005 91.3 5941 82.3 6212 65.9 
Blood pressure                     
Low 20 1 22 0.6 44 0.7 61 0.8 98 1 
Normal 466 23.2 934 23.5 1492 22.7 1796 24.9 2743 29.1 
Borderline high 382 19 685 17.2 1157 17.6 1361 18.9 2145 22.8 
Stage 1 hypertension 144 7.2 264 6.6 476 7.2 507 7 958 10.2 
Stage 2 hypertension 71 3.5 154 3.9 279 4.2 287 4 431 4.6 
Missing 926 46.1 1923 48.3 3126 47.6 3206 44.4 3051 32.4 
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Table A1A, continued. Select predictor variable values at ART initiation for all clinics by year of initiation. 
  2009 2010 2011 2012 2013 
N 11,196 11,104 8,704 7,257 3,684 
Baseline variable: N % N % N % N % N % 
Female 7121 63.6 7272 65.5 5496 63.1 4648 64.1 46 61.3 
Age                     
< 25 660 5.9 702 6.3 510 5.9 494 6.8 273 7.4 
25–29.9 1744 15.6 1796 16.2 1392 16 1175 16.2 663 18 
30–34.9 2510 22.4 2434 21.9 1883 21.6 1580 21.8 801 21.7 
35–39.9 2304 20.6 2318 20.9 1875 21.5 1518 20.9 748 20.3 
40–44.9 1645 14.7 1623 14.6 1268 14.6 1040 14.3 486 13.2 
45–49.9 1141 10.2 1113 10 850 9.8 678 9.3 351 9.5 
50–54.9 626 5.6 602 5.4 500 5.7 412 5.7 189 5.1 
55+ 566 5.1 516 4.7 426 4.9 360 5 173 4.7 
TB positive 2041 18.2 1923 17.3 1209 13.9 658 9.1 302 8.2 
NRTI in first line 
regimen                     
TDF 619 5.5 5504 49.6 7435 85.4 6266 86.3 3413 92.6 
AZT 671 6 771 6.9 376 4.3 320 4.4 120 3.3 
D4T 9906 88.5 4829 43.5 893 10.3 671 9.3 151 4.1 
NNRTI in first line 
regimen                     
EFV 9486 84.7 9689 87.3 7787 89.5 6727 92.7 3560 96.6 
NVP 1710 15.3 1415 12.7 917 10.5 530 7.3 124 3.4 
Missed visits in first 6 
months on 
treatment 
2544 22.7 2846 25.6 2310 26.5 2454 33.8 1279 34.7 
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WHO stage                     
Stage I 7900 70.6 8153 73.4 6780 77.9 6039 83.2 3120 84.7 
Stage II 159 1.4 105 1 46 0.5 41 0.6 21 0.6 
Stage III 2613 23.3 2394 21.6 1563 18 988 13.6 480 13 
Stage IV 524 4.7 452 4.1 315 3.6 189 2.6 63 1.7 
BMI                     
< 18.5 1360 12.1 1197 10.8 787 9 577 8 288 7.8 
18.5–24.9 5179 46.3 4709 42.4 3707 42.6 2866 39.5 1459 39.6 
25 – 29.9 1682 15 1804 16.2 1506 17.3 1331 18.3 671 18.2 
30 and up 754 6.7 989 8.9 874 10 895 12.3 424 11.5 
Missing 2221 19.8 2405 21.7 1830 21 1588 21.9 842 22.9 
CD4 count                     
0–25 948 8.5 942 8.5 652 7.5 455 6.3 250 6.8 
25–50 848 7.6 785 7.1 565 6.5 376 5.2 208 5.6 
51–100 1644 14.7 1493 13.4 1041 12 652 9 375 10.2 
101–200 3373 30.1 3098 27.9 2093 24 1438 19.8 787 21.4 
201–350 1448 12.9 2106 19 1798 20.7 2154 29.7 1023 27.8 
>350 463 4.1 334 3 362 4.2 396 5.5 336 9.1 
Missing 2472 22.1 2346 21.1 2193 25.2 1786 24.6 705 19.1 
Hemoglobin                     
<10 2019 18 1908 17.2 1368 15.7 1035 14.3 494 13.4 
>10 6201 55.4 6499 58.5 5219 60 4710 64.9 2368 64.3 
Missing 2976 26.6 2697 24.3 2117 24.3 1512 20.8 822 22.3 
Creatinine clearance                     
Normal (>=90) 3868 34.5 5653 50.9 4939 56.7 4475 61.7 2248 61 
Mild (60–89) 1365 12.2 1073 9.7 902 10.4 687 9.5 320 8.7 
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Moderate (30–59) 324 2.9 277 2.5 224 2.6 176 2.4 84 2.3 
Severe (<30) 78 0.7 162 1.5 65 0.7 56 0.8 39 1.1 
Missing 5561 49.7 3939 35.5 2574 29.6 1863 25.7 993 27 
Blood pressure                     
Low 95 0.8 115 1 69 0.8 44 0.7 24 0.7 
Normal 3604 32.2 3306 29.8 2268 26.1 1829 27.9 1144 31.1 
Borderline high 3147 28.1 3121 28.1 2563 29.4 2117 32.3 1209 32.8 
Stage 1 hypertension 1528 13.6 1653 14.9 1612 18.5 1204 18.4 578 15.7 
Stage 2 hypertension 800 7.1 894 8.1 933 10.7 663 10.1 309 8.4 
Missing 2022 18.1 2015 18.1 1259 14.5 696 10.6 420 11.4 
 
  
 
 
193 
Table A1B. Select predictor variable values stratified by clinic. 
  Clinic A Clinic B Clinic C Clinic D Clinic E 
N 20,334 8,554 4,874 6,241 7,278 
Baseline variable: N % N % N % N % N % 
Female 12802 62.96 5852 68.41 3062 62.82 4221 67.63 4786 65.76 
Age                     
< 25 999 4.91 577 6.75 255 5.23 463 7.42 626 8.6 
25–29.9 3002 14.76 1537 17.97 687 14.1 1144 18.33 1241 17.05 
30–34.9 4640 22.82 2066 24.15 959 19.68 1519 24.34 1499 20.6 
35–39.9 4384 21.56 1826 21.35 982 20.15 1331 21.33 1307 17.96 
40–44.9 3191 15.69 1168 13.65 725 14.87 822 13.17 952 13.08 
45–49.9 2050 10.08 741 8.66 518 10.63 502 8.04 663 9.11 
50–54.9 1171 5.76 359 4.2 331 6.79 283 4.53 461 6.33 
55+ 897 4.41 280 3.27 417 8.56 177 2.84 529 7.27 
Year of initiation                     
2004 1346 6.62 90 1.05 108 2.22 49 0.79 107 1.47 
2005 1857 9.13 306 3.58 181 3.71 142 2.28 351 4.82 
2006 2374 11.68 430 5.03 495 10.16 199 3.19 843 11.58 
2007 2154 10.59 550 6.43 538 11.04 321 5.14 1151 15.81 
2008 2078 10.22 704 8.23 618 12.68 939 15.05 1562 21.46 
2009 2613 12.85 1233 14.41 986 20.23 1228 19.68 1586 21.79 
2010 2562 12.6 1761 20.59 697 14.3 1510 24.19 1089 14.96 
2011 2516 12.37 1359 15.89 633 12.99 876 14.04 264 3.63 
2012 2098 10.32 1227 14.34 408 8.37 654 10.48 199 2.73 
2013 736 3.62 894 10.45 210 4.31 323 5.18 126 1.73 
TB positive 4352 21.4 1147 13.41 874 17.93 418 6.7 590 8.11 
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NRTI in first line regimen                     
TDF 6621 32.56 3732 43.63 1196 24.54 2806 44.96 1118 15.36 
AZT 946 4.65 464 5.42 389 7.98 565 9.05 87 1.2 
D4T 12767 62.79 4358 50.95 3289 67.48 2870 45.99 6073 83.44 
NNRTI in first line regimen                     
EFV 18362 90.3 7569 88.48 4653 95.47 4768 76.4 5302 72.85 
NVP 1972 9.7 985 11.52 221 4.53 1473 23.6 1976 27.15 
Missed visits in first 6 
months on treatment 4410 21.69 1871 21.87 1573 32.27 1084 17.37 1552 21.32 
WHO stage                     
Stage I 13444 66.12 6394 74.75 2885 59.19 5213 83.53 5542 76.15 
Stage II 248 1.22 104 1.22 67 1.37 30 0.48 284 3.9 
Stage III 5436 26.73 1776 20.76 1529 31.37 768 12.31 1207 16.58 
Stage IV 1206 5.93 280 3.27 393 8.06 230 3.69 245 3.37 
BMI                     
< 18.5 2832 13.9 482 5.6 898 18.4 559 9 689 9.5 
18.5–24.9 9455 46.5 3872 45.3 2146 44 2225 35.7 2833 38.9 
25–29.9 3049 15 1754 20.5 661 13.6 720 11.5 928 12.8 
30 and up 1475 7.3 1065 12.5 345 7.1 370 5.9 399 5.5 
Missing 3523 17.3 1381 16.1 824 16.9 2367 37.9 2429 33.4 
CD4 count                     
0–25 2640 12.98 505 5.9 666 13.66 480 7.69 485 6.66 
25–50 1906 9.37 509 5.95 420 8.62 418 6.7 476 6.54 
51–100 3111 15.3 947 11.07 623 12.78 872 13.97 966 13.27 
101–200 5702 28.04 2057 24.05 1100 22.57 1730 27.72 2405 33.04 
201–350 3070 15.1 1970 23.03 950 19.49 627 10.05 1153 15.84 
>350 720 3.54 444 5.19 245 5.03 142 2.28 171 2.35 
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Missing 3185 15.66 2122 24.81 870 17.85 1972 31.6 1622 22.29 
Hemoglobin                     
<10 3461 17.02 1261 14.74 1381 28.33 583 9.34 1379 18.95 
>10 13671 67.23 5854 68.44 2446 50.18 2846 45.6 2166 29.76 
Missing 3202 15.75 1439 16.82 1047 21.48 2812 45.06 3733 51.29 
Creatinine clearance                     
Normal (>=90) 6834 33.61 4021 47.01 1267 26 2092 33.52 1727 23.73 
Mild (60–89) 1683 8.28 548 6.41 441 9.05 427 6.84 525 7.21 
Moderate (30–59) 473 2.33 103 1.2 146 3 89 1.43 187 2.57 
Severe (<30) 186 0.91 29 0.34 34 0.7 15 0.24 123 1.69 
Missing 11158 54.87 3853 45.04 2986 61.26 3618 57.97 4716 64.8 
Blood pressure                     
Low 185 0.91 28 0.33 26 0.53 103 1.65 120 1.65 
Normal 6194 30.46 2534 29.62 1373 28.17 1849 29.63 2829 38.87 
Borderline high 5851 28.77 2826 33.04 1707 35.02 1196 19.16 1330 18.27 
Stage 1 hypertension 2994 14.72 1343 15.7 999 20.5 454 7.27 373 5.13 
Stage 2 hypertension 1673 8.23 596 6.97 563 11.55 308 4.94 182 2.5 
Missing 3437 16.9 1227 14.34 206 4.23 2331 37.35 2444 33.58 
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Table A1B, continued. Select predictor variable values stratified by clinic. 
  Clinic F Clinic G Clinic H Clinic I 
N 7,888 3,961 10,620 1,404 
Baseline variable: N % N % N % N % 
Female 5185 65.73 2693 67.99 6714 63.22 900 64.1 
Age                 
< 25 465 5.9 268 6.77 587 5.53 71 5.06 
25–29.9 1198 15.19 753 19.01 1595 15.02 206 14.67 
30–34.9 1708 21.65 1000 25.25 2363 22.25 386 27.49 
35–39.9 1596 20.23 864 21.81 2330 21.94 312 22.22 
40–44.9 1222 15.49 520 13.13 1638 15.42 216 15.38 
45–49.9 884 11.21 303 7.65 1058 9.96 116 8.26 
50–54.9 499 6.33 155 3.91 593 5.58 49 3.49 
55+ 316 4.01 98 2.47 456 4.29 48 3.42 
Year of initiation                 
2004 149 1.89 12 0.3 73 0.69 75 5.34 
2005 714 9.05 45 1.14 266 2.5 120 8.55 
2006 1201 15.23 111 2.8 807 7.6 114 8.12 
2007 1209 15.33 252 6.36 848 7.98 195 13.89 
2008 1393 17.66 485 12.24 1457 13.72 190 13.53 
2009 1037 13.15 580 14.64 1733 16.32 200 14.25 
2010 794 10.07 756 19.09 1739 16.37 196 13.96 
2011 608 7.71 767 19.36 1498 14.11 183 13.03 
2012 537 6.81 644 16.26 1381 13 109 7.76 
2013 246 3.12 309 7.8 818 7.7 22 1.57 
TB positive 947 12.01 414 10.45 1620 15.25 115 8.19 
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NRTI in first line regimen                 
TDF 1753 22.22 1688 42.62 4355 41.01 786 55.98 
AZT 278 3.52 315 7.95 877 8.26 400 28.49 
D4T 5857 74.25 1958 49.43 5388 50.73 218 15.53 
NNRTI in first line regimen                 
EFV 7381 93.57 3300 83.31 9324 87.8 6727 92.7 
NVP 507 6.43 661 16.69 1296 12.2 530 7.3 
Missed visits in first 6 
months on treatment 1680 21.3 1006 25.4 3028 28.51 69 4.91 
WHO stage                 
Stage I 5609 71.11 3245 81.92 7890 74.29 1133 80.7 
Stage II 94 1.19 9 0.23 67 0.63 30 2.14 
Stage III 1515 19.21 614 15.5 2119 19.95 138 9.83 
Stage IV 670 8.49 93 2.35 544 5.12 103 7.34 
BMI                 
< 18.5 1197 15.2 307 7.8 714 6.7 59 4.2 
18.5–24.9 3531 44.8 1341 33.9 4003 37.7 282 20.1 
25–29.9 1094 13.9 421 10.6 1686 15.9 209 14.9 
30 and up 580 7.4 195 4.9 984 9.3 114 8.1 
Missing 1486 18.8 1697 42.8 3233 30.4 740 52.7 
CD4 count                 
0–25 774 9.81 219 5.53 833 7.84 71 5.06 
25–50 581 7.37 216 5.45 816 7.68 50 3.56 
51–100 1096 13.89 459 11.59 1448 13.63 88 6.27 
101–200 2066 26.19 978 24.69 2764 26.03 230 16.38 
201–350 549 6.96 654 16.51 1425 13.42 309 22.01 
>350 101 1.28 125 3.16 334 3.15 237 16.88 
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Missing 2721 34.5 1310 33.07 3000 28.25 419 29.84 
Hemoglobin                 
<10 1578 20.01 423 10.68 1571 14.79 86 6.13 
>10 4257 53.97 1803 45.52 6307 59.39 709 50.5 
Missing 2053 26.03 1735 43.8 2742 25.82 609 43.38 
Creatinine clearance                 
Normal (>=90) 2512 31.85 1201 30.32 4727 44.51 299 21.3 
Mild (60–89) 937 11.88 197 4.97 943 8.88 24 1.71 
Moderate (30–59) 227 2.88 32 0.81 189 1.78 6 0.43 
Severe (<30) 92 1.17 5 0.13 44 0.41 3 0.21 
Missing 4120 52.23 2526 63.77 4717 44.42 1072 76.35 
Blood pressure                 
Low 34 0.43 32 0.81 67 0.63 2 0.14 
Normal 988 12.53 1051 26.53 2707 25.49 272 19.37 
Borderline high 1132 14.35 997 25.17 2737 25.77 295 21.01 
Stage 1 hypertension 773 9.8 548 13.83 1397 13.15 135 9.62 
Stage 2 hypertension 467 5.92 303 7.65 729 6.86 45 3.21 
Missing 4494 56.97 1030 26 2983 28.09 655 46.65 
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Table A1C. Log likelihood for different survival distributions in accelerated failure time models to predict first line treatment 
failure, including sex, age, CD4 count and NNRTI as predictors.  
All clinics 
  -2 log likelihood Log likelihood 
Exponential 43949.56 -21974.78 
Weibull 43727.14 -21863.57 
Lognormal 43362.28 -21681.14 
Excluding Clinics E and I 
  -2 log likelihood Log likelihood 
Exponential 40010.57 -20005.285 
Weibull 39691.29 -19845.645 
Lognormal 39339.34 -19669.670 
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Table A1D. Unadjusted results for predictor variables in a Weibull accelerated failure time model. 
    
AFT 
Model 
Estimate 
LCL UCL p-value HR 
Year 2004 0 . . . Ref 
  2005 -0.121 -0.276 0.035 0.129 1.12 
  2006 -0.066 -0.214 0.083 0.388 1.06 
  2007 -0.096 -0.245 0.052 0.204 1.09 
  2008 -0.199 -0.343 -0.055 0.007 1.2 
  2009 -0.287 -0.43 -0.145 <.0001 1.3 
  2010 -0.492 -0.635 -0.35 <.0001 1.56 
  2011 -0.619 -0.768 -0.471 <.0001 1.75 
  2012 -0.666 -0.83 -0.502 <.0001 1.83 
  2013 -0.598 -0.871 -0.324 <.0001 1.72 
  Scale 1.103 1.08 1.126     
Clinic Clinic C 0.226 0.093 0.359 0.001 0.82 
  Clinic H 0.203 0.093 0.313 0 0.84 
  Clinic G 0.008 -0.132 0.148 0.911 0.99 
  Clinic I 0.471 0.235 0.707 <.0001 0.66 
  Clinic D 0.118 -0.009 0.245 0.068 0.9 
  Clinic F 0.16 0.036 0.284 0.011 0.87 
  Clinic E -0.23 -0.352 -0.109 0 1.22 
  Clinic A 0.03 -0.065 0.125 0.538 0.97 
  Clinic B 0 . . . Ref 
  Scale 1.152 1.129 1.175     
Age < 25 -0.446 -0.558 -0.333 <.0001 1.47 
  25–29.9 -0.186 -0.271 -0.102 <.0001 1.18 
  30–34.9 0 . . . Ref 
  35–39.9 0.141 0.059 0.224 0.001 0.88 
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  40–44.9 0.182 0.089 0.275 0 0.85 
  45–49.9 0.223 0.114 0.332 <.0001 0.82 
  50–54.9 0.279 0.139 0.419 <.0001 0.79 
  55+ 0.327 0.167 0.488 <.0001 0.75 
  Scale 1.154 1.131 1.177     
Sex Female 0 . . . Ref 
  Male -0.163 -0.219 -0.106 <.0001 1.15 
  Scale 1.158 1.135 1.181     
Missed 
visits in first 
6 months 
Yes -0.396 -0.46 -0.332 <.0001 1.41 
No 0 . . . Ref 
  Scale 1.15 1.128 1.173     
NRTI AZT 0.049 -0.061 0.16 0.381 0.96 
  TDF -0.306 -0.368 -0.244 <.0001 1.31 
  d4T 0 . . . Ref 
  Scale 0.948 0.928 0.968     
NNRTI NVP -0.32 -0.392 -0.247 <.0001 1.32 
  EFV 0 . . . Ref 
  Scale 1.159 1.136 1.182     
CD4 0–25 -0.697 -0.791 -0.604 <.0001 1.8 
  25–50 -0.477 -0.583 -0.371 <.0001 1.49 
  51–100 -0.288 -0.38 -0.196 <.0001 1.27 
  101–200 0 . . . Ref 
  201–350 0.107 -0.001 0.215 0.053 0.91 
  >350 0.229 0.029 0.428 0.025 0.82 
  Scale 1.188 1.161 1.215     
BMI < 18.5 -0.145 -0.235 -0.056 0.001 1.13 
  18.5–24.9 0 . . . Ref 
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  25 – 29.9 0.118 0.031 0.205 0.008 0.91 
  30 and up 0.24 0.118 0.362 0 0.82 
  Scale 1.188 1.161 1.215     
WHO stage Stage I – II 0.147 0.088 0.207 <.0001 0.88 
  Stage III – IV 0 . . . Ref 
  Scale 1.16 1.137 1.184     
Hemoglobin <12 -0.197 -0.264 -0.13 <.0001 1.18 
  12+ 0 . . . Ref 
  Scale 1.194 1.167 1.222     
MCV <80 0 . . . Ref 
  80–95 -0.107 -0.21 -0.004 0.041 1.1 
  95+ -0.144 -0.271 -0.017 0.026 1.13 
  Scale 1.177 1.148 1.206     
RBC <4 -0.142 -0.212 -0.072 <.0001 1.13 
  4+ 0 . . . Ref 
  Scale 1.18 1.151 1.21     
Creatinine 
serum 0 – 0.55 -0.165 -0.337 0.006 0.059 1.2 
  0.55–1.15 -0.003 -0.152 0.147 0.971 1 
  1.15+ 0 . . . Ref 
  Scale 0.918 0.888 0.947     
Blood 
pressure Low BP 0.109 -0.209 0.427 0.501 0.91 
  Normal BP 0 . . . Ref 
  Borderline high BP 0.204 0.128 0.28 <.0001 0.84 
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  Stage 1 hypertension 0.277 0.179 0.376 <.0001 0.79 
  Stage 2 hypertension 0.345 0.217 0.474 <.0001 0.75 
  Scale 1.187 1.16 1.215     
ALT <40 0 . . . Ref 
  >40 -0.097 -0.181 -0.013 0.024 1.08 
  Scale 1.211 1.183 1.24     
AST <40 0 . . . Ref 
  >40 -0.09 -0.17 -0.01 0.027 1.08 
  Scale 1.17 1.137 1.203     
TB Positive -0.174 -0.245 -0.103 <.0001 1.16 
  Negative 0 . . . Ref 
  Scale 1.16 1.137 1.183     
Creatinine 
Clearance 
(2011–2013 
data only) 
Normal 
(>=90) 0 . . . Ref 
Mild (60–89) 0.27 0.042 0.498 0.02 1.26 
Moderate 
(30–59) -0.047 -0.44 0.346 0.814 0.96 
Severe (<30) 0.003 -0.721 0.727 0.993 1 
  Scale 1.161 1.098 1.227     
Peripheral 
neuropathy Positive 0.042 -0.176 0.259 0.708 0.96 
  Negative 0 . . . Ref 
  Scale 1.158 1.135 1.182     
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Pregnant Yes 0.01 -0.159 0.179 0.904 0.99 
  No 0 . . . Ref 
  Scale 1.158 1.136 1.182     
Alcohol Yes -0.009 -0.13 0.113 0.886 1.01 
  No 0 . . . Ref 
  Scale 1.158 1.135 1.182     
Smoking Yes -0.181 -0.297 -0.065 0.002 1.17 
  No 0 . . . Ref 
  Scale 1.158 1.135 1.181     
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Table A1E. Predictors of hazards of subject censoring before the study end date. 
    Any censoring LTFU 
Switch to second-
line Transfer Death 
N 38262 14325 2900 17668 3369 
Predictor Adj. HR 95% CI Adj. HR 95% CI 
Adj. 
HR 95% CI 
Adj. 
HR 95% CI 
Adj. 
HR 95% CI 
Clinic Clinic C 0.49 0.46 0.53 0.5 0.45 0.56 1.25 1.01 1.55 0.28 0.25 0.31 1.71 1.37 2.14 
  Clinic H 0.58 0.55 0.61 0.82 0.75 0.89 1.15 0.94 1.4 0.29 0.26 0.32 1.09 0.87 1.37 
  Clinic G 0.53 0.48 0.58 0.89 0.79 1 0.65 0.47 0.91 0.25 0.21 0.29 0.63 0.42 0.94 
  Clinic I 1.1 1 1.22 2.72 2.4 3.08 2.28 1.69 3.09 0.11 0.08 0.17 1.15 0.73 1.83 
  Clinic D 1.26 1.18 1.34 1.46 1.32 1.62 1.24 0.95 1.6 1.17 1.07 1.29 0.44 0.28 0.7 
  Clinic F 1.62 1.53 1.7 1.11 1.01 1.21 0.84 0.65 1.07 2.02 1.88 2.17 3.07 2.49 3.79 
  Clinic E 2.14 2.02 2.26 1.34 1.21 1.48 0.17 0.1 0.28 3.31 3.07 3.56 1.83 1.43 2.34 
  Clinic A 0.68 0.64 0.71 0.7 0.65 0.75 1.27 1.06 1.5 0.5 0.47 0.54 1.62 1.34 1.97 
  Clinic B Ref 
 
   
 
   
 
   
 
   
 
  
Year of 
initiation 2004 0.57 0.49 0.66 0.34 0.27 0.42 2.28 1.13 4.59 0.49 0.37 0.64 11.74 3.73 37.03 
  2005 0.58 0.5 0.66 0.36 0.29 0.43 1.76 0.88 3.5 0.56 0.43 0.72 11.2 3.58 35.02 
  2006 0.67 0.58 0.76 0.39 0.33 0.47 2.08 1.06 4.08 0.71 0.56 0.92 11 3.53 34.27 
  2007 0.68 0.6 0.78 0.41 0.35 0.49 2.01 1.02 3.94 0.78 0.61 1 9.47 3.04 29.53 
  2008 0.77 0.67 0.87 0.47 0.4 0.56 2.53 1.29 4.94 0.9 0.71 1.15 9.21 2.96 28.67 
  2009 0.86 0.76 0.98 0.6 0.51 0.71 2.55 1.31 4.98 1.05 0.83 1.34 7.24 2.32 22.55 
  2010 0.9 0.79 1.02 0.64 0.55 0.75 2.15 1.1 4.2 1.13 0.88 1.44 6.9 2.21 21.55 
  2011 0.89 0.78 1.01 0.72 0.61 0.84 2.25 1.15 4.43 1.05 0.82 1.34 4.37 1.39 13.75 
  2012 0.87 0.76 0.99 0.82 0.69 0.97 1.44 0.71 2.89 0.9 0.69 1.16 2.53 0.78 8.2 
  2013 Ref 
 
   
 
   
 
   
 
   
 
  
Age 18–24.9 1.23 1.16 1.31 1.44 1.31 1.58 1.42 1.17 1.74 1.02 0.93 1.12 1.34 1.08 1.67 
  25–29.9 1.11 1.07 1.16 1.21 1.13 1.3 1.27 1.1 1.46 1.01 0.94 1.08 1.05 0.9 1.23 
  30–34.9 Ref 
 
   
 
   
 
   
 
   
 
  
 
 
206 
  35–39.9 0.93 0.89 0.97 0.82 0.77 0.88 0.84 0.73 0.97 1 0.94 1.06 1.18 1.03 1.36 
  40–44.9 0.93 0.89 0.97 0.81 0.75 0.87 0.75 0.64 0.88 1.01 0.95 1.09 1.3 1.12 1.5 
  45–49.9 0.91 0.86 0.96 0.76 0.7 0.83 0.56 0.45 0.69 1.02 0.94 1.1 1.44 1.23 1.69 
  50–54.9 0.91 0.85 0.97 0.71 0.63 0.8 0.61 0.47 0.8 0.99 0.9 1.08 1.74 1.45 2.08 
  55+ 1 0.94 1.07 0.78 0.69 0.88 0.74 0.57 0.98 1.08 0.98 1.2 2 1.65 2.41 
Sex Female 0.96 0.93 0.99 0.78 0.74 0.82 1.25 1.12 1.4 1.18 1.13 1.24 0.68 0.62 0.74 
  Male Ref 
 
   
 
   
 
   
 
   
 
  
NNRTI NVP 1.01 0.97 1.06 0.97 0.9 1.04 1.34 1.16 1.56 1.05 0.98 1.12 0.83 0.69 0.99 
  EFV Ref 
 
   
 
   
 
   
 
   
 
  
CD4 0–25 0.97 0.93 1.02 0.92 0.85 0.99 1.4 1.21 1.63 0.84 0.79 0.9 1.45 1.28 1.64 
  25–50 0.99 0.94 1.04 0.98 0.9 1.06 1.3 1.11 1.53 0.9 0.84 0.97 1.23 1.07 1.41 
  51–100 0.99 0.96 1.03 0.99 0.93 1.05 1.22 1.06 1.4 0.95 0.89 1 1.13 1 1.27 
  101–200 Ref 
 
   
 
   
 
   
 
   
 
  
  201–350 0.95 0.91 0.99 0.91 0.86 0.98 1.02 0.87 1.18 1.02 0.96 1.08 0.76 0.64 0.9 
  >350 0.95 0.88 1.02 0.96 0.86 1.08 0.91 0.7 1.19 0.95 0.84 1.07 0.93 0.71 1.23 
MCV <80 Ref 
 
   
 
   
 
   
 
   
 
  
  80–95 1.01 0.97 1.05 0.96 0.9 1.02 1.1 0.96 1.27 1.03 0.97 1.1 0.93 0.82 1.06 
  95+ 1.13 1.07 1.19 1.14 1.05 1.24 1.13 0.94 1.36 1.08 1 1.17 1.21 1.03 1.41 
Hemoglobin <12 Ref 
 
   
 
   
 
   
 
   
 
  
  12+ 0.89 0.87 0.92 0.87 0.83 0.91 0.94 0.85 1.05 0.99 0.94 1.03 0.64 0.58 0.71 
History of TB No Ref 
 
   
 
   
 
   
 
   
 
  
  Yes 1.01 0.97 1.05 1 0.94 1.06 0.96 0.85 1.08 1.04 0.98 1.1 0.99 0.89 1.1 
Missed visits No Ref 
 
   
 
   
 
   
 
   
 
  
  Yes 1.44 1.4 1.49 0.46 0.43 0.48 0.93 0.83 1.04 0.95 0.9 0.99 0.88 0.79 0.97 
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Table A1F. Hazard ratio estimates for sensitivity analysis assuming date of switch to second line is date of treatment 
failure. 
Variable   Estimate 95% Confidence Limits Pr > |t| HR 
HR 95% 
LCL 
HR 95% 
UCL 
HR from 
predictive 
model 
Intercept  9.330286 9.21901 9.44156 <.0001 
   
  
Age 18–24.9 -0.34683 -0.45042 -0.24324 <.0001 0.39 0.30 0.52 1.47 
  25–29.9 -0.205642 -0.28516 -0.12612 <.0001 0.57 0.46 0.71 1.22 
  30–34.9 0 . . . Ref 
  
Ref 
  35–39.9 0.260082 0.17248 0.34768 <.0001 2.02 1.59 2.56 0.84 
  40–44.9 0.339672 0.2368 0.44255 <.0001 2.50 1.90 3.31 0.80 
  45–49.9 0.483893 0.35669 0.61109 <.0001 3.70 2.62 5.21 0.74 
  50–54.9 0.509719 0.34153 0.67791 <.0001 3.96 2.52 6.24 0.78 
  55+ 0.568047 0.3686 0.76749 <.0001 4.64 2.71 7.95 0.73 
Sex Male 0.070466 -0.03035 0.17128 0.1707 1.21 0.92 1.59 1.12 
  Female 0 . . . Ref 
  
Ref 
NNRTI NVP -0.238139 -0.30315 -0.17313 <.0001 0.53 0.44 0.63 1.33 
  EFV 0 . . . Ref 
  
Ref 
CD4 count 0–25 -0.520716 -0.60254 -0.4389 <.0001 0.24 0.20 0.31 1.73 
  25–50 -0.339557 -0.42209 -0.25703 <.0001 0.40 0.32 0.50 1.41 
  51–100 -0.236127 -0.31103 -0.16123 <.0001 0.53 0.43 0.65 1.25 
  101–200 0 . . . Ref 
  
Ref 
  201–350 0.076878 -0.00619 0.15994 0.0696 1.23 0.98 1.54 0.87 
  >350 0.204537 0.03823 0.37084 0.0175 1.74 1.11 2.72 0.73 
MCV <80 0 . . . Ref 
  
Ref 
  80–95 -0.11779 -0.19474 -0.04084 0.003 0.73 0.59 0.90 1.14 
  95+ -0.218684 -0.32346 -0.11391 0.0001 0.55 0.42 0.74 1.27 
Hemoglobin <12 0 . . . Ref 
  
1.10 
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  12+ -0.074122 -0.12993 -0.01832 0.0096 0.82 0.70 0.95 Ref 
History of TB Yes -0.078341 -0.13927 -0.01741 0.0117 0.81 0.69 0.95 1.05 
  No 0 . . . Ref 
  
Ref 
Missed visits Yes -0.306886 -0.36155 -0.25222 <.0001 0.44 0.38 0.51 1.41 
  No 0 . . . Ref 
  
Ref 
Sex*age Female & 18–25 0 . . . Ref 
  
Ref 
  Female & 25–30 0 . . . Ref 
  
Ref 
  Female & 30–35 0 . . . Ref 
  
Ref 
  Female & 35–40 0 . . . Ref 
  
Ref 
  Female & 40–45 0 . . . Ref 
  
Ref 
  Female & 45–50 0 . . . Ref 
  
Ref 
  Female & 50–55 0 . . . Ref 
  
Ref 
  Female & >55 0 . . . Ref 
  
Ref 
  Male & 18–25 0.165266 -0.11831 0.44885 0.2534 1.56 0.73 3.36 0.84 
  Male & 25–30 0.160607 -0.00765 0.32886 0.0614 1.54 0.98 2.43 0.88 
  Male & 30–35 0 . . . Ref 
  
Ref 
  Male & 35–40 -0.183926 -0.32725 -0.0406 0.0119 0.61 0.41 0.90 1.13 
  Male & 40–45 -0.301298 -0.4611 -0.14149 0.0002 0.44 0.29 0.68 1.18 
  Male & 45–50 -0.404848 -0.59613 -0.21357 <.0001 0.33 0.20 0.56 1.33 
  Male & 50–55 -0.37015 -0.61267 -0.12763 0.0028 0.37 0.19 0.71 1.11 
  Male & >55 -0.461924 -0.73749 -0.18635 0.001 0.29 0.14 0.60 1.16 
Scale   1.107               
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Table A1G. Hazard ratio estimates for sensitivity analysis where person time is censored at missing viral load. 
Variable   Estimate 95% Confidence Limits Pr > |t| HR 
HR 
95% 
LCL 
HR 
95% 
UCL 
HR from 
predictive 
model 
Intercept  10.36941 10.20398 10.53484 <.0001    
 
  
Age 18–24.9 -0.348433 -0.49949 -0.19737 <.0001 1.32 1.17 1.48 1.47 
  25–29.9 -0.20581 -0.32262 -0.089 0.0006 1.18 1.07 1.29 1.22 
  30–34.9 0 . . . 1.00  
 
Ref 
  35–39.9 0.224861 0.09805 0.35167 0.0005 0.84 0.76 0.93 0.84 
  40–44.9 0.261294 0.11464 0.40795 0.0005 0.81 0.72 0.91 0.80 
  45–49.9 0.411644 0.23265 0.59064 <.0001 0.72 0.63 0.83 0.74 
  50–54.9 0.287431 0.06224 0.51262 0.0124 0.80 0.67 0.95 0.78 
  55+ 0.367241 0.10257 0.63191 0.0065 0.75 0.61 0.92 0.73 
Sex Male -0.094088 -0.23383 0.04565 0.1869 1.08 0.96 1.20 1.12 
  Female 0 . . . 1.00  
 
Ref 
NNRTI NVP -0.371757 -0.46653 -0.27699 <.0001 1.34 1.24 1.45 1.33 
  EFV 0 . . . 1.00  
 
Ref 
CD4 count 0–25 -0.736941 -0.84109 -0.63279 <.0001 1.79 1.65 1.94 1.73 
  25–50 -0.469743 -0.58559 -0.3539 <.0001 1.45 1.32 1.59 1.41 
  51–100 -0.322471 -0.42652 -0.21842 <.0001 1.29 1.19 1.40 1.25 
  101–200 0 . . . 1.00  
 
Ref 
  201–350 0.145316 0.0205 0.27013 0.0228 0.89 0.81 0.98 0.87 
  >350 0.391809 0.16236 0.62126 0.0012 0.73 0.61 0.88 0.73 
MCV <80 0 . . . 1.00  
 
Ref 
  80–95 -0.191413 -0.30056 -0.08227 0.0007 1.16 1.07 1.27 1.14 
  95+ -0.318081 -0.461 -0.17516 <.0001 1.29 1.15 1.44 1.27 
Hemoglobin <12 -0.094918 -0.17532 -0.01452 0.0211 1.08 1.01 1.15 1.10 
  12+ 0 . . . 1.00  
 
Ref 
History of TB Yes -0.047488 -0.1317 0.03673 0.2691 1.04 0.97 1.11 1.05 
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  No 0 . . . 1.00  
 
Ref 
Missed visits Yes -0.316515 -0.39061 -0.24242 <.0001 1.28 1.21 1.36 1.41 
  No 0 . . . 1.00  
 
Ref 
Sex*age Female & 18–25 0 . . . 1.00  
 
Ref 
  Female & 25–30 0 . . . 1.00  
 
Ref 
  Female & 30–35 0 . . . 1.00  
 
Ref 
  Female & 35–40 0 . . . 1.00  
 
Ref 
  Female & 40–45 0 . . . 1.00  
 
Ref 
  Female & 45–50 0 . . . 1.00  
 
Ref 
  Female & 50–55 0 . . . 1.00  
 
Ref 
  Female & >55 0 . . . 1.00  
 
Ref 
  Male & 18–25 0.16541 -0.22094 0.55176 0.4014 0.88 0.65 1.19 0.84 
  Male & 25–30 0.137125 -0.09267 0.36692 0.2422 0.90 0.75 1.08 0.88 
  Male & 30–35 0 . . . 1.00  
 
Ref 
  Male & 35–40 -0.185862 -0.38396 0.01224 0.0659 1.16 0.99 1.35 1.13 
  Male & 40–45 -0.213972 -0.4353 0.00736 0.0581 1.18 0.99 1.41 1.18 
  Male & 45–50 -0.408593 -0.66783 -0.14936 0.002 1.38 1.13 1.70 1.33 
  Male & 50–55 -0.105708 -0.433 0.22159 0.5267 1.09 0.84 1.41 1.11 
  Male & >55 -0.15858 -0.53081 0.21365 0.4037 1.13 0.84 1.52 1.16 
Scale   1.265               
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Table A2A. Variations of crude rates of outcomes by time to switch to second line ART group. 
  Time to switch group: 
  0 to 1.5 mo 1.5 to 3 mo 3 to 6 mo 6 to 12 mo >12 mo 
N 1114 669 688 593 642 
Among patients with 12 months of potential follow-up on second line 
N 1106 646 623 477 424 
     Confirmed failure on second line 
Number failed 182 104 107 70 52 
Total person-days 739802 449738.5 397027 295469 247086 
Total person-years 2027 1232 1088 810 677 
Rate (failures per person 
year) 0.0898 0.0844 0.0984 0.0865 0.0768 
Crude IRR Ref 0.94 1.1 0.96 0.86 
            
     Single failure on second line 
Number failed 446 259 251 197 149 
Total person-days 601796.5 365127 320459.5 233455 206470.5 
Total person-years 1649 1000 878 640 566 
Rate (failures per person 
year) 0.271 0.259 0.286 0.308 0.263 
Crude IRR Ref 0.96 1.06 1.14 0.97 
            
     Single suppressed viral load on second line 
Number suppressed 785 469 441 352 291 
Total person-days 226583 137937 133316 92971.5 92174.5 
Total person-years 621 378 365 255 253 
Rate (suppressions per 
person year) 1.26 1.24 1.21 1.38 1.15 
Crude IRR Ref 0.98 0.95 1.09 0.91 
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Among patients with 24 months of potential follow-up on second line 
N 934 519 469 312 286 
     Confirmed failure on second line 
Number failed 162 88 88 60 43 
Total person-days 663301 395943 329053 221709 187200 
Total person-years 1817 1085 902 607 513 
Rate (failures per person 
year) 0.0891 0.0811 0.0976 0.0988 0.0838 
Crude IRR Ref 0.9 1.09 1.1 0.93 
            
     Single failure on second line 
Number failed 389 212 200 151 115 
Total person-days 537365 321646 262206 169713.5 153671 
Total person-years 1472 881 718 465 421 
Rate (failures per person 
year) 0.264 0.241 0.278 0.325 0.273 
Crude IRR Ref 0.89 1.03 1.2 1.01 
            
     Single suppressed viral load on second line 
Number suppressed 660 383 323 224 195 
Total person-days 189453 110986.5 100753 60432.5 61089 
Total person-years 519 304 276 166 167 
Rate (suppressions per 
person year) 1.27 1.26 1.17 1.35 1.17 
Crude IRR Ref 1 0.93 1.07 0.92 
            
All patients with at least 12 weeks of potential follow-up time on second line switch, using a 12 week delay 
N 1114 669 688 591 606 
     Confirmed failure on second line 
Number failed 171 97 100 63 48 
Total person-days 657225.5 404762 361974.5 275629 236806.5 
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Total person-years 1801 1109 992 755 649 
Rate (failures per person 
year) 0.095 0.0875 0.1008 0.0834 0.074 
Crude IRR Ref 0.97 1.12 0.93 0.82 
            
     Single failure on second line on second line 
Number failed 405 245 245 189 160 
Total person-days 533462.5 329334 291384 226382.5 199344 
Total person-years 1462 902 798 620 546 
Rate (failures per person 
year) 0.277 0.272 0.307 0.305 0.293 
Crude IRR Ref 1 1.13 1.13 1.08 
            
Among patients who suppress on second line, rate of single failing viral load after suppression 
N 367 212 172 131 105 
     Confirmed failure on second line 
Number failed 46 19 21 11 11 
Total person-days 213798 122554.5 91401.5 69359.5 47045.5 
Total person-years 586 336 250 190 129 
Rate (failures per person 
year) 0.0785 0.0566 0.0839 0.0579 0.0853 
Crude IRR Ref 0.63 0.93 0.64 0.95 
            
     Single failure on second line 
Number failed 116 45 53 36 33 
Total person-days 187304 111460 78867 60800 40749 
Total person-years 513 305 216 167 112 
Rate (failures per person 
year) 0.226 0.147 0.245 0.216 0.296 
Crude IRR Ref 0.54 0.91 0.8 1.09 
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Table A2B. Marginal structural model and Cox model results for hazards of virologic suppression after first line failure. 
  
All patients 
    Marginal structural model Cox model 
Variables   HR 95% LCL 
95% 
UCL HR 
95% 
LCL 
95% 
UCL 
Time to switch: No switch 0.56 0.50 0.62 0.52 0.46 0.59 
  0–1.5 months Ref 
 
  Ref 
    1.5–3 months 0.89 0.80 0.99 0.86 0.75 0.99 
  3–6 months 0.86 0.77 0.95 0.69 0.60 0.79 
  6–12 months 0.67 0.60 0.74 0.58 0.50 0.68 
  >12 months 0.61 0.55 0.68 0.64 0.55 0.75 
Gender Female Ref 
 
  Ref 
    Male 0.88 0.78 0.98 0.85 0.78 0.93 
Age 18–25 0.70 0.55 0.87 0.67 0.55 0.81 
  25–30 0.77 0.66 0.91 0.80 0.70 0.91 
  30–35 Ref 
 
  Ref 
    35–40 1.00 0.86 1.17 1.09 0.96 1.23 
  40–45 1.08 0.91 1.28 1.07 0.94 1.23 
  45–50 0.99 0.81 1.22 0.97 0.82 1.14 
  50–55 0.96 0.75 1.24 0.94 0.77 1.15 
  55+ 0.92 0.67 1.27 0.87 0.68 1.12 
Failing viral load 1000–9999 1.84 1.60 2.12 1.63 1.45 1.83 
  10,000–59,999 1.28 1.09 1.49 1.25 1.11 1.42 
  60,000+ Ref 
 
  Ref 
  CD4 count at 
failure 0–49 1.16 0.91 1.49 1.04 0.86 1.26 
  50–99 Ref 
 
  Ref 
    100–250 1.12 0.92 1.36 1.09 0.94 1.26 
  >250 1.54 1.27 1.88 1.27 1.10 1.48 
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Table A2B, continued. Marginal structural model and Cox model results for hazards of virologic suppression after first line failure. 
  
Peak CD4 <= 100 Peak CD4 >100 
    
Marginal structural 
model Cox model 
Marginal structural 
model Cox model 
Variables   HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Time to switch: No switch 0.32 0.23 0.45 0.25 0.17 0.36 0.60 0.54 0.68 0.58 0.51 0.67 
  0–1.5 months Ref 
 
  Ref 
  
Ref 
 
  Ref 
 
  
  1.5–3 months 0.72 0.52 1.00 0.90 0.64 1.28 0.93 0.83 1.05 0.87 0.75 1.01 
  3–6 months 0.66 0.50 0.88 0.64 0.44 0.92 0.90 0.81 1.00 0.70 0.60 0.81 
  6–12 months 0.42 0.30 0.57 0.48 0.32 0.71 0.72 0.64 0.80 0.60 0.51 0.71 
  >12 months 0.37 0.27 0.50 0.70 0.45 1.08 0.66 0.58 0.73 0.64 0.54 0.75 
Gender Female Ref 
 
  Ref 
  
Ref 
 
  Ref 
 
  
  Male 0.97 0.71 1.33 0.95 0.73 1.23 0.86 0.76 0.98 0.83 0.75 0.92 
Age 18–25 0.70 0.36 1.38 0.60 0.35 1.05 0.69 0.54 0.89 0.68 0.56 0.84 
  25–30 0.72 0.44 1.19 0.86 0.60 1.23 0.78 0.66 0.93 0.80 0.70 0.92 
  30–35 Ref 
 
  Ref 
  
Ref 
 
  Ref 
 
  
  35–40 1.05 0.67 1.64 1.25 0.90 1.75 1.01 0.85 1.19 1.07 0.94 1.22 
  40–45 1.17 0.75 1.84 1.09 0.76 1.55 1.05 0.87 1.26 1.05 0.91 1.22 
  45–50 0.85 0.42 1.72 0.89 0.53 1.51 1.00 0.81 1.25 0.96 0.81 1.15 
  50–55 0.43 0.17 1.13 0.58 0.28 1.20 1.02 0.79 1.33 0.99 0.80 1.22 
  55+ 0.34 0.14 0.81 0.47 0.18 1.18 0.99 0.71 1.38 0.95 0.73 1.23 
Failing viral 
load 1000–9999 1.18 0.78 1.77 1.22 0.88 1.68 1.93 1.65 2.26 1.71 1.50 1.94 
  
10,000–
59,999 1.31 0.89 1.94 1.10 0.83 1.47 1.30 1.09 1.55 1.31 1.14 1.51 
  60,000+ Ref 
 
  Ref 
  
Ref 
 
  Ref 
 
  
CD4 count at 
failure 0–49   
 
  
   
1.12 0.76 1.67 1.13 0.83 1.53 
  50–99   
 
  
   
Ref 
 
  Ref 
 
  
  100–250   
 
  
   
0.98 0.75 1.28 1.03 0.85 1.26 
  >250         1.32 1.01 1.73 1.21 0.98 1.48 
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APPENDIX FIGURES 
Figure A1A. Cox-Snell residuals for accelerated failure time models with different 
survival distributions and accounting for basic predictors (age, gender, NNRTI, CD4 
count). Straight line with a slope of 1 indicates good fit. 
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Figure A1B. Diagnostic plots for different distribution's fit to crude data. Straight line 
indicates good fit. 
1. Exponential model fit. 
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2. Weibull model fit 
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3. Lognormal model fit 
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Figure A1C. Comparison plot of accelerated failure time models with different 
distributions compared to a non-parametric model, including age, sex, CD4 and NNRTI 
predictors. Shaded line represents exponential model prediction, and circles represent 
prediction of failure from a non-parametric survival model. 
1. Exponential model fit. 
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2. Weibull model fit. 
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3. Lognormal model fit 
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4. Loglogistic model fit. 
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Figure A1D. Cumulative incidence of failure (1) crude Kaplan-Meier curve; (2) adjusting 
for death and switch to second line as competing risks. 
1. Cumulative incidence of failure unadjusted for competing risks, over days on ART 
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2. Cumulative incidence of failure adjusted for death and switch to second line as 
competing risks, over days on ART. 
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Figure A1E. Sensitivity analysis results displaying rate of failure for: (0) unadjusted data; 
(1) switch to second line as treatment failure; (2) death while in care as treatment 
failure; (3) parts 1 and 2 combined. 
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Figure A2A. Crude Kaplan-Meier curves showing time to failure on second line stratified 
by predictor variables. 
a) Time to switch to second line group. 
 
b) Viral load at first line failure. 
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c) Gender. 
 
 
d) Age. 
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e) History of TB. 
 
 
f) CD4 count at failure. 
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g) Hemoglobin at failure. 
 
 
h) BMI at failure. 
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i) Proportion of missed visits before failure 
 
 
j) Time between failing viral loads on first line. 
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Figure A3A. Histograms for propensity scores for switch in NRTI at second line ART. 
1) Overlap in propensity scores in South Africa data for switch to TDF vs. remain on AZT 
for patients initiated on AZT. 
 
2) Overlap in propensity scores in Zambia data for switch to TDF vs. remain on AZT for 
patients initiated on AZT. 
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3) Overlap in propensity scores in South Africa data for switch to ABC vs. remain on AZT 
for patients initiated on AZT. 
 
4) Overlap in propensity scores in Zambia data for switch to ABC vs. remain on AZT for 
patients initiated on AZT. 
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5) Overlap in propensity scores in South Africa data for switch to AZT vs. remain on TDF 
for patients initiated on TDF. 
 
 
6) Overlap in propensity scores in Zambia data for switch to AZT vs. remain on TDF for 
patients initiated on TDF. 
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7) Overlap in propensity scores in South Africa data for switch to ABC vs. remain on TDF 
for patients initiated on TDF. 
 
8) Overlap in propensity scores in Zambia data for switch to ABC vs. remain on TDF for 
patients initiated on TDF. 
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9) Overlap in propensity scores in South Africa data for switch to TDF vs. remain on d4T 
for patients initiated on d4T. 
 
 
10) Overlap in propensity scores in Zambia data for switch to TDF vs. remain on d4T for 
patients initiated on d4T. 
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11) Overlap in propensity scores in South Africa data for switch to AZT vs. remain on d4T 
for patients initiated on d4T. 
 
12) Overlap in propensity scores in Zambia data for switch to AZT vs. remain on d4T for 
patients initiated on d4T. 
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13) Overlap in propensity scores in South Africa data for switch to ABC vs. remain on d4T 
for patients initiated on d4T. 
 
14) Overlap in propensity scores in Zambia data for switch to ABC vs. remain on d4T for patients 
initiated on d4T. 
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